US20210154190A1 - Shp2 inhibitor compositions and methods for treating cancer - Google Patents
Shp2 inhibitor compositions and methods for treating cancer Download PDFInfo
- Publication number
- US20210154190A1 US20210154190A1 US17/064,317 US202017064317A US2021154190A1 US 20210154190 A1 US20210154190 A1 US 20210154190A1 US 202017064317 A US202017064317 A US 202017064317A US 2021154190 A1 US2021154190 A1 US 2021154190A1
- Authority
- US
- United States
- Prior art keywords
- formula
- shp2
- cancer
- alkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 title claims abstract description 319
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 title claims abstract description 314
- 239000003112 inhibitor Substances 0.000 title claims abstract description 161
- 238000000034 method Methods 0.000 title claims abstract description 103
- 206010028980 Neoplasm Diseases 0.000 title claims description 40
- 201000011510 cancer Diseases 0.000 title claims description 27
- 239000000203 mixture Substances 0.000 title description 38
- 230000035772 mutation Effects 0.000 claims abstract description 151
- 229940125528 allosteric inhibitor Drugs 0.000 claims abstract description 84
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 59
- 230000003281 allosteric effect Effects 0.000 claims abstract description 57
- 201000010099 disease Diseases 0.000 claims abstract description 33
- 208000035475 disorder Diseases 0.000 claims abstract description 26
- 150000001875 compounds Chemical class 0.000 claims description 118
- 102200155721 rs121918464 Human genes 0.000 claims description 24
- 102200155473 rs121918461 Human genes 0.000 claims description 23
- 102220011044 rs397507539 Human genes 0.000 claims description 22
- 102220565090 Myocilin_S502P_mutation Human genes 0.000 claims description 21
- 102200155671 rs121918463 Human genes 0.000 claims description 21
- 102220248453 rs1555459201 Human genes 0.000 claims description 18
- 102200154901 rs387906999 Human genes 0.000 claims description 18
- 102200155728 rs121918462 Human genes 0.000 claims description 15
- 102200155477 rs397507511 Human genes 0.000 claims description 15
- 102220011057 rs397507548 Human genes 0.000 claims description 15
- 238000003205 genotyping method Methods 0.000 claims description 12
- YGUFCDOEKKVKJK-UHFFFAOYSA-N 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical compound NC1(CCN(CC1)C1=CN=C(C(=N1)N)C1=C(C(=CC=C1)Cl)Cl)C YGUFCDOEKKVKJK-UHFFFAOYSA-N 0.000 claims description 11
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 11
- 239000012472 biological sample Substances 0.000 claims description 10
- UCJZOKGUEJUNIO-IINYFYTJSA-N (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@@H]1OCC2(CCN(CC2)C2=CN=C(SC3=C(Cl)C(N)=NC=C3)C(N)=N2)[C@@H]1N UCJZOKGUEJUNIO-IINYFYTJSA-N 0.000 claims description 9
- 229940125811 TNO155 Drugs 0.000 claims description 9
- 229940126062 Compound A Drugs 0.000 claims description 8
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 8
- 206010029748 Noonan syndrome Diseases 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 208000012239 Developmental disease Diseases 0.000 claims description 6
- 208000005101 LEOPARD Syndrome Diseases 0.000 claims description 6
- 206010062901 Multiple lentigines syndrome Diseases 0.000 claims description 6
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 claims description 6
- 208000010708 Noonan syndrome with multiple lentigines Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 206010029260 Neuroblastoma Diseases 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 201000002313 intestinal cancer Diseases 0.000 claims description 4
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 241000321096 Adenoides Species 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims description 3
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 3
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 210000002534 adenoid Anatomy 0.000 claims description 3
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 3
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims description 3
- 210000003192 autonomic ganglia Anatomy 0.000 claims description 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 3
- 201000007455 central nervous system cancer Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000002445 cystadenocarcinoma Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 208000024519 eye neoplasm Diseases 0.000 claims description 3
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 230000002607 hemopoietic effect Effects 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000022006 malignant tumor of meninges Diseases 0.000 claims description 3
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 3
- 230000002071 myeloproliferative effect Effects 0.000 claims description 3
- 201000008106 ocular cancer Diseases 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000007312 paraganglioma Diseases 0.000 claims description 3
- 201000002628 peritoneum cancer Diseases 0.000 claims description 3
- 208000028591 pheochromocytoma Diseases 0.000 claims description 3
- 201000002511 pituitary cancer Diseases 0.000 claims description 3
- 201000003437 pleural cancer Diseases 0.000 claims description 3
- 210000005000 reproductive tract Anatomy 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000023747 urothelial carcinoma Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 208000012991 uterine carcinoma Diseases 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- 201000008761 vulvar melanoma Diseases 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 abstract description 11
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 description 326
- 125000001072 heteroaryl group Chemical group 0.000 description 172
- 125000000753 cycloalkyl group Chemical group 0.000 description 144
- 125000002950 monocyclic group Chemical group 0.000 description 130
- 125000003118 aryl group Chemical group 0.000 description 128
- 229910052736 halogen Inorganic materials 0.000 description 123
- 150000002367 halogens Chemical class 0.000 description 123
- 125000000217 alkyl group Chemical group 0.000 description 121
- 229910052757 nitrogen Inorganic materials 0.000 description 101
- -1 e.g. Proteins 0.000 description 96
- 229910052717 sulfur Inorganic materials 0.000 description 81
- 125000005842 heteroatom Chemical group 0.000 description 79
- 125000003342 alkenyl group Chemical group 0.000 description 77
- 229910052698 phosphorus Inorganic materials 0.000 description 76
- 125000003367 polycyclic group Chemical group 0.000 description 75
- 125000000304 alkynyl group Chemical group 0.000 description 59
- 125000000392 cycloalkenyl group Chemical group 0.000 description 58
- 108090000765 processed proteins & peptides Proteins 0.000 description 52
- 229910052760 oxygen Inorganic materials 0.000 description 48
- 230000036515 potency Effects 0.000 description 40
- 125000004429 atom Chemical group 0.000 description 38
- 125000004585 polycyclic heterocycle group Chemical group 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 32
- 239000003814 drug Substances 0.000 description 28
- 0 *.*CC1=C([4*])N=C(CC)C([2*])=N1.CC Chemical compound *.*CC1=C([4*])N=C(CC)C([2*])=N1.CC 0.000 description 25
- 229910052799 carbon Inorganic materials 0.000 description 25
- 235000002639 sodium chloride Nutrition 0.000 description 25
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 24
- 230000005764 inhibitory process Effects 0.000 description 24
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 150000003839 salts Chemical class 0.000 description 22
- 239000000651 prodrug Substances 0.000 description 21
- 229940002612 prodrug Drugs 0.000 description 21
- 229940124597 therapeutic agent Drugs 0.000 description 21
- 239000012453 solvate Substances 0.000 description 20
- 150000004677 hydrates Chemical class 0.000 description 18
- 125000004433 nitrogen atom Chemical group N* 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 18
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 18
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 17
- 230000004913 activation Effects 0.000 description 17
- 150000001721 carbon Chemical group 0.000 description 17
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 102000016914 ras Proteins Human genes 0.000 description 15
- 230000003213 activating effect Effects 0.000 description 14
- 230000037361 pathway Effects 0.000 description 13
- 230000011664 signaling Effects 0.000 description 13
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 12
- 102000043136 MAP kinase family Human genes 0.000 description 12
- 108091054455 MAP kinase family Proteins 0.000 description 12
- 239000003085 diluting agent Substances 0.000 description 12
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 125000003373 pyrazinyl group Chemical group 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 9
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 6
- 229940124647 MEK inhibitor Drugs 0.000 description 6
- 229910017711 NHRa Inorganic materials 0.000 description 6
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 5
- DZANYXOTJVLAEE-UHFFFAOYSA-N 6,8-difluoro-4-methylumbelliferyl phosphate Chemical compound FC1=C(OP(O)(O)=O)C(F)=CC2=C1OC(=O)C=C2C DZANYXOTJVLAEE-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- IKUYEYLZXGGCRD-ORAYPTAESA-N [3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(=NC(=C(N=1)C)C1=C(C(=CC=C1)Cl)Cl)CO)C IKUYEYLZXGGCRD-ORAYPTAESA-N 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 235000001727 glucose Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- PSKJCIJLNDJVDV-GFCCVEGCSA-N (4R)-8-[6-amino-5-(2,3-dichloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=C(N=CC(=N1)N1CCC2(CCC[C@H]2N)CC1)SC1=C(C(=NC=C1)Cl)Cl PSKJCIJLNDJVDV-GFCCVEGCSA-N 0.000 description 4
- 238000012815 AlphaLISA Methods 0.000 description 4
- 101150086096 Eif2ak3 gene Proteins 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 229940125999 RMC-4550 Drugs 0.000 description 4
- 102000014400 SH2 domains Human genes 0.000 description 4
- 108050003452 SH2 domains Proteins 0.000 description 4
- 230000008850 allosteric inhibition Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002853 nucleic acid probe Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000013517 stratification Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 3
- PIDVFBONFRIFJQ-UHFFFAOYSA-N CC1(N)CCN(C2=CN=C(SC3=C(Cl)C(Cl)=CC=C3)C(C#N)=N2)CC1 Chemical compound CC1(N)CCN(C2=CN=C(SC3=C(Cl)C(Cl)=CC=C3)C(C#N)=N2)CC1 PIDVFBONFRIFJQ-UHFFFAOYSA-N 0.000 description 3
- CZBXUKCRXYIFKY-UHFFFAOYSA-N CC1(N)CCN(C2=CN=C(SC3=C(Cl)C(Cl)=CC=C3)C(C(F)(F)F)=N2)CC1 Chemical compound CC1(N)CCN(C2=CN=C(SC3=C(Cl)C(Cl)=CC=C3)C(C(F)(F)F)=N2)CC1 CZBXUKCRXYIFKY-UHFFFAOYSA-N 0.000 description 3
- GAIDNTMBQJHECM-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=CN=C1C1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC(C)(N)CC2)=CN=C1C1=CC=CC(Cl)=C1Cl GAIDNTMBQJHECM-UHFFFAOYSA-N 0.000 description 3
- XUAGNDDSKCPCMN-CQSZACIVSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1C1=CC=NC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1C1=CC=NC(Cl)=C1Cl XUAGNDDSKCPCMN-CQSZACIVSA-N 0.000 description 3
- IFLTYBXKRJVZTD-CQSZACIVSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=C(Cl)C(N)=NC=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=C(Cl)C(N)=NC=C1 IFLTYBXKRJVZTD-CQSZACIVSA-N 0.000 description 3
- QYSLFNYIPROSAC-MRXNPFEDSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl QYSLFNYIPROSAC-MRXNPFEDSA-N 0.000 description 3
- QOMUEBKPXSNZES-XJKSGUPXSA-N CO[C@H]1C[C@@H](N)C2(CCN(C3=C(CO)N=C(SC4=CC=NC(N)=C4Cl)C(C)=N3)CC2)C1 Chemical compound CO[C@H]1C[C@@H](N)C2(CCN(C3=C(CO)N=C(SC4=CC=NC(N)=C4Cl)C(C)=N3)CC2)C1 QOMUEBKPXSNZES-XJKSGUPXSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229930189065 blasticidin Natural products 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 102200155752 rs397507526 Human genes 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- TZHDOIFXTXRLQE-OAHLLOKOSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(N)=O)N=C1C1=C(Cl)C(Cl)=CC=C1 Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(N)=O)N=C1C1=C(Cl)C(Cl)=CC=C1 TZHDOIFXTXRLQE-OAHLLOKOSA-N 0.000 description 2
- QEPRITSJJUZLGE-OAHLLOKOSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=NC(F)=C1Cl Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=NC(F)=C1Cl QEPRITSJJUZLGE-OAHLLOKOSA-N 0.000 description 2
- ZWHDTSFCWWSFAP-QGZVFWFLSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=C(Cl)C(Cl)=CC=C1 Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=C(Cl)C(Cl)=CC=C1 ZWHDTSFCWWSFAP-QGZVFWFLSA-N 0.000 description 2
- FIMYFEGKMOCQKT-UHFFFAOYSA-N 3,4-difluoro-2-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide Chemical compound FC=1C(F)=C(NC=2C(=CC(I)=CC=2)F)C(C(=O)NOCCO)=CC=1CN1OCCCC1=O FIMYFEGKMOCQKT-UHFFFAOYSA-N 0.000 description 2
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- LTGUQYIJFZLDDC-VBKZILBWSA-N CC1=C(C2=CC=C3N=CNC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 Chemical compound CC1=C(C2=CC=C3N=CNC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 LTGUQYIJFZLDDC-VBKZILBWSA-N 0.000 description 2
- RGRSQEFFZSXKCU-UHFFFAOYSA-N CC1=NC(N2CCC(O)(CN)CC2)=C(CO)N=C1C1=C(Cl)C(Cl)=CC=C1 Chemical compound CC1=NC(N2CCC(O)(CN)CC2)=C(CO)N=C1C1=C(Cl)C(Cl)=CC=C1 RGRSQEFFZSXKCU-UHFFFAOYSA-N 0.000 description 2
- NNUVSQDHTKGCRB-VBKZILBWSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=CC(C#N)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=CC(C#N)=C1Cl NNUVSQDHTKGCRB-VBKZILBWSA-N 0.000 description 2
- QRHNLPFCILRYCI-MAUKXSAKSA-N CC1=NC(N2CCC3(CC2)C[C@@H](OC2CC2)C[C@H]3N)=C(CO)N=C1SC1=CC=NC(N)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)C[C@@H](OC2CC2)C[C@H]3N)=C(CO)N=C1SC1=CC=NC(N)=C1Cl QRHNLPFCILRYCI-MAUKXSAKSA-N 0.000 description 2
- BDHWHUQRQLMNPK-IUODEOHRSA-N CC1=NC(N2CCC3(CC2)C[C@H](O)C[C@H]3N)=C(CO)N=C1SC1=CC=NC(N)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)C[C@H](O)C[C@H]3N)=C(CO)N=C1SC1=CC=NC(N)=C1Cl BDHWHUQRQLMNPK-IUODEOHRSA-N 0.000 description 2
- BJVBMHADMOUTPE-OAHLLOKOSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(O)(F)F)N=C1C1=C(Cl)C(Cl)=CC=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(O)(F)F)N=C1C1=C(Cl)C(Cl)=CC=C1 BJVBMHADMOUTPE-OAHLLOKOSA-N 0.000 description 2
- UCNKCCMXXQXNIN-QGZVFWFLSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(Cl)C(Cl)=C(C#N)C=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(Cl)C(Cl)=C(C#N)C=C1 UCNKCCMXXQXNIN-QGZVFWFLSA-N 0.000 description 2
- YCDJCDMWDOVAPO-LJQANCHMSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(Cl)C2=C(C=C1)CCCO2 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(Cl)C2=C(C=C1)CCCO2 YCDJCDMWDOVAPO-LJQANCHMSA-N 0.000 description 2
- SYQCTFOOGKRKMA-HXUWFJFHSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=C2C(=CC=C1)C=CN2C Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=C2C(=CC=C1)C=CN2C SYQCTFOOGKRKMA-HXUWFJFHSA-N 0.000 description 2
- WHOJEOQBBJXBPN-CQSZACIVSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1C1=C(C)N=C(Cl)C=N1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1C1=C(C)N=C(Cl)C=N1 WHOJEOQBBJXBPN-CQSZACIVSA-N 0.000 description 2
- VFYBBHPUFYWVDE-MRXNPFEDSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=C(Cl)C(N)=CC=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=C(Cl)C(N)=CC=C1 VFYBBHPUFYWVDE-MRXNPFEDSA-N 0.000 description 2
- ZSPLBZYNMBENGY-CQSZACIVSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=NC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=NC(Cl)=C1Cl ZSPLBZYNMBENGY-CQSZACIVSA-N 0.000 description 2
- XKDSEGQHEVKRAQ-QGZVFWFLSA-N CCC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CCC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl XKDSEGQHEVKRAQ-QGZVFWFLSA-N 0.000 description 2
- BYNUAZOUJNNIJQ-OAHLLOKOSA-N COC(=O)C1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1C1=CC=CC(Cl)=C1Cl Chemical compound COC(=O)C1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1C1=CC=CC(Cl)=C1Cl BYNUAZOUJNNIJQ-OAHLLOKOSA-N 0.000 description 2
- BJUSFNPWGSLLMK-KBXCAEBGSA-N CO[C@H]1C[C@@H](N)C2(CCN(C3=C(CO)N=C(C4=CC=CC(Cl)=C4Cl)C(C)=N3)CC2)C1 Chemical compound CO[C@H]1C[C@@H](N)C2(CCN(C3=C(CO)N=C(C4=CC=CC(Cl)=C4Cl)C(C)=N3)CC2)C1 BJUSFNPWGSLLMK-KBXCAEBGSA-N 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- LBYBTJWHPKCFFR-UHFFFAOYSA-N Cc(nc(cn1)NCC2CCNCC2)c1Sc(cccc1Cl)c1Cl Chemical compound Cc(nc(cn1)NCC2CCNCC2)c1Sc(cccc1Cl)c1Cl LBYBTJWHPKCFFR-UHFFFAOYSA-N 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 101150018665 MAPK3 gene Proteins 0.000 description 2
- UQVPPYAPHIUMDV-MRXNPFEDSA-N N#CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound N#CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl UQVPPYAPHIUMDV-MRXNPFEDSA-N 0.000 description 2
- YPUCJXDFYPVEOY-CQSZACIVSA-N N#CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=NC(Cl)=C1Cl Chemical compound N#CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=NC(Cl)=C1Cl YPUCJXDFYPVEOY-CQSZACIVSA-N 0.000 description 2
- HJDHHSWCDVFMGL-CQSZACIVSA-N N[C@@H]1CCCC12CCN(C1=CN=C(SC3=CC=CC(Cl)=C3Cl)C(C(F)(F)F)=N1)CC2 Chemical compound N[C@@H]1CCCC12CCN(C1=CN=C(SC3=CC=CC(Cl)=C3Cl)C(C(F)(F)F)=N1)CC2 HJDHHSWCDVFMGL-CQSZACIVSA-N 0.000 description 2
- VNKCUBGTZNSZFM-HXUWFJFHSA-N N[C@@H]1CCCC12CCN(C1=CN=C(SC3=CC=CC(Cl)=C3Cl)C(C3=CC=CC=C3)=N1)CC2 Chemical compound N[C@@H]1CCCC12CCN(C1=CN=C(SC3=CC=CC(Cl)=C3Cl)C(C3=CC=CC=C3)=N1)CC2 VNKCUBGTZNSZFM-HXUWFJFHSA-N 0.000 description 2
- RNNVTAVZEMDYQA-OAHLLOKOSA-N N[C@@H]1CCCC12CCN(C1=CN=C(SC3=CC=NC(Cl)=C3Cl)C(C3CC3)=N1)CC2 Chemical compound N[C@@H]1CCCC12CCN(C1=CN=C(SC3=CC=NC(Cl)=C3Cl)C(C3CC3)=N1)CC2 RNNVTAVZEMDYQA-OAHLLOKOSA-N 0.000 description 2
- 101150048674 PTPN11 gene Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000004305 biphenyl Chemical group 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960002271 cobimetinib Drugs 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000004613 furo[2,3-c]pyridinyl group Chemical group O1C(=CC=2C1=CN=CC2)* 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 2
- 229940097277 hygromycin b Drugs 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- XQPIKFNIZLZHRT-JSTCDSMHSA-N *.*.CC1=NC(N)=C(CO)N=C1SC1=CC=CC(Cl)=C1Cl.CCC1(CC)C[C@@H](O)C[C@H]1N Chemical compound *.*.CC1=NC(N)=C(CO)N=C1SC1=CC=CC(Cl)=C1Cl.CCC1(CC)C[C@@H](O)C[C@H]1N XQPIKFNIZLZHRT-JSTCDSMHSA-N 0.000 description 1
- BLKZATOQEQXGOJ-SUMWQHHRSA-N *.*.CC1=NC(N2CCC3(CC2)C[C@@H](O)C[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl Chemical compound *.*.CC1=NC(N2CCC3(CC2)C[C@@H](O)C[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl BLKZATOQEQXGOJ-SUMWQHHRSA-N 0.000 description 1
- YKEZDLQESKFHRN-QGZVFWFLSA-N *.C=CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1C1=CC=CC(Cl)=C1Cl Chemical compound *.C=CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1C1=CC=CC(Cl)=C1Cl YKEZDLQESKFHRN-QGZVFWFLSA-N 0.000 description 1
- BMITVLGPICLYHP-UHFFFAOYSA-N *.CC.CCC(C)(C)C Chemical compound *.CC.CCC(C)(C)C BMITVLGPICLYHP-UHFFFAOYSA-N 0.000 description 1
- UPAGZFGEGKEHBL-QGZVFWFLSA-N *.CC1=C(SC2=C(Cl)C(Cl)=CC=C2)N=C(NCCO)C(N2CCC3(CCC[C@H]3N)CC2)=N1 Chemical compound *.CC1=C(SC2=C(Cl)C(Cl)=CC=C2)N=C(NCCO)C(N2CCC3(CCC[C@H]3N)CC2)=N1 UPAGZFGEGKEHBL-QGZVFWFLSA-N 0.000 description 1
- JBBHYLSNGGWLHD-NIFFTEIASA-N *.CC1=NC(N)=C(CO)N=C1C1=C(Cl)C(Cl)=NC=C1.CCC1(CC)CCC[C@H]1N Chemical compound *.CC1=NC(N)=C(CO)N=C1C1=C(Cl)C(Cl)=NC=C1.CCC1(CC)CCC[C@H]1N JBBHYLSNGGWLHD-NIFFTEIASA-N 0.000 description 1
- QHUKKKVLNDRHIV-NIFFTEIASA-N *.CC1=NC(N)=C(CO)N=C1C1=CC2=C(C=C1)NC=C2.CCC1(CC)CCC[C@H]1N Chemical compound *.CC1=NC(N)=C(CO)N=C1C1=CC2=C(C=C1)NC=C2.CCC1(CC)CCC[C@H]1N QHUKKKVLNDRHIV-NIFFTEIASA-N 0.000 description 1
- IZEDOWQSLXMTAQ-NIFFTEIASA-N *.CC1=NC(N)=C(CO)N=C1C1=CC=C2C=CNC2=C1.CCC1(CC)CCC[C@H]1N Chemical compound *.CC1=NC(N)=C(CO)N=C1C1=CC=C2C=CNC2=C1.CCC1(CC)CCC[C@H]1N IZEDOWQSLXMTAQ-NIFFTEIASA-N 0.000 description 1
- CCJSPKFXEKEXHY-NIFFTEIASA-N *.CC1=NC(N)=CN=C1C1=CC=CC(Cl)=C1Cl.CCC1(CC)CCC[C@H]1N Chemical compound *.CC1=NC(N)=CN=C1C1=CC=CC(Cl)=C1Cl.CCC1(CC)CCC[C@H]1N CCJSPKFXEKEXHY-NIFFTEIASA-N 0.000 description 1
- VKQBZWMOANUNKO-QGZVFWFLSA-N *.CC1=NC(N2CCC3(CC2)COC[C@H]3N)=C(CO)N=C1C1=CC=CC2=C1NC(=O)C2 Chemical compound *.CC1=NC(N2CCC3(CC2)COC[C@H]3N)=C(CO)N=C1C1=CC=CC2=C1NC(=O)C2 VKQBZWMOANUNKO-QGZVFWFLSA-N 0.000 description 1
- QQSAHAATIIGUNR-UFIUYGHPSA-N *.CC1=NC(N2CCC3(CC2)C[C@H](O)C[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl.S Chemical compound *.CC1=NC(N2CCC3(CC2)C[C@H](O)C[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl.S QQSAHAATIIGUNR-UFIUYGHPSA-N 0.000 description 1
- HYSNFNXFEGVSHG-XRZFDKQNSA-N *.CC1=NC(N2CCC3(CC2)C[C@H](O)C[C@H]3N)=C(CO)N=C1SC1=CC=NC(N)=C1Cl.S Chemical compound *.CC1=NC(N2CCC3(CC2)C[C@H](O)C[C@H]3N)=C(CO)N=C1SC1=CC=NC(N)=C1Cl.S HYSNFNXFEGVSHG-XRZFDKQNSA-N 0.000 description 1
- GOTVHDKAROPIFB-QGZVFWFLSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C#N)N=C1C1=C(Cl)C(Cl)=CC=C1 Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C#N)N=C1C1=C(Cl)C(Cl)=CC=C1 GOTVHDKAROPIFB-QGZVFWFLSA-N 0.000 description 1
- LNVVCASYHPGRIF-QGZVFWFLSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(=O)N2CC(O)(C(F)(F)F)C2)N=C1C1=CC=CC(Cl)=C1Cl Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(=O)N2CC(O)(C(F)(F)F)C2)N=C1C1=CC=CC(Cl)=C1Cl LNVVCASYHPGRIF-QGZVFWFLSA-N 0.000 description 1
- LMJIHOFFMRLUCF-UUSAFJCLSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(=O)N2CCCC2CO)N=C1C1=CC=CC(Cl)=C1Cl Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(=O)N2CCCC2CO)N=C1C1=CC=CC(Cl)=C1Cl LMJIHOFFMRLUCF-UUSAFJCLSA-N 0.000 description 1
- PRMJJQZRGAQZEY-LRTDYKAYSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(=O)NC2CCOC2)N=C1C1=CC=CC(Cl)=C1Cl Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(=O)NC2CCOC2)N=C1C1=CC=CC(Cl)=C1Cl PRMJJQZRGAQZEY-LRTDYKAYSA-N 0.000 description 1
- CMQQKKDSNCEUCC-OAHLLOKOSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(=O)NO)N=C1C1=CC=CC(Cl)=C1Cl Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(=O)NO)N=C1C1=CC=CC(Cl)=C1Cl CMQQKKDSNCEUCC-OAHLLOKOSA-N 0.000 description 1
- VUGFMSUCVDCMAY-QGZVFWFLSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(C)(C)O)N=C1SC1=C(Cl)C(Cl)=CC=C1 Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(C)(C)O)N=C1SC1=C(Cl)C(Cl)=CC=C1 VUGFMSUCVDCMAY-QGZVFWFLSA-N 0.000 description 1
- DPSMOOBWAGNLBR-FBMWCMRBSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(C)O)N=C1C1=CC=CC(Cl)=C1Cl Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(C)O)N=C1C1=CC=CC(Cl)=C1Cl DPSMOOBWAGNLBR-FBMWCMRBSA-N 0.000 description 1
- VUDUQPZQJQESMP-GOSISDBHSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C2=CC=NN2)N=C1SC1=C(Cl)C(Cl)=CC=C1 Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C2=CC=NN2)N=C1SC1=C(Cl)C(Cl)=CC=C1 VUDUQPZQJQESMP-GOSISDBHSA-N 0.000 description 1
- FPEYFTNMDRBCHB-QGZVFWFLSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(Cl)C(Cl)=CC=C1 Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(Cl)C(Cl)=CC=C1 FPEYFTNMDRBCHB-QGZVFWFLSA-N 0.000 description 1
- HSFLTVIZUPNIRZ-QGZVFWFLSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC(Cl)=CC(Cl)=C1Cl Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC(Cl)=CC(Cl)=C1Cl HSFLTVIZUPNIRZ-QGZVFWFLSA-N 0.000 description 1
- ZQWUIXSMGHDSPD-GOSISDBHSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=C(Cl)C(C#N)=C1Cl Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=C(Cl)C(C#N)=C1Cl ZQWUIXSMGHDSPD-GOSISDBHSA-N 0.000 description 1
- KIZSELRSFOSBEC-MRXNPFEDSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=C(Cl)C(Cl)=C1Cl Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=C(Cl)C(Cl)=C1Cl KIZSELRSFOSBEC-MRXNPFEDSA-N 0.000 description 1
- SUMGRXRSNDPCQP-QGZVFWFLSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC(F)=C1Cl Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC(F)=C1Cl SUMGRXRSNDPCQP-QGZVFWFLSA-N 0.000 description 1
- MXGZIVTXBANDKG-GOSISDBHSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC2=C1C(=O)NC2 Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC2=C1C(=O)NC2 MXGZIVTXBANDKG-GOSISDBHSA-N 0.000 description 1
- KXLYMPMOHFKSBT-QGZVFWFLSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC2=C1NC(=O)N2 Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC2=C1NC(=O)N2 KXLYMPMOHFKSBT-QGZVFWFLSA-N 0.000 description 1
- MDCRDPUESAQNFV-GOSISDBHSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC2=C1OCO2 Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC2=C1OCO2 MDCRDPUESAQNFV-GOSISDBHSA-N 0.000 description 1
- NMOHLICJZNBYCK-OAHLLOKOSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=CC=NC(Cl)=C1Cl Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=CC=NC(Cl)=C1Cl NMOHLICJZNBYCK-OAHLLOKOSA-N 0.000 description 1
- ZOJLZINVXNXHMO-OAHLLOKOSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=CC=NC(N)=C1Cl Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=CC=NC(N)=C1Cl ZOJLZINVXNXHMO-OAHLLOKOSA-N 0.000 description 1
- UDDBGZBVIYXXCM-OAHLLOKOSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(N)N=C1C1=C(Cl)C(Cl)=CC=C1 Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(N)N=C1C1=C(Cl)C(Cl)=CC=C1 UDDBGZBVIYXXCM-OAHLLOKOSA-N 0.000 description 1
- OCKHTKFJJBUUQO-OAHLLOKOSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(O)N=C1C1=C(Cl)C(Cl)=CC=C1 Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(O)N=C1C1=C(Cl)C(Cl)=CC=C1 OCKHTKFJJBUUQO-OAHLLOKOSA-N 0.000 description 1
- WEZZQEAMXIJPPU-MRXNPFEDSA-N *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=CC(F)=C1F Chemical compound *.CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=CC(F)=C1F WEZZQEAMXIJPPU-MRXNPFEDSA-N 0.000 description 1
- IKMOKPBFMQPKLP-JZKFLRDJSA-N *.CC1=NC(NC[C@@H]2CCNC[C@@H]2O)=CN=C1SC1=CC=CC(Cl)=C1Cl.S Chemical compound *.CC1=NC(NC[C@@H]2CCNC[C@@H]2O)=CN=C1SC1=CC=CC(Cl)=C1Cl.S IKMOKPBFMQPKLP-JZKFLRDJSA-N 0.000 description 1
- MQEDLFSASLXEJB-NIFFTEIASA-N *.CCC1(CC)CCC[C@H]1N.COC1=C(C2=NC(CO)=C(N)N=C2C)C=CN=C1 Chemical compound *.CCC1(CC)CCC[C@H]1N.COC1=C(C2=NC(CO)=C(N)N=C2C)C=CN=C1 MQEDLFSASLXEJB-NIFFTEIASA-N 0.000 description 1
- FZLHQKJWNIBIAZ-NIFFTEIASA-N *.CCC1(CC)CCC[C@H]1N.COC1=C(OC)C(C2=NC(CO)=C(N)N=C2C)=CC=C1 Chemical compound *.CCC1(CC)CCC[C@H]1N.COC1=C(OC)C(C2=NC(CO)=C(N)N=C2C)=CC=C1 FZLHQKJWNIBIAZ-NIFFTEIASA-N 0.000 description 1
- VTQRGWTUJOLJTD-NIFFTEIASA-N *.CCC1(CC)CCC[C@H]1N.N#CC1=NC(N)=CN=C1C1=CC=CC(Cl)=C1Cl Chemical compound *.CCC1(CC)CCC[C@H]1N.N#CC1=NC(N)=CN=C1C1=CC=CC(Cl)=C1Cl VTQRGWTUJOLJTD-NIFFTEIASA-N 0.000 description 1
- DHDUGOLFJVDKNK-GOSISDBHSA-N *.CCC1=NC=CC(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)=C1Cl Chemical compound *.CCC1=NC=CC(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)=C1Cl DHDUGOLFJVDKNK-GOSISDBHSA-N 0.000 description 1
- VBXKWSKEAFEKHU-MRXNPFEDSA-N *.COC(=O)C1=C(N2CCC3(CCC[C@H]3N)CC2)N=C(C)C(C2=CC=CC(Cl)=C2Cl)=N1 Chemical compound *.COC(=O)C1=C(N2CCC3(CCC[C@H]3N)CC2)N=C(C)C(C2=CC=CC(Cl)=C2Cl)=N1 VBXKWSKEAFEKHU-MRXNPFEDSA-N 0.000 description 1
- ZMMYQUTZFXIJDB-MRXNPFEDSA-N *.COC1=C(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)C=CC(Cl)=N1 Chemical compound *.COC1=C(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)C=CC(Cl)=N1 ZMMYQUTZFXIJDB-MRXNPFEDSA-N 0.000 description 1
- WPYRWXNNJLPIBA-QGZVFWFLSA-N *.COC1=C(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)C=CC=N1 Chemical compound *.COC1=C(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)C=CC=N1 WPYRWXNNJLPIBA-QGZVFWFLSA-N 0.000 description 1
- PIVSRJIVIYZGRN-MRXNPFEDSA-N *.COC1=CC=C(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)C(Cl)=N1 Chemical compound *.COC1=CC=C(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)C(Cl)=N1 PIVSRJIVIYZGRN-MRXNPFEDSA-N 0.000 description 1
- MXINIYXJCMUUQU-GOSISDBHSA-N *.COC1=CC=NC(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)=C1 Chemical compound *.COC1=CC=NC(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)=C1 MXINIYXJCMUUQU-GOSISDBHSA-N 0.000 description 1
- XKXCFTITRIMPBC-MRXNPFEDSA-N *.COC1=NC=CC(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)=C1Br Chemical compound *.COC1=NC=CC(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)=C1Br XKXCFTITRIMPBC-MRXNPFEDSA-N 0.000 description 1
- OOYJKHIGIBJBOW-CQSZACIVSA-N *.N#CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=C(Cl)C(N)=NC=C1 Chemical compound *.N#CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=C(Cl)C(N)=NC=C1 OOYJKHIGIBJBOW-CQSZACIVSA-N 0.000 description 1
- GKUNMUKLLYSGTH-MRXNPFEDSA-N *.N[C@@H]1CCCC12CCN(C1=CN=C(C3=CC=CC(Cl)=C3Cl)C(CO)=N1)CC2 Chemical compound *.N[C@@H]1CCCC12CCN(C1=CN=C(C3=CC=CC(Cl)=C3Cl)C(CO)=N1)CC2 GKUNMUKLLYSGTH-MRXNPFEDSA-N 0.000 description 1
- PUVKJBYZLZELGL-CQSZACIVSA-N *.N[C@@H]1CCCC12CCN(C1=CN=C(C3=CC=CC(Cl)=C3Cl)C(O)=N1)CC2 Chemical compound *.N[C@@H]1CCCC12CCN(C1=CN=C(C3=CC=CC(Cl)=C3Cl)C(O)=N1)CC2 PUVKJBYZLZELGL-CQSZACIVSA-N 0.000 description 1
- JQLMRIWMSXFSIE-CQSZACIVSA-N *.N[C@@H]1CCCC12CCN(C1=CN=C(SC3=CC=CC(Cl)=C3Cl)C(O)=N1)CC2 Chemical compound *.N[C@@H]1CCCC12CCN(C1=CN=C(SC3=CC=CC(Cl)=C3Cl)C(O)=N1)CC2 JQLMRIWMSXFSIE-CQSZACIVSA-N 0.000 description 1
- XFMWGJSUHOCFRC-NFWSUKNGSA-N *.S.[H][C@]12CCC[C@]([H])(C[C@H](NC3=CN=C(SC4=CC=CC(Cl)=C4Cl)C(C)=N3)C1)N2C Chemical compound *.S.[H][C@]12CCC[C@]([H])(C[C@H](NC3=CN=C(SC4=CC=CC(Cl)=C4Cl)C(C)=N3)C1)N2C XFMWGJSUHOCFRC-NFWSUKNGSA-N 0.000 description 1
- HAAZDNBCNADZOH-RTUWITSCSA-N *.[H][C@@]12CN(C3=CN=C(SC4=CC=CC(Cl)=C4Cl)C(C)=N3)C[C@]1([H])[C@H]2N Chemical compound *.[H][C@@]12CN(C3=CN=C(SC4=CC=CC(Cl)=C4Cl)C(C)=N3)C[C@]1([H])[C@H]2N HAAZDNBCNADZOH-RTUWITSCSA-N 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- IDUSJBBWEKNWAK-UHFFFAOYSA-N 3,4-dihydro-2h-1,2-benzothiazine Chemical compound C1=CC=C2SNCCC2=C1 IDUSJBBWEKNWAK-UHFFFAOYSA-N 0.000 description 1
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 1
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 description 1
- 108010017443 B 43 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- UVLZCAHQSIHMQZ-UHFFFAOYSA-N C(C1C2)C1C1C2C(C2)C22C1C2 Chemical compound C(C1C2)C1C1C2C(C2)C22C1C2 UVLZCAHQSIHMQZ-UHFFFAOYSA-N 0.000 description 1
- UVHXNPNPJZEDIT-PPHPATTJSA-N C.CC1=NC(N2CC[C@@H](CN)C2)=CN=C1SC1=C(Cl)C(N)=NC=C1 Chemical compound C.CC1=NC(N2CC[C@@H](CN)C2)=CN=C1SC1=C(Cl)C(N)=NC=C1 UVHXNPNPJZEDIT-PPHPATTJSA-N 0.000 description 1
- UVHXNPNPJZEDIT-HNCPQSOCSA-N C.CC1=NC(N2CC[C@H](CN)C2)=CN=C1SC1=C(Cl)C(N)=NC=C1 Chemical compound C.CC1=NC(N2CC[C@H](CN)C2)=CN=C1SC1=C(Cl)C(N)=NC=C1 UVHXNPNPJZEDIT-HNCPQSOCSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- KNAQFCUHIOOYBI-UHFFFAOYSA-N C=C(C1=CC=C(Cl)C=C1)C1=NC=C(N2CCC(C)(N)CC2)N=C1C Chemical compound C=C(C1=CC=C(Cl)C=C1)C1=NC=C(N2CCC(C)(N)CC2)N=C1C KNAQFCUHIOOYBI-UHFFFAOYSA-N 0.000 description 1
- JYNFQNCNCBNBIF-MUJYYYPQSA-N C=Cc1nc(N[C@@H](C[C@H]2CCC3)C[C@H]3N2C=C)cnc1Sc(cccc1Cl)c1Cl Chemical compound C=Cc1nc(N[C@@H](C[C@H]2CCC3)C[C@H]3N2C=C)cnc1Sc(cccc1Cl)c1Cl JYNFQNCNCBNBIF-MUJYYYPQSA-N 0.000 description 1
- BXAXYSIFBJNFKH-LHSJRXKWSA-N CC(=O)NC1=CC(C2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=CC=C1O Chemical compound CC(=O)NC1=CC(C2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=CC=C1O BXAXYSIFBJNFKH-LHSJRXKWSA-N 0.000 description 1
- DYFLQNOUUYXZHS-UHFFFAOYSA-O CC(CC1)(CCN1c(nc1C)c(CO)nc1Sc(ccnc1N)c1Cl)[NH3+] Chemical compound CC(CC1)(CCN1c(nc1C)c(CO)nc1Sc(ccnc1N)c1Cl)[NH3+] DYFLQNOUUYXZHS-UHFFFAOYSA-O 0.000 description 1
- XKRIGJBTBURJKH-UHFFFAOYSA-O CC(CC1)(CCN1c(nc1C)cnc1Sc1cccc(Cl)c1Cl)[NH3+] Chemical compound CC(CC1)(CCN1c(nc1C)cnc1Sc1cccc(Cl)c1Cl)[NH3+] XKRIGJBTBURJKH-UHFFFAOYSA-O 0.000 description 1
- LIWSWQAIOKBUBJ-UHFFFAOYSA-O CC(CC1)(CCN1c(nc1C=O)cnc1-c(cn1)cc(Cl)c1Cl)[NH3+] Chemical compound CC(CC1)(CCN1c(nc1C=O)cnc1-c(cn1)cc(Cl)c1Cl)[NH3+] LIWSWQAIOKBUBJ-UHFFFAOYSA-O 0.000 description 1
- YCLGWUGLNPJORK-UHFFFAOYSA-O CC(CC1)(CCN1c1c(CO)nc(-c(cccc2Cl)c2Cl)c(OC)n1)[NH3+] Chemical compound CC(CC1)(CCN1c1c(CO)nc(-c(cccc2Cl)c2Cl)c(OC)n1)[NH3+] YCLGWUGLNPJORK-UHFFFAOYSA-O 0.000 description 1
- GWFHRUVQCDVDRF-UHFFFAOYSA-N CC1(CN)CCN(C2=CN=C(C3=C(Cl)C(Cl)=CC=C3)C(C#N)=N2)CC1 Chemical compound CC1(CN)CCN(C2=CN=C(C3=C(Cl)C(Cl)=CC=C3)C(C#N)=N2)CC1 GWFHRUVQCDVDRF-UHFFFAOYSA-N 0.000 description 1
- TYAVRLYLYVMGQS-UHFFFAOYSA-N CC1(N)CCN(C2=C(CO)N=C(C3=C(Cl)C(Cl)=CC=C3)C(O)=N2)CC1 Chemical compound CC1(N)CCN(C2=C(CO)N=C(C3=C(Cl)C(Cl)=CC=C3)C(O)=N2)CC1 TYAVRLYLYVMGQS-UHFFFAOYSA-N 0.000 description 1
- WRSRUUSROLBGEY-UHFFFAOYSA-N CC1(N)CCN(C2=C(CO)N=C(SC3=CC=CC(Cl)=C3Cl)C(O)=N2)CC1 Chemical compound CC1(N)CCN(C2=C(CO)N=C(SC3=CC=CC(Cl)=C3Cl)C(O)=N2)CC1 WRSRUUSROLBGEY-UHFFFAOYSA-N 0.000 description 1
- AZKPIZRXUKNDJH-UHFFFAOYSA-N CC1(N)CCN(C2=CN=C(C3=CC=CC(Cl)=C3Cl)C(C#N)=N2)CC1 Chemical compound CC1(N)CCN(C2=CN=C(C3=CC=CC(Cl)=C3Cl)C(C#N)=N2)CC1 AZKPIZRXUKNDJH-UHFFFAOYSA-N 0.000 description 1
- PDJDOYAPTVDFOX-UHFFFAOYSA-N CC1(N)CCN(C2=CN=C(C3=CC=CC(Cl)=C3Cl)C(O)=N2)CC1 Chemical compound CC1(N)CCN(C2=CN=C(C3=CC=CC(Cl)=C3Cl)C(O)=N2)CC1 PDJDOYAPTVDFOX-UHFFFAOYSA-N 0.000 description 1
- QVONHVCDZAAHAB-UHFFFAOYSA-N CC1(N)CCN(C2=CN=C(SC3=CC=CC(Cl)=C3Cl)C(O)=N2)CC1 Chemical compound CC1(N)CCN(C2=CN=C(SC3=CC=CC(Cl)=C3Cl)C(O)=N2)CC1 QVONHVCDZAAHAB-UHFFFAOYSA-N 0.000 description 1
- FXLZFLKWGZDCNF-KSFYIVLOSA-N CC1=C(C2=C(C)N=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)C(CO)=N2)C=C2C(=C1)C=NN2C Chemical compound CC1=C(C2=C(C)N=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)C(CO)=N2)C=C2C(=C1)C=NN2C FXLZFLKWGZDCNF-KSFYIVLOSA-N 0.000 description 1
- DQSXIQOGDNOMNH-YCRPNKLZSA-N CC1=C(C2=C(C)N=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)C(CO)=N2)C=C2NN=CC2=C1 Chemical compound CC1=C(C2=C(C)N=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)C(CO)=N2)C=C2NN=CC2=C1 DQSXIQOGDNOMNH-YCRPNKLZSA-N 0.000 description 1
- RGQLIFRYUQCGLI-NIFFTEIASA-N CC1=C(C2=C(Cl)C(Cl)=C(N)C=C2)N=C(CO)C(N)=N1.CCC1(CC)CCC[C@H]1N Chemical compound CC1=C(C2=C(Cl)C(Cl)=C(N)C=C2)N=C(CO)C(N)=N1.CCC1(CC)CCC[C@H]1N RGQLIFRYUQCGLI-NIFFTEIASA-N 0.000 description 1
- CPQIRUZFLAGNNY-NIFFTEIASA-N CC1=C(C2=C(Cl)C(Cl)=C(N)N=C2)N=C(CO)C(N)=N1.CCC1(CC)CCC[C@H]1N Chemical compound CC1=C(C2=C(Cl)C(Cl)=C(N)N=C2)N=C(CO)C(N)=N1.CCC1(CC)CCC[C@H]1N CPQIRUZFLAGNNY-NIFFTEIASA-N 0.000 description 1
- JKQKLTMSNMMLDZ-NIFFTEIASA-N CC1=C(C2=C(Cl)C(Cl)=CC(C(N)=O)=C2)N=C(CO)C(N)=N1.CCC1(CC)CCC[C@H]1N Chemical compound CC1=C(C2=C(Cl)C(Cl)=CC(C(N)=O)=C2)N=C(CO)C(N)=N1.CCC1(CC)CCC[C@H]1N JKQKLTMSNMMLDZ-NIFFTEIASA-N 0.000 description 1
- DBNQYJFXJAMWOG-NIFFTEIASA-N CC1=C(C2=C(Cl)C(Cl)=CC(N)=C2)N=C(CO)C(N)=N1.CCC1(CC)CCC[C@H]1N Chemical compound CC1=C(C2=C(Cl)C(Cl)=CC(N)=C2)N=C(CO)C(N)=N1.CCC1(CC)CCC[C@H]1N DBNQYJFXJAMWOG-NIFFTEIASA-N 0.000 description 1
- WRRLPCOGMGSJOW-YEJXKQKISA-N CC1=C(C2=C(Cl)C=C3CC(=O)NC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 Chemical compound CC1=C(C2=C(Cl)C=C3CC(=O)NC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 WRRLPCOGMGSJOW-YEJXKQKISA-N 0.000 description 1
- AKBHQIILKOQRRW-RNODOKPDSA-N CC1=C(C2=CC(Cl)=C3C=NNC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 Chemical compound CC1=C(C2=CC(Cl)=C3C=NNC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 AKBHQIILKOQRRW-RNODOKPDSA-N 0.000 description 1
- HDXCHNJRPFORAM-LHSJRXKWSA-N CC1=C(C2=CC3=C(C=CC=C3Cl)N2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 Chemical compound CC1=C(C2=CC3=C(C=CC=C3Cl)N2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 HDXCHNJRPFORAM-LHSJRXKWSA-N 0.000 description 1
- XPTNYPPJYJBDNG-JSTCDSMHSA-N CC1=C(C2=CC3=CC=NN3C=C2)N=C(CO)C(N)=N1.CCC1(CC)CO[C@@H](C)[C@H]1N Chemical compound CC1=C(C2=CC3=CC=NN3C=C2)N=C(CO)C(N)=N1.CCC1(CC)CO[C@@H](C)[C@H]1N XPTNYPPJYJBDNG-JSTCDSMHSA-N 0.000 description 1
- WLDPTLCAYSEFPP-JSTCDSMHSA-N CC1=C(C2=CC3=NN=CN3C=C2)N=C(CO)C(N)=N1.CCC1(CC)CO[C@@H](C)[C@H]1N Chemical compound CC1=C(C2=CC3=NN=CN3C=C2)N=C(CO)C(N)=N1.CCC1(CC)CO[C@@H](C)[C@H]1N WLDPTLCAYSEFPP-JSTCDSMHSA-N 0.000 description 1
- USMIJUGTKIPIMF-VBKZILBWSA-N CC1=C(C2=CC=C(O)C(C)=C2Cl)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 Chemical compound CC1=C(C2=CC=C(O)C(C)=C2Cl)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 USMIJUGTKIPIMF-VBKZILBWSA-N 0.000 description 1
- DGXUUBJIJMKYNM-VBKZILBWSA-N CC1=C(C2=CC=C3C=NNC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 Chemical compound CC1=C(C2=CC=C3C=NNC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 DGXUUBJIJMKYNM-VBKZILBWSA-N 0.000 description 1
- PTUDGDLQUOPVIU-AAKYCSGMSA-N CC1=C(C2=CC=C3C=NNC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1.S.S Chemical compound CC1=C(C2=CC=C3C=NNC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1.S.S PTUDGDLQUOPVIU-AAKYCSGMSA-N 0.000 description 1
- QNZAOTKWDDKKQE-VBKZILBWSA-N CC1=C(C2=CC=C3C=NOC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 Chemical compound CC1=C(C2=CC=C3C=NOC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 QNZAOTKWDDKKQE-VBKZILBWSA-N 0.000 description 1
- LHBPLOMJMDAINX-LHSJRXKWSA-N CC1=C(C2=CC=C3N=CC=NC3=C2Cl)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 Chemical compound CC1=C(C2=CC=C3N=CC=NC3=C2Cl)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 LHBPLOMJMDAINX-LHSJRXKWSA-N 0.000 description 1
- TXNBFORBOSRLNL-VBKZILBWSA-N CC1=C(C2=CC=C3N=COC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 Chemical compound CC1=C(C2=CC=C3N=COC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 TXNBFORBOSRLNL-VBKZILBWSA-N 0.000 description 1
- UUPXMTCXNMYJLG-VBKZILBWSA-N CC1=C(C2=CC=C3N=NN(C)C3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 Chemical compound CC1=C(C2=CC=C3N=NN(C)C3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 UUPXMTCXNMYJLG-VBKZILBWSA-N 0.000 description 1
- YOEYMPPTWJDJQR-ORAYPTAESA-N CC1=C(C2=CC=C3N=NNC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 Chemical compound CC1=C(C2=CC=C3N=NNC3=C2)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 YOEYMPPTWJDJQR-ORAYPTAESA-N 0.000 description 1
- DHZJPSDSQOJKJH-KSFYIVLOSA-N CC1=C(C2=CC=CC(OC(C)C)=C2Cl)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 Chemical compound CC1=C(C2=CC=CC(OC(C)C)=C2Cl)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 DHZJPSDSQOJKJH-KSFYIVLOSA-N 0.000 description 1
- DBPMHJXODKLJBG-SJKOYZFVSA-N CC1=C(C2=CC=NC(Cl)=C2Cl)N=C(CO)C(N2CCC3(CC2)CO[C@H](C)[C@H]3N)=N1 Chemical compound CC1=C(C2=CC=NC(Cl)=C2Cl)N=C(CO)C(N2CCC3(CC2)CO[C@H](C)[C@H]3N)=N1 DBPMHJXODKLJBG-SJKOYZFVSA-N 0.000 description 1
- WUAJELRVBGNNSK-OMOCHNIRSA-N CC1=C(SC2=C(Cl)C(Cl)=CC=C2)N=C(C(O)CO)C(N2CCC3(CCC[C@H]3N)CC2)=N1 Chemical compound CC1=C(SC2=C(Cl)C(Cl)=CC=C2)N=C(C(O)CO)C(N2CCC3(CCC[C@H]3N)CC2)=N1 WUAJELRVBGNNSK-OMOCHNIRSA-N 0.000 description 1
- ZUHLAYZOACYLRW-MEDUHNTESA-N CC1=C(SC2=CC(N)=NC(Cl)=C2Cl)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 Chemical compound CC1=C(SC2=CC(N)=NC(Cl)=C2Cl)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 ZUHLAYZOACYLRW-MEDUHNTESA-N 0.000 description 1
- WCNLIHXBGBWLRG-CXAGYDPISA-N CC1=C(SC2=CC=CN=C2C(F)(F)F)N=C(CO)C(N2CCC3(CC[C@@H](C)[C@H]3N)CC2)=N1 Chemical compound CC1=C(SC2=CC=CN=C2C(F)(F)F)N=C(CO)C(N2CCC3(CC[C@@H](C)[C@H]3N)CC2)=N1 WCNLIHXBGBWLRG-CXAGYDPISA-N 0.000 description 1
- VNDYLIAPVPCXJH-HNAYVOBHSA-N CC1=C(SC2=CC=NC(NC(C)C)=C2Cl)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 Chemical compound CC1=C(SC2=CC=NC(NC(C)C)=C2Cl)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 VNDYLIAPVPCXJH-HNAYVOBHSA-N 0.000 description 1
- GBQCYQBBUCAXLG-MGPUTAFESA-N CC1=C(SC2=CC=NC(NC3CCC3)=C2Cl)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 Chemical compound CC1=C(SC2=CC=NC(NC3CCC3)=C2Cl)N=C(CO)C(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=N1 GBQCYQBBUCAXLG-MGPUTAFESA-N 0.000 description 1
- PXHYDJXXCIHHLN-GOSISDBHSA-N CC1=CC(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)=CC=N1 Chemical compound CC1=CC(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)=CC=N1 PXHYDJXXCIHHLN-GOSISDBHSA-N 0.000 description 1
- VOPPSFPEXKTTQQ-QGZVFWFLSA-N CC1=CC=C(SC2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)C(Cl)=C1Cl Chemical compound CC1=CC=C(SC2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)C(Cl)=C1Cl VOPPSFPEXKTTQQ-QGZVFWFLSA-N 0.000 description 1
- OZBDPNFSXHHRBH-UHFFFAOYSA-N CC1=NC(C(=O)N2CCC(C)(N)CC2)=CN=C1C1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(C(=O)N2CCC(C)(N)CC2)=CN=C1C1=CC=CC(Cl)=C1Cl OZBDPNFSXHHRBH-UHFFFAOYSA-N 0.000 description 1
- VJJYIKMTSCYRRJ-UHFFFAOYSA-N CC1=NC(C(=O)N2CCC(C)(N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(C(=O)N2CCC(C)(N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl VJJYIKMTSCYRRJ-UHFFFAOYSA-N 0.000 description 1
- LJVKFLNXZNLYAW-UHFFFAOYSA-N CC1=NC(C2(N)CC2)=CN=C1SC1=C(Cl)C(Cl)=CC=C1 Chemical compound CC1=NC(C2(N)CC2)=CN=C1SC1=C(Cl)C(Cl)=CC=C1 LJVKFLNXZNLYAW-UHFFFAOYSA-N 0.000 description 1
- NZLYPDHGIBBTKK-UHFFFAOYSA-N CC1=NC(C2CCC(C)(C[H]N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(C2CCC(C)(C[H]N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl NZLYPDHGIBBTKK-UHFFFAOYSA-N 0.000 description 1
- QIFGKBYHVQJKIW-UHFFFAOYSA-N CC1=NC(C2CCC(C)(N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(C2CCC(C)(N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl QIFGKBYHVQJKIW-UHFFFAOYSA-N 0.000 description 1
- PSHLPWNSXYGVCR-UHFFFAOYSA-N CC1=NC(C2CCC(C)(N)CC2)=CN=C1SC1=CC=NC(Cl)=C1Cl Chemical compound CC1=NC(C2CCC(C)(N)CC2)=CN=C1SC1=CC=NC(Cl)=C1Cl PSHLPWNSXYGVCR-UHFFFAOYSA-N 0.000 description 1
- DVLCJVJHNVAZJV-UHFFFAOYSA-N CC1=NC(C2CCC(O)C2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(C2CCC(O)C2)=CN=C1SC1=CC=CC(Cl)=C1Cl DVLCJVJHNVAZJV-UHFFFAOYSA-N 0.000 description 1
- CZOINGFBQISSAL-UHFFFAOYSA-N CC1=NC(C2CCC(O)C2)=CN=C1SC1=CC=NC(Cl)=C1Cl Chemical compound CC1=NC(C2CCC(O)C2)=CN=C1SC1=CC=NC(Cl)=C1Cl CZOINGFBQISSAL-UHFFFAOYSA-N 0.000 description 1
- GGGCQSSOGBLWBD-UHFFFAOYSA-N CC1=NC(C2CCCC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(C2CCCC2)=CN=C1SC1=CC=CC(Cl)=C1Cl GGGCQSSOGBLWBD-UHFFFAOYSA-N 0.000 description 1
- DKRSYXHFRHSRAT-UHFFFAOYSA-N CC1=NC(C2CCCC2)=CN=C1SC1=CC=NC(Cl)=C1Cl Chemical compound CC1=NC(C2CCCC2)=CN=C1SC1=CC=NC(Cl)=C1Cl DKRSYXHFRHSRAT-UHFFFAOYSA-N 0.000 description 1
- IACOMMPAMWMZJO-UHFFFAOYSA-N CC1=NC(C2CCCCC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(C2CCCCC2)=CN=C1SC1=CC=CC(Cl)=C1Cl IACOMMPAMWMZJO-UHFFFAOYSA-N 0.000 description 1
- ITDBIOUCRQAGEB-UHFFFAOYSA-N CC1=NC(C2CCCCC2)=CN=C1SC1=CC=NC(Cl)=C1Cl Chemical compound CC1=NC(C2CCCCC2)=CN=C1SC1=CC=NC(Cl)=C1Cl ITDBIOUCRQAGEB-UHFFFAOYSA-N 0.000 description 1
- SXITYWUGJYRYIJ-UHFFFAOYSA-N CC1=NC(CN2CCC(C)(N)CC2)=CN=C1C1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(CN2CCC(C)(N)CC2)=CN=C1C1=CC=CC(Cl)=C1Cl SXITYWUGJYRYIJ-UHFFFAOYSA-N 0.000 description 1
- MNXFMDLOCGJBRO-UHFFFAOYSA-N CC1=NC(CN2CCC(C)(N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(CN2CCC(C)(N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl MNXFMDLOCGJBRO-UHFFFAOYSA-N 0.000 description 1
- OQPVJTDWSRNBCA-NIFFTEIASA-N CC1=NC(N)=C(CO)N=C1C1=C(Cl)C(Cl)=C(C)C=C1.CCC1(CC)CCC[C@H]1N Chemical compound CC1=NC(N)=C(CO)N=C1C1=C(Cl)C(Cl)=C(C)C=C1.CCC1(CC)CCC[C@H]1N OQPVJTDWSRNBCA-NIFFTEIASA-N 0.000 description 1
- OVGGCGBZCKWTKW-WFVMVMIPSA-N CC1=NC(N)=C(CO)N=C1C1=C(Cl)C(Cl)=CC=C1.CCC1(CC)CO[C@@H](C)[C@@H]1N Chemical compound CC1=NC(N)=C(CO)N=C1C1=C(Cl)C(Cl)=CC=C1.CCC1(CC)CO[C@@H](C)[C@@H]1N OVGGCGBZCKWTKW-WFVMVMIPSA-N 0.000 description 1
- UCKAQFMTFZMLQU-NIFFTEIASA-N CC1=NC(N)=C(CO)N=C1C1=C(Cl)C(O)=CC=C1.CCC1(CC)CCC[C@H]1N Chemical compound CC1=NC(N)=C(CO)N=C1C1=C(Cl)C(O)=CC=C1.CCC1(CC)CCC[C@H]1N UCKAQFMTFZMLQU-NIFFTEIASA-N 0.000 description 1
- NNYWLVLZWOSLTF-NIFFTEIASA-N CC1=NC(N)=C(CO)N=C1C1=C2C=CCC2=NC=C1.CCC1(CC)CCC[C@H]1N Chemical compound CC1=NC(N)=C(CO)N=C1C1=C2C=CCC2=NC=C1.CCC1(CC)CCC[C@H]1N NNYWLVLZWOSLTF-NIFFTEIASA-N 0.000 description 1
- DAZYXTFBXLEWIN-UHFFFAOYSA-N CC1=NC(N)=C(CO)N=C1C1=CC(Cl)=C2C=CNC2=C1.CCC(C)(N)CC Chemical compound CC1=NC(N)=C(CO)N=C1C1=CC(Cl)=C2C=CNC2=C1.CCC(C)(N)CC DAZYXTFBXLEWIN-UHFFFAOYSA-N 0.000 description 1
- JHVMNXGEIJTNJP-NIFFTEIASA-N CC1=NC(N)=C(CO)N=C1C1=CC2=C(C=C1)C=CN2C.CCC1(CC)CCC[C@H]1N Chemical compound CC1=NC(N)=C(CO)N=C1C1=CC2=C(C=C1)C=CN2C.CCC1(CC)CCC[C@H]1N JHVMNXGEIJTNJP-NIFFTEIASA-N 0.000 description 1
- LHGAFIWTIDBRFN-NIFFTEIASA-N CC1=NC(N)=C(CO)N=C1C1=CC2=C(C=C1)C=NN2.CCC1(CC)CCC[C@H]1N Chemical compound CC1=NC(N)=C(CO)N=C1C1=CC2=C(C=C1)C=NN2.CCC1(CC)CCC[C@H]1N LHGAFIWTIDBRFN-NIFFTEIASA-N 0.000 description 1
- CDCFFVOHWFADPQ-NIFFTEIASA-N CC1=NC(N)=C(CO)N=C1C1=CC2=C(C=C1)CCN2.CCC1(CC)CCC[C@H]1N Chemical compound CC1=NC(N)=C(CO)N=C1C1=CC2=C(C=C1)CCN2.CCC1(CC)CCC[C@H]1N CDCFFVOHWFADPQ-NIFFTEIASA-N 0.000 description 1
- VCZRUCNPBDWKHF-NIFFTEIASA-N CC1=NC(N)=C(CO)N=C1C1=CC2=C(C=C1)CNC2=O.CCC1(CC)CCC[C@H]1N Chemical compound CC1=NC(N)=C(CO)N=C1C1=CC2=C(C=C1)CNC2=O.CCC1(CC)CCC[C@H]1N VCZRUCNPBDWKHF-NIFFTEIASA-N 0.000 description 1
- QNEXOPXVWUHVMD-NIFFTEIASA-N CC1=NC(N)=C(CO)N=C1C1=CC2=C(C=CN2)N=C1.CCC1(CC)CCC[C@H]1N Chemical compound CC1=NC(N)=C(CO)N=C1C1=CC2=C(C=CN2)N=C1.CCC1(CC)CCC[C@H]1N QNEXOPXVWUHVMD-NIFFTEIASA-N 0.000 description 1
- KDRDXHDGMNRTQK-JSTCDSMHSA-N CC1=NC(N)=C(CO)N=C1C1=CC2=CC=CC=C2N1C.CCC1(CC)CO[C@@H](C)[C@H]1N Chemical compound CC1=NC(N)=C(CO)N=C1C1=CC2=CC=CC=C2N1C.CCC1(CC)CO[C@@H](C)[C@H]1N KDRDXHDGMNRTQK-JSTCDSMHSA-N 0.000 description 1
- GWLGRRLQCMXLRM-NIFFTEIASA-N CC1=NC(N)=C(CO)N=C1C1=CC=C2NC(=O)CC2=C1.CCC1(CC)CCC[C@H]1N Chemical compound CC1=NC(N)=C(CO)N=C1C1=CC=C2NC(=O)CC2=C1.CCC1(CC)CCC[C@H]1N GWLGRRLQCMXLRM-NIFFTEIASA-N 0.000 description 1
- OVGGCGBZCKWTKW-JSTCDSMHSA-N CC1=NC(N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl.CCC1(CC)CO[C@@H](C)[C@H]1N Chemical compound CC1=NC(N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl.CCC1(CC)CO[C@@H](C)[C@H]1N OVGGCGBZCKWTKW-JSTCDSMHSA-N 0.000 description 1
- JDSJHPULRFHFAN-NIFFTEIASA-N CC1=NC(N)=C(CO)N=C1C1=CC=NC([H]N)=C1Cl.CCC1(CC)CCC[C@H]1N Chemical compound CC1=NC(N)=C(CO)N=C1C1=CC=NC([H]N)=C1Cl.CCC1(CC)CCC[C@H]1N JDSJHPULRFHFAN-NIFFTEIASA-N 0.000 description 1
- ZROKOOUJGCNBFE-NIFFTEIASA-N CC1=NC(N)=C(CO)N=C1SC1=CC=CC(C#N)=C1Cl.CCC1(CC)CCC[C@H]1N Chemical compound CC1=NC(N)=C(CO)N=C1SC1=CC=CC(C#N)=C1Cl.CCC1(CC)CCC[C@H]1N ZROKOOUJGCNBFE-NIFFTEIASA-N 0.000 description 1
- JTSLLNBYWCVHDB-NIFFTEIASA-N CC1=NC(N)=C(CO)N=C1SC1=CC=CC(Cl)=C1C#N.CCC1(CC)CCC[C@H]1N Chemical compound CC1=NC(N)=C(CO)N=C1SC1=CC=CC(Cl)=C1C#N.CCC1(CC)CCC[C@H]1N JTSLLNBYWCVHDB-NIFFTEIASA-N 0.000 description 1
- MSRURKMFUCXRAP-UHFFFAOYSA-N CC1=NC(N)=C(CO)N=C1SC1=CC=CC(Cl)=C1Cl.CCC(C)(N)CC Chemical compound CC1=NC(N)=C(CO)N=C1SC1=CC=CC(Cl)=C1Cl.CCC(C)(N)CC MSRURKMFUCXRAP-UHFFFAOYSA-N 0.000 description 1
- XTFGMWSZFBDECK-UHFFFAOYSA-N CC1=NC(N)=CN=C1C1=C(Cl)C(Cl)=NC=C1.CCC(C)(N)CC Chemical compound CC1=NC(N)=CN=C1C1=C(Cl)C(Cl)=NC=C1.CCC(C)(N)CC XTFGMWSZFBDECK-UHFFFAOYSA-N 0.000 description 1
- DOGHIRGHASORKJ-UHFFFAOYSA-N CC1=NC(N)=CN=C1C1=C(Cl)C=CC=C1.CCC(C)(N)CC Chemical compound CC1=NC(N)=CN=C1C1=C(Cl)C=CC=C1.CCC(C)(N)CC DOGHIRGHASORKJ-UHFFFAOYSA-N 0.000 description 1
- CPIAHFYEBYDSOY-UHFFFAOYSA-N CC1=NC(N)=CN=C1C1=CC(Cl)=C(Cl)N=C1.CCC(C)(N)CC Chemical compound CC1=NC(N)=CN=C1C1=CC(Cl)=C(Cl)N=C1.CCC(C)(N)CC CPIAHFYEBYDSOY-UHFFFAOYSA-N 0.000 description 1
- NCARPLPQXCUNAM-UHFFFAOYSA-N CC1=NC(N)=CN=C1C1=CC(Cl)=C2C=CNC2=C1.CCC(C)(N)CC Chemical compound CC1=NC(N)=CN=C1C1=CC(Cl)=C2C=CNC2=C1.CCC(C)(N)CC NCARPLPQXCUNAM-UHFFFAOYSA-N 0.000 description 1
- QLEVHNRWKCIUOS-UHFFFAOYSA-N CC1=NC(N)=CN=C1C1=CC=C(Cl)N=C1.CCC(C)(N)CC Chemical compound CC1=NC(N)=CN=C1C1=CC=C(Cl)N=C1.CCC(C)(N)CC QLEVHNRWKCIUOS-UHFFFAOYSA-N 0.000 description 1
- LVWRGWDOIOLOEN-UHFFFAOYSA-N CC1=NC(N)=CN=C1S(=O)(=O)C1=C(Cl)C(Cl)=CC=C1.CCC(C)(N)CC Chemical compound CC1=NC(N)=CN=C1S(=O)(=O)C1=C(Cl)C(Cl)=CC=C1.CCC(C)(N)CC LVWRGWDOIOLOEN-UHFFFAOYSA-N 0.000 description 1
- LLDDFCWLTLEFFV-UHFFFAOYSA-N CC1=NC(N)=CN=C1SC1=C(Cl)C(Cl)=CC=C1.CCC(C)(N)CC Chemical compound CC1=NC(N)=CN=C1SC1=C(Cl)C(Cl)=CC=C1.CCC(C)(N)CC LLDDFCWLTLEFFV-UHFFFAOYSA-N 0.000 description 1
- NLUZTZIIDCEFBV-UHFFFAOYSA-N CC1=NC(N)=CN=C1SC1=CC=CC(Cl)=C1Cl.CCC1(CC)CC(N)C1 Chemical compound CC1=NC(N)=CN=C1SC1=CC=CC(Cl)=C1Cl.CCC1(CC)CC(N)C1 NLUZTZIIDCEFBV-UHFFFAOYSA-N 0.000 description 1
- IZNWVHVTRHRGFL-UHFFFAOYSA-N CC1=NC(N2C3CCC2CC(N)C3)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2C3CCC2CC(N)C3)=CN=C1SC1=CC=CC(Cl)=C1Cl IZNWVHVTRHRGFL-UHFFFAOYSA-N 0.000 description 1
- IRVCRLBLFBOVDM-UHFFFAOYSA-N CC1=NC(N2CC(C)(N)C2)=CN=C1C1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CC(C)(N)C2)=CN=C1C1=CC=CC(Cl)=C1Cl IRVCRLBLFBOVDM-UHFFFAOYSA-N 0.000 description 1
- CFCSVSSANZCVKR-UHFFFAOYSA-N CC1=NC(N2CC(C)(N)C2)=CN=C1CC1=CC(Cl)=C(Cl)C=C1 Chemical compound CC1=NC(N2CC(C)(N)C2)=CN=C1CC1=CC(Cl)=C(Cl)C=C1 CFCSVSSANZCVKR-UHFFFAOYSA-N 0.000 description 1
- ZRVHTZLSMFGRPR-UHFFFAOYSA-N CC1=NC(N2CC(O)(C3CCCCN3)C2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CC(O)(C3CCCCN3)C2)=CN=C1SC1=CC=CC(Cl)=C1Cl ZRVHTZLSMFGRPR-UHFFFAOYSA-N 0.000 description 1
- XFCLAYVGWVODHT-UHFFFAOYSA-N CC1=NC(N2CC3(CC(N)C3)C2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CC3(CC(N)C3)C2)=CN=C1SC1=CC=CC(Cl)=C1Cl XFCLAYVGWVODHT-UHFFFAOYSA-N 0.000 description 1
- KMNZMNDNOXHZFL-UHFFFAOYSA-N CC1=NC(N2CCC(C)(C)CC2)=CN=C1CS(=O)(=O)C1=CC=CC=C1 Chemical compound CC1=NC(N2CCC(C)(C)CC2)=CN=C1CS(=O)(=O)C1=CC=CC=C1 KMNZMNDNOXHZFL-UHFFFAOYSA-N 0.000 description 1
- XOAIUYCKIIFNRB-UHFFFAOYSA-N CC1=NC(N2CCC(C)(CN)CC2)=CN=C1C1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC(C)(CN)CC2)=CN=C1C1=CC=CC(Cl)=C1Cl XOAIUYCKIIFNRB-UHFFFAOYSA-N 0.000 description 1
- MQXLMLJVCLMSGP-UHFFFAOYSA-N CC1=NC(N2CCC(C)(CN)CC2)=CN=C1SC1=CC=NC(N)=C1Cl Chemical compound CC1=NC(N2CCC(C)(CN)CC2)=CN=C1SC1=CC=NC(N)=C1Cl MQXLMLJVCLMSGP-UHFFFAOYSA-N 0.000 description 1
- XUPPMIBOEGSHDI-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(C(O)(F)F)N=C1SC1=C(Cl)C(Cl)=CC=C1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(C(O)(F)F)N=C1SC1=C(Cl)C(Cl)=CC=C1 XUPPMIBOEGSHDI-UHFFFAOYSA-N 0.000 description 1
- XSYYEDHJPBHKJI-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=C(Br)C(Cl)=NC=C1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=C(Br)C(Cl)=NC=C1 XSYYEDHJPBHKJI-UHFFFAOYSA-N 0.000 description 1
- VCJRKDFGJNJGGD-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=C(Br)C(O)=NC=C1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=C(Br)C(O)=NC=C1 VCJRKDFGJNJGGD-UHFFFAOYSA-N 0.000 description 1
- RQEHECXCGZBXKH-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=C(Cl)C(C#N)=C(Cl)C=C1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=C(Cl)C(C#N)=C(Cl)C=C1 RQEHECXCGZBXKH-UHFFFAOYSA-N 0.000 description 1
- UMDIPOISWYLRIC-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=C(Cl)C(Cl)=CC=C1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=C(Cl)C(Cl)=CC=C1 UMDIPOISWYLRIC-UHFFFAOYSA-N 0.000 description 1
- BWXKLAKBXYPRBK-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=C(Cl)C(Cl)=NC=C1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=C(Cl)C(Cl)=NC=C1 BWXKLAKBXYPRBK-UHFFFAOYSA-N 0.000 description 1
- ZHIXUGDOTOOFAO-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=C2C=CNC2=NC=C1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=C2C=CNC2=NC=C1 ZHIXUGDOTOOFAO-UHFFFAOYSA-N 0.000 description 1
- SSENBNYRYLGLFY-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC(C2=CC=NN2C)=CC=C1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC(C2=CC=NN2C)=CC=C1 SSENBNYRYLGLFY-UHFFFAOYSA-N 0.000 description 1
- RITTYISCDKRQIQ-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC2=C(C=C1)NC=C2 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC2=C(C=C1)NC=C2 RITTYISCDKRQIQ-UHFFFAOYSA-N 0.000 description 1
- GQCAIUPDUMTGSS-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC=C(Cl)C(Cl)=C1Cl Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC=C(Cl)C(Cl)=C1Cl GQCAIUPDUMTGSS-UHFFFAOYSA-N 0.000 description 1
- NYAGSLORDZKVQQ-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC=C2C=CNC2=C1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC=C2C=CNC2=C1 NYAGSLORDZKVQQ-UHFFFAOYSA-N 0.000 description 1
- MSKNFVKYVOXRTD-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC=CC(Br)=C1Br Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC=CC(Br)=C1Br MSKNFVKYVOXRTD-UHFFFAOYSA-N 0.000 description 1
- GFLOQVHMTKOCCC-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC=CC(Cl)=C1O Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC=CC(Cl)=C1O GFLOQVHMTKOCCC-UHFFFAOYSA-N 0.000 description 1
- YLTKFTBSSXXGID-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC=CC2=C1NN=C2 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC=CC2=C1NN=C2 YLTKFTBSSXXGID-UHFFFAOYSA-N 0.000 description 1
- CGTJVEPXNJEAAI-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC=NC(Br)=C1Cl Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC=NC(Br)=C1Cl CGTJVEPXNJEAAI-UHFFFAOYSA-N 0.000 description 1
- NKTQKHQSNJNENV-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CNC2=CC=CC=C21 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CNC2=CC=CC=C21 NKTQKHQSNJNENV-UHFFFAOYSA-N 0.000 description 1
- KRGZTJSQCTXMSO-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1SC1=CC=NC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1SC1=CC=NC(Cl)=C1Cl KRGZTJSQCTXMSO-UHFFFAOYSA-N 0.000 description 1
- DYFLQNOUUYXZHS-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1SC1=CC=NC(N)=C1Cl Chemical compound CC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1SC1=CC=NC(N)=C1Cl DYFLQNOUUYXZHS-UHFFFAOYSA-N 0.000 description 1
- NUQVWBOARBPVJJ-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=CN=C1C1=C(C)N=C(Cl)C=N1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=CN=C1C1=C(C)N=C(Cl)C=N1 NUQVWBOARBPVJJ-UHFFFAOYSA-N 0.000 description 1
- SHYZPGNLNHVLKU-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=CN=C1C1=C(F)C(F)=CC=C1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=CN=C1C1=C(F)C(F)=CC=C1 SHYZPGNLNHVLKU-UHFFFAOYSA-N 0.000 description 1
- DGQBUAZBRGBPRJ-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=CN=C1C1=C(F)C=CC=C1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=CN=C1C1=C(F)C=CC=C1 DGQBUAZBRGBPRJ-UHFFFAOYSA-N 0.000 description 1
- ZBEHXHCEXSFEMM-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=CN=C1C1=CC(Cl)=C(Cl)C=C1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=CN=C1C1=CC(Cl)=C(Cl)C=C1 ZBEHXHCEXSFEMM-UHFFFAOYSA-N 0.000 description 1
- OHRCVLHOGAGCCN-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=CN=C1C1=CC=C(Cl)C=C1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=CN=C1C1=CC=C(Cl)C=C1 OHRCVLHOGAGCCN-UHFFFAOYSA-N 0.000 description 1
- ALCKCSGHEKRCOY-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=CN=C1C1=CC=NC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC(C)(N)CC2)=CN=C1C1=CC=NC(Cl)=C1Cl ALCKCSGHEKRCOY-UHFFFAOYSA-N 0.000 description 1
- OYCXYPPDNXJSES-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=CN=C1CC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC(C)(N)CC2)=CN=C1CC1=CC=CC(Cl)=C1Cl OYCXYPPDNXJSES-UHFFFAOYSA-N 0.000 description 1
- XKRIGJBTBURJKH-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=CN=C1SC1=C(Cl)C(Cl)=CC=C1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=CN=C1SC1=C(Cl)C(Cl)=CC=C1 XKRIGJBTBURJKH-UHFFFAOYSA-N 0.000 description 1
- SSWBRTPWPRFSDH-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=CN=C1SC1=C(Cl)C(N)=NC=C1 Chemical compound CC1=NC(N2CCC(C)(N)CC2)=CN=C1SC1=C(Cl)C(N)=NC=C1 SSWBRTPWPRFSDH-UHFFFAOYSA-N 0.000 description 1
- CIXWDOXBRQTRKS-UHFFFAOYSA-N CC1=NC(N2CCC(C)(N)CC2)=CN=C1SC1=CC=CC(F)=C1F Chemical compound CC1=NC(N2CCC(C)(N)CC2)=CN=C1SC1=CC=CC(F)=C1F CIXWDOXBRQTRKS-UHFFFAOYSA-N 0.000 description 1
- QNKIZTYLUGQPHV-UHFFFAOYSA-N CC1=NC(N2CCC(CN)(C3=CN=CC=C3)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC(CN)(C3=CN=CC=C3)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl QNKIZTYLUGQPHV-UHFFFAOYSA-N 0.000 description 1
- NHNWAJPMLCZBPD-UHFFFAOYSA-N CC1=NC(N2CCC(N)(C(=O)NC3CCC3)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC(N)(C(=O)NC3CCC3)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl NHNWAJPMLCZBPD-UHFFFAOYSA-N 0.000 description 1
- MYNXAXDDJQHRFU-UHFFFAOYSA-N CC1=NC(N2CCC(N)(C(=O)NC3CCOCC3)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC(N)(C(=O)NC3CCOCC3)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl MYNXAXDDJQHRFU-UHFFFAOYSA-N 0.000 description 1
- UUCYEHGLQXVOCP-UHFFFAOYSA-N CC1=NC(N2CCC(N)(C(N)=O)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC(N)(C(N)=O)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl UUCYEHGLQXVOCP-UHFFFAOYSA-N 0.000 description 1
- HKDSPCUEDQTREH-UHFFFAOYSA-N CC1=NC(N2CCC(N)(CO)CC2)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC(N)(CO)CC2)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl HKDSPCUEDQTREH-UHFFFAOYSA-N 0.000 description 1
- HZECQILCCOSYNN-MRXNPFEDSA-N CC1=NC(N2CCC3(CC2)CC(F)(F)C[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CC(F)(F)C[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl HZECQILCCOSYNN-MRXNPFEDSA-N 0.000 description 1
- MLOOJUIMLGUALM-MRXNPFEDSA-N CC1=NC(N2CCC3(CC2)COC[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)COC[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl MLOOJUIMLGUALM-MRXNPFEDSA-N 0.000 description 1
- DBPMHJXODKLJBG-YVEFUNNKSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=C(Cl)C(Cl)=NC=C1 Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=C(Cl)C(Cl)=NC=C1 DBPMHJXODKLJBG-YVEFUNNKSA-N 0.000 description 1
- IPXZUHKZOBXKAL-RNODOKPDSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=C(Cl)C2=C(C=C1)C=NN2 Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=C(Cl)C2=C(C=C1)C=NN2 IPXZUHKZOBXKAL-RNODOKPDSA-N 0.000 description 1
- DKICIWFEJUIWJI-LHSJRXKWSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=C(Cl)C2=C(C=C1)C=NN2C Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=C(Cl)C2=C(C=C1)C=NN2C DKICIWFEJUIWJI-LHSJRXKWSA-N 0.000 description 1
- MQKWAPTWBGVDFH-OYHNWAKOSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=C(Cl)C2=C(C=C1)CCCO2 Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=C(Cl)C2=C(C=C1)CCCO2 MQKWAPTWBGVDFH-OYHNWAKOSA-N 0.000 description 1
- DKFYEQJNIHKGBG-LHSJRXKWSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=C(Cl)C2=C(C=C1)CCO2 Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=C(Cl)C2=C(C=C1)CCO2 DKFYEQJNIHKGBG-LHSJRXKWSA-N 0.000 description 1
- XPMXEINIUMTSRS-APPDUMDISA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC(N)=NC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC(N)=NC(Cl)=C1Cl XPMXEINIUMTSRS-APPDUMDISA-N 0.000 description 1
- RSXSSINQNWIBDD-YCRPNKLZSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC2=C(C=C1)C(C)=NN2 Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC2=C(C=C1)C(C)=NN2 RSXSSINQNWIBDD-YCRPNKLZSA-N 0.000 description 1
- VORJQNROQPXXPL-YCRPNKLZSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC2=C(C=C1)C=NC=N2 Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC2=C(C=C1)C=NC=N2 VORJQNROQPXXPL-YCRPNKLZSA-N 0.000 description 1
- CRCQIDGLPXTCRJ-YCRPNKLZSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC2=C(C=C1)C=NN2C Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC2=C(C=C1)C=NN2C CRCQIDGLPXTCRJ-YCRPNKLZSA-N 0.000 description 1
- MCBLEWHTOVUVHF-VBKZILBWSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC2=C(C=C1)NN=C2 Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC2=C(C=C1)NN=C2 MCBLEWHTOVUVHF-VBKZILBWSA-N 0.000 description 1
- RUEKPOPUBSLKDP-RNODOKPDSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC2=C(C=NN2)C(F)=C1 Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC2=C(C=NN2)C(F)=C1 RUEKPOPUBSLKDP-RNODOKPDSA-N 0.000 description 1
- LFZMSFPTDNAOIH-RNODOKPDSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC2=C(C=NN2)C=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC2=C(C=NN2)C=C1Cl LFZMSFPTDNAOIH-RNODOKPDSA-N 0.000 description 1
- ULVZNRNUGHZBHK-YCRPNKLZSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=C2C=COC2=C1 Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=C2C=COC2=C1 ULVZNRNUGHZBHK-YCRPNKLZSA-N 0.000 description 1
- VDIAEPVOKVLELQ-YCRPNKLZSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=C2N=CN(C)C2=C1 Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=C2N=CN(C)C2=C1 VDIAEPVOKVLELQ-YCRPNKLZSA-N 0.000 description 1
- XHOTURQUONDMSU-HXPMCKFVSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=C2OC(F)(F)OC2=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=C2OC(F)(F)OC2=C1Cl XHOTURQUONDMSU-HXPMCKFVSA-N 0.000 description 1
- FXDFKEQEXHBPHZ-LHSJRXKWSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=C2OCCNC2=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=C2OCCNC2=C1Cl FXDFKEQEXHBPHZ-LHSJRXKWSA-N 0.000 description 1
- ZUTQLTSJSMFOOP-RNODOKPDSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=C2OCOC2=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=C2OCOC2=C1Cl ZUTQLTSJSMFOOP-RNODOKPDSA-N 0.000 description 1
- XSSUAWJMHZFMOG-AAKYCSGMSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=CC(C#N)=C1Cl.S.S Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=CC(C#N)=C1Cl.S.S XSSUAWJMHZFMOG-AAKYCSGMSA-N 0.000 description 1
- XMLITKRXQLBSAH-MWBKYOBMSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl.S.S Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl.S.S XMLITKRXQLBSAH-MWBKYOBMSA-N 0.000 description 1
- UKRYRPRAHVTOEB-ORAYPTAESA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=CC(OC(F)(F)F)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=CC(OC(F)(F)F)=C1Cl UKRYRPRAHVTOEB-ORAYPTAESA-N 0.000 description 1
- VTJOGOHKMZKRJG-ORAYPTAESA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=NC(C#N)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1C1=CC=NC(C#N)=C1Cl VTJOGOHKMZKRJG-ORAYPTAESA-N 0.000 description 1
- BGLQLHSDBFWAPC-MGPUTAFESA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=C(Cl)C(N2CC(C#N)C2)=NC=C1 Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=C(Cl)C(N2CC(C#N)C2)=NC=C1 BGLQLHSDBFWAPC-MGPUTAFESA-N 0.000 description 1
- FBGMRFKOADSWLG-MGPUTAFESA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=C(Cl)C(N2CC(S(C)(=O)=O)C2)=NC=C1 Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=C(Cl)C(N2CC(S(C)(=O)=O)C2)=NC=C1 FBGMRFKOADSWLG-MGPUTAFESA-N 0.000 description 1
- FECMJKBVXOAUCP-VRFXWXFCSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=C(Cl)C(N2CC(S(C)(=O)=O)C2)=NC=C1.S.S Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=C(Cl)C(N2CC(S(C)(=O)=O)C2)=NC=C1.S.S FECMJKBVXOAUCP-VRFXWXFCSA-N 0.000 description 1
- AQPYQYBTFLCRGH-PGRDOPGGSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=C(Cl)C(N2CC3(CCOCC3)C2)=NC=C1 Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=C(Cl)C(N2CC3(CCOCC3)C2)=NC=C1 AQPYQYBTFLCRGH-PGRDOPGGSA-N 0.000 description 1
- GVIXNAQQRFQZLD-NWZZKEMCSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=C(Cl)C(N2C[C@@H]3C[C@H]2CO3)=NC=C1 Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=C(Cl)C(N2C[C@@H]3C[C@H]2CO3)=NC=C1 GVIXNAQQRFQZLD-NWZZKEMCSA-N 0.000 description 1
- MPUKZLNIWCKIEK-SCLBCKFNSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=CC(Cl)=C1Cl MPUKZLNIWCKIEK-SCLBCKFNSA-N 0.000 description 1
- AEFTZPRSCGZBCT-PPQVVJRISA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=CC(Cl)=C1Cl.S.S Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=CC(Cl)=C1Cl.S.S AEFTZPRSCGZBCT-PPQVVJRISA-N 0.000 description 1
- DYRHNYBNHPDXPR-SCLBCKFNSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(C#N)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(C#N)=C1Cl DYRHNYBNHPDXPR-SCLBCKFNSA-N 0.000 description 1
- RADSRFPWFZBKNC-BLLLJJGKSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(Cl)=C1Cl RADSRFPWFZBKNC-BLLLJJGKSA-N 0.000 description 1
- YCDNIKUCCWKVKV-GWPSCLBYSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(Cl)=C1Cl.S.S Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(Cl)=C1Cl.S.S YCDNIKUCCWKVKV-GWPSCLBYSA-N 0.000 description 1
- JFWKDYUIJCSHIG-KBXCAEBGSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N(C)C)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N(C)C)=C1Cl JFWKDYUIJCSHIG-KBXCAEBGSA-N 0.000 description 1
- HISJAYUQVHMWTA-BLLLJJGKSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N)=C1Cl HISJAYUQVHMWTA-BLLLJJGKSA-N 0.000 description 1
- SSNPRZHQEAONIU-GWPSCLBYSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N)=C1Cl.S.S Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N)=C1Cl.S.S SSNPRZHQEAONIU-GWPSCLBYSA-N 0.000 description 1
- CBDXYHUBFSUPIM-HNAYVOBHSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N2C=CN=C2)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N2C=CN=C2)=C1Cl CBDXYHUBFSUPIM-HNAYVOBHSA-N 0.000 description 1
- VOENNMYVIQADCN-IFXJQAMLSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N2CC(O)C2)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N2CC(O)C2)=C1Cl VOENNMYVIQADCN-IFXJQAMLSA-N 0.000 description 1
- BNHPWZJJEIWKED-YRRRDGBXSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N2CC(O)C2)=C1Cl.S.S Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N2CC(O)C2)=C1Cl.S.S BNHPWZJJEIWKED-YRRRDGBXSA-N 0.000 description 1
- PVMQCWRCWUDBOX-OXJNMPFZSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N2CC3(CCS3(=O)=O)C2)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N2CC3(CCS3(=O)=O)C2)=C1Cl PVMQCWRCWUDBOX-OXJNMPFZSA-N 0.000 description 1
- CHBWXFPAVXXQFQ-OXJNMPFZSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N2CC3(COC3)C2)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N2CC3(COC3)C2)=C1Cl CHBWXFPAVXXQFQ-OXJNMPFZSA-N 0.000 description 1
- TXKLSJJJQSFZOX-OXJNMPFZSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N2CCOCC2)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(N2CCOCC2)=C1Cl TXKLSJJJQSFZOX-OXJNMPFZSA-N 0.000 description 1
- LWMBZVMGVFZBKL-IFXJQAMLSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(NC2CC2)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(NC2CC2)=C1Cl LWMBZVMGVFZBKL-IFXJQAMLSA-N 0.000 description 1
- XCGPXMCMFLJFRU-HRAATJIYSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(NC2CCOCC2)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(NC2CCOCC2)=C1Cl XCGPXMCMFLJFRU-HRAATJIYSA-N 0.000 description 1
- MIHPTDFNPYPIPK-IFXJQAMLSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(NC2COC2)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(NC2COC2)=C1Cl MIHPTDFNPYPIPK-IFXJQAMLSA-N 0.000 description 1
- BXFLAAQOXHJYKM-IFXJQAMLSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(OC2CC2)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(OC2CC2)=C1Cl BXFLAAQOXHJYKM-IFXJQAMLSA-N 0.000 description 1
- XGOIJYLCPSFTFI-YRRRDGBXSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(OC2CC2)=C1Cl.S.S Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(OC2CC2)=C1Cl.S.S XGOIJYLCPSFTFI-YRRRDGBXSA-N 0.000 description 1
- GFZDGZWYKUVLMZ-HRAATJIYSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(OC2CCOCC2)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(OC2CCOCC2)=C1Cl GFZDGZWYKUVLMZ-HRAATJIYSA-N 0.000 description 1
- NYULVVAORRYEFY-IFXJQAMLSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(OC2COC2)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=C(CO)N=C1SC1=CC=NC(OC2COC2)=C1Cl NYULVVAORRYEFY-IFXJQAMLSA-N 0.000 description 1
- BYWSUFZZEDVWMT-GWPSCLBYSA-N CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=CN=C1SC1=CC=NC(N)=C1Cl.S.S Chemical compound CC1=NC(N2CCC3(CC2)CO[C@@H](C)[C@H]3N)=CN=C1SC1=CC=NC(N)=C1Cl.S.S BYWSUFZZEDVWMT-GWPSCLBYSA-N 0.000 description 1
- IKUYEYLZXGGCRD-YJYMSZOUSA-N CC1=NC(N2CCC3(CC2)CO[C@H](C)[C@@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@H](C)[C@@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl IKUYEYLZXGGCRD-YJYMSZOUSA-N 0.000 description 1
- IKUYEYLZXGGCRD-BFUOFWGJSA-N CC1=NC(N2CCC3(CC2)CO[C@H](C)[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)CO[C@H](C)[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl IKUYEYLZXGGCRD-BFUOFWGJSA-N 0.000 description 1
- UCMHAJVCFXSHJP-MRXNPFEDSA-N CC1=NC(N2CCC3(CC2)CS(=O)(=O)C[C@H]3N)=C(CO)N=C1C1=C(Cl)C(Cl)=CC=C1 Chemical compound CC1=NC(N2CCC3(CC2)CS(=O)(=O)C[C@H]3N)=C(CO)N=C1C1=C(Cl)C(Cl)=CC=C1 UCMHAJVCFXSHJP-MRXNPFEDSA-N 0.000 description 1
- TUUKPSVRLLXYLM-SUMWQHHRSA-N CC1=NC(N2CCC3(CC2)C[C@@H](F)C[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)C[C@@H](F)C[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl TUUKPSVRLLXYLM-SUMWQHHRSA-N 0.000 description 1
- BDHWHUQRQLMNPK-SWLSCSKDSA-N CC1=NC(N2CCC3(CC2)C[C@@H](O)C[C@H]3N)=C(CO)N=C1SC1=CC=NC(N)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)C[C@@H](O)C[C@H]3N)=C(CO)N=C1SC1=CC=NC(N)=C1Cl BDHWHUQRQLMNPK-SWLSCSKDSA-N 0.000 description 1
- YJODZSCTTVZBKV-OXJNMPFZSA-N CC1=NC(N2CCC3(CC2)C[C@@H](OC2CC2)C[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)C[C@@H](OC2CC2)C[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl YJODZSCTTVZBKV-OXJNMPFZSA-N 0.000 description 1
- TUUKPSVRLLXYLM-CXAGYDPISA-N CC1=NC(N2CCC3(CC2)C[C@H](F)C[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)C[C@H](F)C[C@H]3N)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl TUUKPSVRLLXYLM-CXAGYDPISA-N 0.000 description 1
- MBJGZHUUOXXKLT-CXAGYDPISA-N CC1=NC(N2CCC3(CC2)C[C@H](O)C[C@H]3N)=C(CO)N=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CC2)C[C@H](O)C[C@H]3N)=C(CO)N=C1SC1=CC=CC(Cl)=C1Cl MBJGZHUUOXXKLT-CXAGYDPISA-N 0.000 description 1
- ZPGQCQUXGJPCKP-CYBMUJFWSA-N CC1=NC(N2CCC3(CCC[C@H]3C)CC2)=C(CO)N=C1C1=C(F)C(Cl)=C(Cl)C=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3C)CC2)=C(CO)N=C1C1=C(F)C(Cl)=C(Cl)C=C1 ZPGQCQUXGJPCKP-CYBMUJFWSA-N 0.000 description 1
- JRFKUZHHVSOJPH-OAHLLOKOSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(N)=O)N=C1SC1=C(Cl)C(Cl)=CC=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(N)=O)N=C1SC1=C(Cl)C(Cl)=CC=C1 JRFKUZHHVSOJPH-OAHLLOKOSA-N 0.000 description 1
- PVJCXWQYZLUFGD-CYBMUJFWSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(N)=O)N=C1SC1=C(Cl)C(Cl)=NC=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(C(N)=O)N=C1SC1=C(Cl)C(Cl)=NC=C1 PVJCXWQYZLUFGD-CYBMUJFWSA-N 0.000 description 1
- WKTGMAFHYRBNJI-OAHLLOKOSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(Br)C(Cl)=NC=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(Br)C(Cl)=NC=C1 WKTGMAFHYRBNJI-OAHLLOKOSA-N 0.000 description 1
- ZFDCJOVIWUPBSV-MRXNPFEDSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(Cl)C(=O)N(C)C=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(Cl)C(=O)N(C)C=C1 ZFDCJOVIWUPBSV-MRXNPFEDSA-N 0.000 description 1
- ZLMGGSALDOKYLZ-QGZVFWFLSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(Cl)C(C(F)(F)F)=CC=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(Cl)C(C(F)(F)F)=CC=C1 ZLMGGSALDOKYLZ-QGZVFWFLSA-N 0.000 description 1
- NPVPDHJZLJTAQX-GOSISDBHSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(Cl)C2=C(C=C1)CCO2 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(Cl)C2=C(C=C1)CCO2 NPVPDHJZLJTAQX-GOSISDBHSA-N 0.000 description 1
- FMLGDQGTRAKROM-GOSISDBHSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(F)C(C#N)=C(Cl)C=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=C(F)C(C#N)=C(Cl)C=C1 FMLGDQGTRAKROM-GOSISDBHSA-N 0.000 description 1
- OLGVRIAKTGDTNA-JOCHJYFZSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC(C2=CC=NN2C)=CC=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC(C2=CC=NN2C)=CC=C1 OLGVRIAKTGDTNA-JOCHJYFZSA-N 0.000 description 1
- UBIJDCQWSWRHAJ-QGZVFWFLSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC(Cl)=CN=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC(Cl)=CN=C1 UBIJDCQWSWRHAJ-QGZVFWFLSA-N 0.000 description 1
- ZCOUFZWTLZRIGR-CQSZACIVSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC(N)=NC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC(N)=NC(Cl)=C1Cl ZCOUFZWTLZRIGR-CQSZACIVSA-N 0.000 description 1
- ALBQPVZFEQVOIZ-LJQANCHMSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC2=C(C=C1)CC(=O)N2 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC2=C(C=C1)CC(=O)N2 ALBQPVZFEQVOIZ-LJQANCHMSA-N 0.000 description 1
- GTUJPGJZDZSQOH-HXUWFJFHSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC2=C(C=C1)CC(=O)N2C Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC2=C(C=C1)CC(=O)N2C GTUJPGJZDZSQOH-HXUWFJFHSA-N 0.000 description 1
- WKNMIOIXYKANSU-LJQANCHMSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=C(C(C)C)N=C1Cl Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=C(C(C)C)N=C1Cl WKNMIOIXYKANSU-LJQANCHMSA-N 0.000 description 1
- AJRWNIPUHLXGBK-GOSISDBHSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=C(Cl)C=C1Cl Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=C(Cl)C=C1Cl AJRWNIPUHLXGBK-GOSISDBHSA-N 0.000 description 1
- JPDOFNCDGQKCKP-GOSISDBHSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=C(F)C(C#N)=C1F Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=C(F)C(C#N)=C1F JPDOFNCDGQKCKP-GOSISDBHSA-N 0.000 description 1
- YMYZGFPDQJGBSF-QGZVFWFLSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC(Br)=C1Br Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC(Br)=C1Br YMYZGFPDQJGBSF-QGZVFWFLSA-N 0.000 description 1
- IKAYIPOXKXFQSB-LJQANCHMSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC(C(F)(F)F)=C1C Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC(C(F)(F)F)=C1C IKAYIPOXKXFQSB-LJQANCHMSA-N 0.000 description 1
- WWGJEUJPSRSTCJ-LJQANCHMSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC(C(F)(F)F)=C1C#N Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC(C(F)(F)F)=C1C#N WWGJEUJPSRSTCJ-LJQANCHMSA-N 0.000 description 1
- XZZFYIXKWLLLSC-GOSISDBHSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC(C)=C1Cl Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC(C)=C1Cl XZZFYIXKWLLLSC-GOSISDBHSA-N 0.000 description 1
- VYMJVPWOHZBISN-LJQANCHMSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC(Cl)=C1C#N Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC(Cl)=C1C#N VYMJVPWOHZBISN-LJQANCHMSA-N 0.000 description 1
- DDYFRSGODCAXJA-LJQANCHMSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC(S(C)(=O)=O)=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=CC(S(C)(=O)=O)=C1 DDYFRSGODCAXJA-LJQANCHMSA-N 0.000 description 1
- SCQVDLBUUKIXLT-MRXNPFEDSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=NC(C(F)(F)F)=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CC=NC(C(F)(F)F)=C1 SCQVDLBUUKIXLT-MRXNPFEDSA-N 0.000 description 1
- XIRSIOKPEKUSOV-HXUWFJFHSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CNC2=CC=CC=C21 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1C1=CNC2=CC=CC=C21 XIRSIOKPEKUSOV-HXUWFJFHSA-N 0.000 description 1
- XEQPXCHVULXYAV-LJQANCHMSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=C(C#N)C(F)=CC=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=C(C#N)C(F)=CC=C1 XEQPXCHVULXYAV-LJQANCHMSA-N 0.000 description 1
- IZMQLFIHXHBJHQ-QGZVFWFLSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=C(Cl)C(F)=CC=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=C(Cl)C(F)=CC=C1 IZMQLFIHXHBJHQ-QGZVFWFLSA-N 0.000 description 1
- OKZNKQZPPBZDJJ-HXUWFJFHSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=CC2=C(C=CN2)C=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=CC2=C(C=CN2)C=C1 OKZNKQZPPBZDJJ-HXUWFJFHSA-N 0.000 description 1
- QOHWBZYQSZXIPH-QGZVFWFLSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=CC=CC(Cl)=C1F Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=CC=CC(Cl)=C1F QOHWBZYQSZXIPH-QGZVFWFLSA-N 0.000 description 1
- SKFLSOYYGRCAEA-LJQANCHMSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=CC=CC(S(C)(=O)=O)=C1 Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=CC=CC(S(C)(=O)=O)=C1 SKFLSOYYGRCAEA-LJQANCHMSA-N 0.000 description 1
- XPPYQCVSSQRQJF-QGZVFWFLSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=CC=NC(C#N)=C1Cl Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=C(CO)N=C1SC1=CC=NC(C#N)=C1Cl XPPYQCVSSQRQJF-QGZVFWFLSA-N 0.000 description 1
- IWOZWFBCXDUSSX-MRXNPFEDSA-N CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1C1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1C1=CC=CC(Cl)=C1Cl IWOZWFBCXDUSSX-MRXNPFEDSA-N 0.000 description 1
- ZYRASWPSHPOGBA-UHFFFAOYSA-N CC1=NC(N2CCCC(N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCCC(N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl ZYRASWPSHPOGBA-UHFFFAOYSA-N 0.000 description 1
- MUOGKCHQBBCPFA-UHFFFAOYSA-N CC1=NC(N2CCCNCC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N2CCCNCC2)=CN=C1SC1=CC=CC(Cl)=C1Cl MUOGKCHQBBCPFA-UHFFFAOYSA-N 0.000 description 1
- WMNLDXSMRYLYHR-UHFFFAOYSA-N CC1=NC(NC2C3CCC2CNC3)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(NC2C3CCC2CNC3)=CN=C1SC1=CC=CC(Cl)=C1Cl WMNLDXSMRYLYHR-UHFFFAOYSA-N 0.000 description 1
- ZZQHXCAVPQUYGC-UHFFFAOYSA-N CC1=NC(NC2CC3CCC(C2)N3)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(NC2CC3CCC(C2)N3)=CN=C1SC1=CC=CC(Cl)=C1Cl ZZQHXCAVPQUYGC-UHFFFAOYSA-N 0.000 description 1
- DEZBSRCXCKGJRI-UHFFFAOYSA-N CC1=NC(NC2CCC3(CNC3)C2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(NC2CCC3(CNC3)C2)=CN=C1SC1=CC=CC(Cl)=C1Cl DEZBSRCXCKGJRI-UHFFFAOYSA-N 0.000 description 1
- BTSKZIFDGWIRDW-UHFFFAOYSA-N CC1=NC(NCC2CC3(CNC3)C2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(NCC2CC3(CNC3)C2)=CN=C1SC1=CC=CC(Cl)=C1Cl BTSKZIFDGWIRDW-UHFFFAOYSA-N 0.000 description 1
- WNHGVIFDUALWIA-UHFFFAOYSA-N CC1=NC(NCC2CCNC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(NCC2CCNC2)=CN=C1SC1=CC=CC(Cl)=C1Cl WNHGVIFDUALWIA-UHFFFAOYSA-N 0.000 description 1
- FJKQXXIIYIROPF-UHFFFAOYSA-N CC1=NC(NCC2CNCCN2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(NCC2CNCCN2)=CN=C1SC1=CC=CC(Cl)=C1Cl FJKQXXIIYIROPF-UHFFFAOYSA-N 0.000 description 1
- IXACHSMYRSLOHT-UHFFFAOYSA-N CC1=NC(NCCC2CNC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(NCCC2CNC2)=CN=C1SC1=CC=CC(Cl)=C1Cl IXACHSMYRSLOHT-UHFFFAOYSA-N 0.000 description 1
- HCYASYNZHFAZCS-UHFFFAOYSA-N CC1=NC(NCCCCN)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(NCCCCN)=CN=C1SC1=CC=CC(Cl)=C1Cl HCYASYNZHFAZCS-UHFFFAOYSA-N 0.000 description 1
- OJMLDNSBMCOUDS-UHFFFAOYSA-N CC1=NC(NCCCN)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(NCCCN)=CN=C1SC1=CC=CC(Cl)=C1Cl OJMLDNSBMCOUDS-UHFFFAOYSA-N 0.000 description 1
- YNYZKTDUBFZKRH-UHFFFAOYSA-N CC1=NC(NCCN)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(NCCN)=CN=C1SC1=CC=CC(Cl)=C1Cl YNYZKTDUBFZKRH-UHFFFAOYSA-N 0.000 description 1
- XJSKNKCPGMSOJY-GHMZBOCLSA-N CC1=NC(N[C@@H]2CC[C@@H](N)C2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound CC1=NC(N[C@@H]2CC[C@@H](N)C2)=CN=C1SC1=CC=CC(Cl)=C1Cl XJSKNKCPGMSOJY-GHMZBOCLSA-N 0.000 description 1
- NBBYZBJOYDAVQR-UHFFFAOYSA-N CC1=NC2=C(N=C1C1=CC=CC(Cl)=C1Cl)C(=O)NCCN2 Chemical compound CC1=NC2=C(N=C1C1=CC=CC(Cl)=C1Cl)C(=O)NCCN2 NBBYZBJOYDAVQR-UHFFFAOYSA-N 0.000 description 1
- OGQBQVLAAYPION-UHFFFAOYSA-N CC1=NC2=C(N=C1SC1=CC=NC(Cl)=C1Cl)C(=O)NCCN2 Chemical compound CC1=NC2=C(N=C1SC1=CC=NC(Cl)=C1Cl)C(=O)NCCN2 OGQBQVLAAYPION-UHFFFAOYSA-N 0.000 description 1
- CXHYPTXSHUMNPH-UHFFFAOYSA-N CC1=NC2=C(N=C1SC1=CC=NC(Cl)=C1Cl)C(=O)NCCN2CCN Chemical compound CC1=NC2=C(N=C1SC1=CC=NC(Cl)=C1Cl)C(=O)NCCN2CCN CXHYPTXSHUMNPH-UHFFFAOYSA-N 0.000 description 1
- YTJBUUSVGUESDB-LHSJRXKWSA-N CC1=NC2=CC(C3=C(C)N=C(N4CCC5(CC4)CO[C@@H](C)[C@H]5N)C(CO)=N3)=CC=C2O1 Chemical compound CC1=NC2=CC(C3=C(C)N=C(N4CCC5(CC4)CO[C@@H](C)[C@H]5N)C(CO)=N3)=CC=C2O1 YTJBUUSVGUESDB-LHSJRXKWSA-N 0.000 description 1
- VMZLVUJJKOZMIJ-LHSJRXKWSA-N CC1=NC2=CC=C(C3=C(C)N=C(N4CCC5(CC4)CO[C@@H](C)[C@H]5N)C(CO)=N3)C=C2O1 Chemical compound CC1=NC2=CC=C(C3=C(C)N=C(N4CCC5(CC4)CO[C@@H](C)[C@H]5N)C(CO)=N3)C=C2O1 VMZLVUJJKOZMIJ-LHSJRXKWSA-N 0.000 description 1
- SAECPUFLMLHBMY-LHSJRXKWSA-N CC1=NC2=CC=C(C3=NC(CO)=C(N4CCC5(CC4)CO[C@@H](C)[C@H]5N)N=C3C)C=C2N1 Chemical compound CC1=NC2=CC=C(C3=NC(CO)=C(N4CCC5(CC4)CO[C@@H](C)[C@H]5N)N=C3C)C=C2N1 SAECPUFLMLHBMY-LHSJRXKWSA-N 0.000 description 1
- AUFHYPUDRZAXPK-GOSISDBHSA-N CC1=NC=C(Br)C=C1C1=NC(CO)=C(N2CCC3(CCC[C@H]3N)CC2)N=C1C Chemical compound CC1=NC=C(Br)C=C1C1=NC(CO)=C(N2CCC3(CCC[C@H]3N)CC2)N=C1C AUFHYPUDRZAXPK-GOSISDBHSA-N 0.000 description 1
- SIOJBFSOQQKWMC-KSFYIVLOSA-N CC1=NN(C)C2=CC(C3=C(C)N=C(N4CCC5(CC4)CO[C@@H](C)[C@H]5N)C(CO)=N3)=CC=C21 Chemical compound CC1=NN(C)C2=CC(C3=C(C)N=C(N4CCC5(CC4)CO[C@@H](C)[C@H]5N)C(CO)=N3)=CC=C21 SIOJBFSOQQKWMC-KSFYIVLOSA-N 0.000 description 1
- TZRSJCJOVBCFDA-NIFFTEIASA-N CCC1(CC)CCC[C@H]1N.COC1=CC=C(C2=NC(CO)=C(N)N=C2C)C(Cl)=C1O Chemical compound CCC1(CC)CCC[C@H]1N.COC1=CC=C(C2=NC(CO)=C(N)N=C2C)C(Cl)=C1O TZRSJCJOVBCFDA-NIFFTEIASA-N 0.000 description 1
- HCWQBKIVMWTNSD-OAHLLOKOSA-N CCC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=NC(Cl)=C1Cl Chemical compound CCC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=NC(Cl)=C1Cl HCWQBKIVMWTNSD-OAHLLOKOSA-N 0.000 description 1
- AHICRSOCXFVFKD-UHFFFAOYSA-N CCC1=NC=CC(C2=NC(CO)=C(N3CCC(C)(N)CC3)N=C2C)=C1Br Chemical compound CCC1=NC=CC(C2=NC(CO)=C(N3CCC(C)(N)CC3)N=C2C)=C1Br AHICRSOCXFVFKD-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- JDIPBSDQYCUXPG-UHFFFAOYSA-N CNC1(C)CCN(C2=CN=C(SC3=C(Cl)C(Cl)=CC=C3)C(C)=N2)CC1 Chemical compound CNC1(C)CCN(C2=CN=C(SC3=C(Cl)C(Cl)=CC=C3)C(C)=N2)CC1 JDIPBSDQYCUXPG-UHFFFAOYSA-N 0.000 description 1
- OROISSBKKWFCJP-SUMWQHHRSA-N CNC1=C(Cl)C(SC2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=CC=N1 Chemical compound CNC1=C(Cl)C(SC2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=CC=N1 OROISSBKKWFCJP-SUMWQHHRSA-N 0.000 description 1
- NNXAYYWKFPIFID-MRXNPFEDSA-N CNC1=C(Cl)C(SC2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)=CC=N1 Chemical compound CNC1=C(Cl)C(SC2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)=CC=N1 NNXAYYWKFPIFID-MRXNPFEDSA-N 0.000 description 1
- BVOBHMMBMCBCDW-KPZWWZAWSA-N CNC1=NC(Cl)=C(Cl)C(C2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=C1 Chemical compound CNC1=NC(Cl)=C(Cl)C(C2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=C1 BVOBHMMBMCBCDW-KPZWWZAWSA-N 0.000 description 1
- BSRFCDIVQGMHCL-GOSISDBHSA-N COC1=C(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)C=CC=C1Cl Chemical compound COC1=C(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)C=CC=C1Cl BSRFCDIVQGMHCL-GOSISDBHSA-N 0.000 description 1
- AWIGPYXXYZNFJK-LHSJRXKWSA-N COC1=C(Cl)C(C2=C(C)N=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)C(CO)=N2)=CC=C1C#N Chemical compound COC1=C(Cl)C(C2=C(C)N=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)C(CO)=N2)=CC=C1C#N AWIGPYXXYZNFJK-LHSJRXKWSA-N 0.000 description 1
- LSGBEUJHTDYVDA-QGZVFWFLSA-N COC1=C(Cl)C(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)=CC=C1Cl Chemical compound COC1=C(Cl)C(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)=CC=C1Cl LSGBEUJHTDYVDA-QGZVFWFLSA-N 0.000 description 1
- ASRUFGYONAKJPY-UHFFFAOYSA-N COC1=C(Cl)C(Cl)=C(C2=NC(CO)=C(N3CCC(C)(N)CC3)N=C2C)C=C1 Chemical compound COC1=C(Cl)C(Cl)=C(C2=NC(CO)=C(N3CCC(C)(N)CC3)N=C2C)C=C1 ASRUFGYONAKJPY-UHFFFAOYSA-N 0.000 description 1
- SRVCWTICLPGYOK-SUMWQHHRSA-N COC1=C(Cl)C(SC2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=CC=N1 Chemical compound COC1=C(Cl)C(SC2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=CC=N1 SRVCWTICLPGYOK-SUMWQHHRSA-N 0.000 description 1
- YDPFGCNBKQODTM-QGZVFWFLSA-N COC1=CC=C(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)C(OC)=N1 Chemical compound COC1=CC=C(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)C(OC)=N1 YDPFGCNBKQODTM-QGZVFWFLSA-N 0.000 description 1
- XZLJJHPTGFBWHB-VBKZILBWSA-N COC1=CC=CC(C2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=C1Cl Chemical compound COC1=CC=CC(C2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=C1Cl XZLJJHPTGFBWHB-VBKZILBWSA-N 0.000 description 1
- YOPYOFMVSRSQHA-AAKYCSGMSA-N COC1=CC=CC(C2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=C1Cl.S.S Chemical compound COC1=CC=CC(C2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=C1Cl.S.S YOPYOFMVSRSQHA-AAKYCSGMSA-N 0.000 description 1
- YLSFEHJFFCTXRA-GOSISDBHSA-N COC1=CC=CC(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)=C1Cl Chemical compound COC1=CC=CC(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)=C1Cl YLSFEHJFFCTXRA-GOSISDBHSA-N 0.000 description 1
- JDECHKQWCWIKOH-KPZWWZAWSA-N COC1=NC(Cl)=C(Cl)C(C2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=C1 Chemical compound COC1=NC(Cl)=C(Cl)C(C2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=C1 JDECHKQWCWIKOH-KPZWWZAWSA-N 0.000 description 1
- YCLGWUGLNPJORK-UHFFFAOYSA-N COC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl Chemical compound COC1=NC(N2CCC(C)(N)CC2)=C(CO)N=C1C1=CC=CC(Cl)=C1Cl YCLGWUGLNPJORK-UHFFFAOYSA-N 0.000 description 1
- XPAKYIZDLWRVFE-MRXNPFEDSA-N COC1=NC=C(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)C(OC)=N1 Chemical compound COC1=NC=C(C2=NC(CO)=C(N3CCC4(CCC[C@H]4N)CC3)N=C2C)C(OC)=N1 XPAKYIZDLWRVFE-MRXNPFEDSA-N 0.000 description 1
- RFMBDMKZLVVUBR-UHFFFAOYSA-N COC1=NC=CC(C2=NC(CO)=C(N3CCC(C)(N)CC3)N=C2C)=C1Cl Chemical compound COC1=NC=CC(C2=NC(CO)=C(N3CCC(C)(N)CC3)N=C2C)=C1Cl RFMBDMKZLVVUBR-UHFFFAOYSA-N 0.000 description 1
- SOFAFFGHNGIZGN-SCLBCKFNSA-N COC1=NC=CC(C2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=C1Cl Chemical compound COC1=NC=CC(C2=NC(CO)=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N=C2C)=C1Cl SOFAFFGHNGIZGN-SCLBCKFNSA-N 0.000 description 1
- VXLNXGFTYDBRIN-UHFFFAOYSA-N COCC1=C(N2CCC(C)(N)CC2)N=C(C)C(C2=C(Cl)C(Cl)=NC=C2)=N1 Chemical compound COCC1=C(N2CCC(C)(N)CC2)N=C(C)C(C2=C(Cl)C(Cl)=NC=C2)=N1 VXLNXGFTYDBRIN-UHFFFAOYSA-N 0.000 description 1
- BJUSFNPWGSLLMK-RDTXWAMCSA-N CO[C@@H]1C[C@@H](N)C2(CCN(C3=C(CO)N=C(C4=CC=CC(Cl)=C4Cl)C(C)=N3)CC2)C1 Chemical compound CO[C@@H]1C[C@@H](N)C2(CCN(C3=C(CO)N=C(C4=CC=CC(Cl)=C4Cl)C(C)=N3)CC2)C1 BJUSFNPWGSLLMK-RDTXWAMCSA-N 0.000 description 1
- KOPWLJQJTZOLHW-RDTXWAMCSA-N CO[C@@H]1C[C@@H](N)C2(CCN(C3=C(CO)N=C(SC4=CC=CC(Cl)=C4Cl)C(C)=N3)CC2)C1 Chemical compound CO[C@@H]1C[C@@H](N)C2(CCN(C3=C(CO)N=C(SC4=CC=CC(Cl)=C4Cl)C(C)=N3)CC2)C1 KOPWLJQJTZOLHW-RDTXWAMCSA-N 0.000 description 1
- CEKIQMJYELCBDX-CZUORRHYSA-N CO[C@@H]1C[C@@H](N)C2(CCN(C3=C(CO)N=C(SC4=CC=NC(Cl)=C4Cl)C(C)=N3)CC2)C1 Chemical compound CO[C@@H]1C[C@@H](N)C2(CCN(C3=C(CO)N=C(SC4=CC=NC(Cl)=C4Cl)C(C)=N3)CC2)C1 CEKIQMJYELCBDX-CZUORRHYSA-N 0.000 description 1
- QOMUEBKPXSNZES-CZUORRHYSA-N CO[C@@H]1C[C@@H](N)C2(CCN(C3=C(CO)N=C(SC4=CC=NC(N)=C4Cl)C(C)=N3)CC2)C1 Chemical compound CO[C@@H]1C[C@@H](N)C2(CCN(C3=C(CO)N=C(SC4=CC=NC(N)=C4Cl)C(C)=N3)CC2)C1 QOMUEBKPXSNZES-CZUORRHYSA-N 0.000 description 1
- KOPWLJQJTZOLHW-KBXCAEBGSA-N CO[C@H]1C[C@@H](N)C2(CCN(C3=C(CO)N=C(SC4=CC=CC(Cl)=C4Cl)C(C)=N3)CC2)C1 Chemical compound CO[C@H]1C[C@@H](N)C2(CCN(C3=C(CO)N=C(SC4=CC=CC(Cl)=C4Cl)C(C)=N3)CC2)C1 KOPWLJQJTZOLHW-KBXCAEBGSA-N 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- UUCYEHGLQXVOCP-UHFFFAOYSA-O Cc1nc(N(CC2)CCC2(C([NH3+])=O)N)cnc1Sc(cccc1Cl)c1Cl Chemical compound Cc1nc(N(CC2)CCC2(C([NH3+])=O)N)cnc1Sc(cccc1Cl)c1Cl UUCYEHGLQXVOCP-UHFFFAOYSA-O 0.000 description 1
- AJYBHKMIYWQQLT-LJQANCHMSA-N Cc1nc(N(CC2)CCC2(CCC2)[C@@H]2N)c(CO)nc1-c1cc([nH]nc2)c2cc1 Chemical compound Cc1nc(N(CC2)CCC2(CCC2)[C@@H]2N)c(CO)nc1-c1cc([nH]nc2)c2cc1 AJYBHKMIYWQQLT-LJQANCHMSA-N 0.000 description 1
- HOEAPMLJRXTUJN-QZTJIDSGSA-N Cc1nc(N(CC2)CCC2(CO[C@H]2I)[C@@H]2N)c(CO)nc1-c(cc1)cc2c1nn[nH]2 Chemical compound Cc1nc(N(CC2)CCC2(CO[C@H]2I)[C@@H]2N)c(CO)nc1-c(cc1)cc2c1nn[nH]2 HOEAPMLJRXTUJN-QZTJIDSGSA-N 0.000 description 1
- DXCNGOHYTRVZSS-RTBURBONSA-N Cc1nc(N(CC2)CCC2(CO[C@H]2I)[C@@H]2N)c(CO)nc1-c1ccc2[nH]ncc2c1 Chemical compound Cc1nc(N(CC2)CCC2(CO[C@H]2I)[C@@H]2N)c(CO)nc1-c1ccc2[nH]ncc2c1 DXCNGOHYTRVZSS-RTBURBONSA-N 0.000 description 1
- SIIWUHDGKUZJJP-TZIWHRDSSA-N Cc1nc(N(CC2)CCC2(CO[C@H]2O)[C@@H]2N)c(CO)nc1-c(ccc1c2nccn1)c2Cl Chemical compound Cc1nc(N(CC2)CCC2(CO[C@H]2O)[C@@H]2N)c(CO)nc1-c(ccc1c2nccn1)c2Cl SIIWUHDGKUZJJP-TZIWHRDSSA-N 0.000 description 1
- CVTZRIFFEJSMLS-SWLSCSKDSA-N Cc1nc(N(CC2)CCC2(C[C@H](C2)OI)[C@@H]2N)c(CO)nc1Sc(ccnc1N)c1Cl Chemical compound Cc1nc(N(CC2)CCC2(C[C@H](C2)OI)[C@@H]2N)c(CO)nc1Sc(ccnc1N)c1Cl CVTZRIFFEJSMLS-SWLSCSKDSA-N 0.000 description 1
- PASHBOSJULOTFP-AAEUAGOBSA-N Cc1nc(NC[C@H](CCNC2)[C@H]2O)cnc1Sc(cccc1Cl)c1Cl Chemical compound Cc1nc(NC[C@H](CCNC2)[C@H]2O)cnc1Sc(cccc1Cl)c1Cl PASHBOSJULOTFP-AAEUAGOBSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000037088 Chromosome Breakage Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700042658 GAP-43 Proteins 0.000 description 1
- 108700032487 GAP-43-3 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000999322 Homo sapiens Putative insulin-like growth factor 2 antisense gene protein Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010024291 Leukaemias acute myeloid Diseases 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101150024075 Mapk1 gene Proteins 0.000 description 1
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- QMEJLMZUXCRJQM-UHFFFAOYSA-N NC1=NC2=C(N=C1C1=CC=CC(Cl)=C1Cl)C(=O)NCCN2 Chemical compound NC1=NC2=C(N=C1C1=CC=CC(Cl)=C1Cl)C(=O)NCCN2 QMEJLMZUXCRJQM-UHFFFAOYSA-N 0.000 description 1
- SRBMFHQXINLPCZ-UHFFFAOYSA-N NCC(CC1)(CCN1c1cnc(-c(cccc2Cl)c2Cl)c(C#N)n1)C=O Chemical compound NCC(CC1)(CCN1c1cnc(-c(cccc2Cl)c2Cl)c(C#N)n1)C=O SRBMFHQXINLPCZ-UHFFFAOYSA-N 0.000 description 1
- GJGKUGBBWTWWSH-MRXNPFEDSA-N NCC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl Chemical compound NCC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=CC(Cl)=C1Cl GJGKUGBBWTWWSH-MRXNPFEDSA-N 0.000 description 1
- KXTVNEWPZLYQKA-CQSZACIVSA-N NCC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=NC(Cl)=C1Cl Chemical compound NCC1=NC(N2CCC3(CCC[C@H]3N)CC2)=CN=C1SC1=CC=NC(Cl)=C1Cl KXTVNEWPZLYQKA-CQSZACIVSA-N 0.000 description 1
- DOZJBSJMCJRCEP-QGZVFWFLSA-N N[C@@H]1CCCC12CCN(C1=CN=C(SC3=CC=CC(Cl)=C3Cl)C(C3CC3)=N1)CC2 Chemical compound N[C@@H]1CCCC12CCN(C1=CN=C(SC3=CC=CC(Cl)=C3Cl)C(C3CC3)=N1)CC2 DOZJBSJMCJRCEP-QGZVFWFLSA-N 0.000 description 1
- BMXRTORJYWPUKS-GFCCVEGCSA-N N[C@@H]1CCCC12CCN(C1=CN=C(SC3=CC=NC(Cl)=C3Cl)C(C(F)(F)F)=N1)CC2 Chemical compound N[C@@H]1CCCC12CCN(C1=CN=C(SC3=CC=NC(Cl)=C3Cl)C(C(F)(F)F)=N1)CC2 BMXRTORJYWPUKS-GFCCVEGCSA-N 0.000 description 1
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 102000007607 Non-Receptor Type 11 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100036485 Putative insulin-like growth factor 2 antisense gene protein Human genes 0.000 description 1
- 108700022176 SOS1 Proteins 0.000 description 1
- 101150036867 SYP gene Proteins 0.000 description 1
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 101800001701 Saposin-C Proteins 0.000 description 1
- 102400000831 Saposin-C Human genes 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 102100032929 Son of sevenless homolog 1 Human genes 0.000 description 1
- 101150100839 Sos1 gene Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 101710204864 Tyrosine-protein phosphatase 2 Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- PQFGWUROZJQILN-UHFFFAOYSA-O [NH3+]C(CC1)(CCN1c1nc(C#N)c(-c(cccc2Cl)c2Cl)nc1)C=O Chemical compound [NH3+]C(CC1)(CCN1c1nc(C#N)c(-c(cccc2Cl)c2Cl)nc1)C=O PQFGWUROZJQILN-UHFFFAOYSA-O 0.000 description 1
- GUWTXVUFNXVQMT-UHFFFAOYSA-N [N]1C=2N(CCC1)C=CC2 Chemical compound [N]1C=2N(CCC1)C=CC2 GUWTXVUFNXVQMT-UHFFFAOYSA-N 0.000 description 1
- IFVGQKHFUZRWNA-ZPZFBZIMSA-L [Na+].[Na+].Oc1c(cc(c2cccnc12)S([O-])(=O)=O)\N=N\c1ccc2cc(ccc2c1)S([O-])(=O)=O Chemical compound [Na+].[Na+].Oc1c(cc(c2cccnc12)S([O-])(=O)=O)\N=N\c1ccc2cc(ccc2c1)S([O-])(=O)=O IFVGQKHFUZRWNA-ZPZFBZIMSA-L 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001908 autoinhibitory effect Effects 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229950003054 binimetinib Drugs 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000005436 dihydrobenzothiophenyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 230000003438 effect on compound Effects 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000004615 furo[2,3-b]pyridinyl group Chemical group O1C(=CC=2C1=NC=CC2)* 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 102000009543 guanyl-nucleotide exchange factor activity proteins Human genes 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229950002592 pimasertib Drugs 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 229950008933 refametinib Drugs 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102200155730 rs121918454 Human genes 0.000 description 1
- 102220011031 rs121918463 Human genes 0.000 description 1
- 102200155463 rs397507509 Human genes 0.000 description 1
- 102220011054 rs397507546 Human genes 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- FYGUBWKMMCWIKB-UHFFFAOYSA-N spiro[2.3]hexane Chemical compound C1CC11CCC1 FYGUBWKMMCWIKB-UHFFFAOYSA-N 0.000 description 1
- LBJQKYPPYSCCBH-UHFFFAOYSA-N spiro[3.3]heptane Chemical compound C1CCC21CCC2 LBJQKYPPYSCCBH-UHFFFAOYSA-N 0.000 description 1
- PHICBFWUYUCFKS-UHFFFAOYSA-N spiro[4.4]nonane Chemical compound C1CCCC21CCCC2 PHICBFWUYUCFKS-UHFFFAOYSA-N 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- VJYJJHQEVLEOFL-UHFFFAOYSA-N thieno[3,2-b]thiophene Chemical compound S1C=CC2=C1C=CS2 VJYJJHQEVLEOFL-UHFFFAOYSA-N 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000036967 uncompetitive effect Effects 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present disclosure relates to methods for the treatment of diseases or disorders (e.g., cancer or an inherited developmental disorder) with inhibitors of the protein tyrosine phosphatase SHP2.
- diseases or disorders e.g., cancer or an inherited developmental disorder
- this invention is concerned with methods of treating diseases or disorders (such as cancer or inherited developmental disorder) in subjects that are identified as candidates for treatment with an allosteric SHP2 inhibitor.
- SHP2 is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene that contributes to multiple cellular functions including proliferation, differentiation, cell cycle maintenance and migration. SHP2 is involved in signaling through the RAS-mitogen-activated protein kinase (MAPK), the JAK-STAT and/or the phosphoinositol 3-kinase-AKT pathways.
- MAPK RAS-mitogen-activated protein kinase
- JAK-STAT the JAK-STAT
- phosphoinositol 3-kinase-AKT phosphoinositol 3-kinase-AKT pathways.
- SHP2 has two N-terminal Src homology 2 domains (N—SH2 and C—SH2), a catalytic domain (PTP), and a C-terminal tail.
- the two SH2 domains control the subcellular localization and functional regulation of SHP2.
- the molecule exists in an inactive, self-inhibited conformation stabilized by a binding network involving residues from both the N—SH2 and PTP domains. Stimulation by, for example, cytokines or growth factors acting through RTKs leads to exposure of the catalytic site resulting in enzymatic activation of SHP2.
- Mutations in the PTPN11 gene and subsequently in SHP2 have been identified in several human developmental diseases, such as Noonan Syndrome and LEOPARD Syndrome, as well as human cancers, such as juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. Some of these mutations destabilize the autoinhibited conformation of SHP2 and promote autoactivation or enhanced growth factor-driven activation of SHP2.
- SHP2 therefore, represents a highly attractive target for the development of novel therapies for the treatment of various diseases including cancer.
- the present disclosure relates to methods of treating diseases or disorders (such as cancer or inherited developmental disorder) in certain subsets of subjects that are determined to be candidates for treatment with an allosteric SHP2 inhibitor.
- diseases or disorders such as cancer or inherited developmental disorder
- the disclosure provides a method of treating a subject having a disease or disorder associated with cells containing a mutant SHP2, comprising administering to the subject an allosteric SHP2 inhibitor, wherein the mutant SHP2 comprises an allosteric inhibitor-sensitive mutation.
- the allosteric inhibitor-sensitive mutation is F285S, L262R, S189A, D61G, E69K, T73I, or Q506P.
- the cells are negative for an allosteric inhibitor-resistant mutation of SHP2.
- the allosteric inhibitor-resistant mutation is E76K, P491S, or S502P.
- the disclosure provides a method of identifying a subject with SHP2 mutations susceptible to a SHP2 inhibitor, comprising genotyping a biological sample from the subject for SHP2 mutations, wherein the subject is identified as susceptible to the SHP2 inhibitor if the SHP2 mutations comprise an allosteric inhibitor-sensitive mutation.
- the allosteric inhibitor-sensitive mutation is F285S, L262R, S189A, D61G, E69K, T73I, or Q506P.
- the disclosure provides a method of identifying a subject as resistant to an allosteric SHP2 inhibitor, comprising genotyping a biological sample from the subject for SHP2 mutations, wherein the subject is identified as resistant to the SHP2 inhibitor if the SHP2 mutations comprise an allosteric inhibitor-resistant mutation.
- the allosteric inhibitor-resistant mutation is E76K, P491S, or S502P.
- the disclosure provides a diagnostic test for allosteric SHP2 inhibitor sensitivity, comprising a nucleic acid probe specific for an allosteric inhibitor-sensitive mutation of SHP2.
- the allosteric inhibitor-sensitive mutation is F285S, L262R, S189A, D61G, E69K, T73I, or Q506P.
- FIG. 1 shows a simple equilibrium model for activation/inhibition by peptide binding, mutation, and inhibitor binding.
- FIG. 2 shows the potency of each compound to inhibit non-activated mutant SHP2 plotted versus the potency to inhibit wild-type SHP2.
- FIG. 3 shows the potency of each compound to inhibit peptide-activated mutant SHP2 plotted versus the potency to inhibit peptide-activated wild-type SHP2.
- FIG. 4 shows negligible shift in potency for inhibition of wild-type SHP2 between non-activated and peptide-activated biochemical experiments.
- FIG. 5 shows addition of activating peptide (NsCs, 0.5 ⁇ M) had negligible effect on inhibitor potency for WT SHP2 and varying effects on mutants S189A ( FIG. 5A ), F285C ( FIG. 5B ), D61G ( FIG. 5C ), and E76K ( FIG. 5D ).
- FIG. 6 shows the generation of isogenic cell lines for SHP2 mutants and their use in cellular assays for SHP2 inhibition.
- FIG. 7 shows EGF-induced pERK activity for various mutant SHP2s at various concentrations of Compound B
- FIG. 8 shows that biochemical data from activated SHP2 is a better predictor of cellular sensitivity than biochemical data from unactivated SHP2.
- FIG. 8A depicts biochemical pIC 50 plotted against cellular pIC 50 for activated SHP2.
- FIG. 8B depicts biochemical pIC 50 plotted against cellular pIC 50 for unactivated SHP2.
- an element means one element or more than one element.
- administer refers to either directly administering a disclosed compound or pharmaceutically acceptable salt of the disclosed compound or a composition to a subject, or administering a prodrug derivative or analog of the compound or pharmaceutically acceptable salt of the compound or composition to the subject, which can form an equivalent amount of active compound within the subject's body.
- carrier encompasses carriers, excipients, and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject.
- RMC-0693943 (abbreviated herein as “RMC-3943”), which has the following structure:
- RMC-0694550 abbreviated herein as “RMC-4550”
- Compound C and “Cmp C” are used interchangeably herein to refer to an allosteric SHP2 inhibitor compound of similar structure to Compounds A and B.
- Compound C is disclosed in PCT/US2017/041577 (WO 2018/013597), incorporated herein by reference in its entirety.
- SHP099 refers to a SHP2 inhibitor having the following structure:
- disorder is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.
- an “effective amount” when used in connection with a compound is an amount effective for treating or preventing a disease or disorder in a subject as described herein.
- inhibitor means a compound that prevents a biomolecule, (e.g., a protein, nucleic acid) from completing or initiating a reaction.
- An inhibitor can inhibit a reaction by competitive, uncompetitive, or non-competitive means.
- Exemplary inhibitors include, but are not limited to, nucleic acids, DNA, RNA, shRNA, siRNA, proteins, protein mimetics, peptides, peptidomimetics, antibodies, small molecules, chemicals, analogs that mimic the binding site of an enzyme, receptor, or other protein, e.g., that is involved in signal transduction, therapeutic agents, pharmaceutical compositions, drugs, and combinations of these.
- the inhibitor can be nucleic acid molecules including, but not limited to, siRNA that reduce the amount of functional protein in a cell. Accordingly, compounds said to be “capable of inhibiting” a particular protein, e.g., SHP2, comprise any such inhibitor.
- allosteric inhibitor means a small-molecule compound capable of inhibiting SHP2 through binding to SHP2 at a site other than the active site of the enzyme.
- exemplary allosteric SHP2 inhibitors disclosed herein include, without limitation: (i) Compound A; (ii) Compound B; (iii) Compound C; (iv) SHP099; (v) an allosteric SHP2 inhibitor compound of any one of Formula I, of Formula II, of Formula III, of Formula I-V1, of Formula I-V2, of Formula I-W, of Formula I-X, of Formula I-Y, of Formula I-Z, of Formula IV, of Formula V, of Formula VI, of Formula IV-X, of Formula IV-Y, of Formula IV-Z, of Formula VII, of Formula VIII, of Formula IX, and of Formula X; (vi) TNO155; (vii) a SHP2 inhibitor disclosed in international PCT application PCT/US2017/041577 (WO2018013597), incorporated herein by reference in its entirety; (
- modulating includes “increasing,” “enhancing” or “stimulating,” as well as “decreasing” or “reducing,” typically in a statistically significant or a physiologically significant amount as compared to a control.
- An “increased,” “stimulated” or “enhanced” amount is typically a “statistically significant” amount, and may include an increase that is 1.1, 1.2, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times (e.g., 500, 1000 times) (including all integers and decimal points in between and above 1, e.g., 1.5, 1.6, 1.7.
- a “decreased” or “reduced” amount is typically a “statistically significant” amount, and may include a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% decrease in the amount produced by no composition (the absence of an agent or compound) or a control composition, including all integers in between.
- mutation indicates any modification of a nucleic acid and/or polypeptide which results in an altered nucleic acid or polypeptide.
- the term “mutation” may include, for example, point mutations, deletions or insertions of single or multiple residues in a polynucleotide, which includes alterations arising within a protein-encoding region of a gene as well as alterations in regions outside of a protein-encoding sequence, such as, but not limited to, regulatory or promoter sequences, as well as amplifications and/or chromosomal breaks or translocations.
- allosteric inhibitor-sensitive mutation when used in reference to a SHP2 mutation, means a mutation in SHP2 that results in a SHP2 polypeptide that may be modulated by a SHP2 allosteric inhibitor (e.g., any one of the SHP2 allosteric inhibitors disclosed herein).
- a SHP2 allosteric inhibitor e.g., any one of the SHP2 allosteric inhibitors disclosed herein.
- modulation of a SHP2 polypeptide comprising an allosteric inhibitor-sensitive mutation will in some embodiments result in a decrease in the activity of the SHP2 polypeptide.
- Such activity may be measured using any suitable activity assay known in the art or disclosed herein (see, e.g., the SHP2 allosteric inhibition assay described herein in Example 1).
- the allosteric inhibitor-sensitive mutation is a SHP2 mutation selected from any one of F285S, L262R, S189A, D61G, E69K, T73I, and Q506P. In some embodiments, the allosteric inhibitor-sensitive mutation may be a combination of two or more SHP2 mutations selected from F285S, L262R, S189A, D61G, E69K, T73I, and Q506P.
- allosteric inhibitor-resistant mutation when used in reference to a SHP2 mutation, means a mutation in SHP2 that renders a SHP2 polypeptide refractory or resistant to inhibition with a SHP2 allosteric inhibitor.
- an allosteric inhibitor-resistant mutation in a SHP2 polypeptide decreases the inhibitory effect that a SHP2 allosteric inhibitor has on the SHP2 polypeptide as compared to the effect the inhibitor has on a similar SHP2 polypeptide differing only in the absence of the allosteric inhibitor-resistant mutation.
- an allosteric inhibitor-resistant mutation in a SHP2 polypeptide abolishes all detectable inhibitory effects that a SHP2 allosteric inhibitor has on the activity of the SHP2 polypeptide, wherein the inhibitor has detectable inhibitory efficacy on a similar SHP2 polypeptide differing only in the absence of the allosteric inhibitor-resistant mutation.
- Such allosteric inhibitor-resistant mutations include, without limitation, mutations that destabilize the autoinhibited conformation of SHP2.
- the allosteric inhibitor-resistant mutation is a SHP2 mutation selected from any one of E76K, P491S, and S502P. In some embodiments, the allosteric inhibitor-resistant mutation is a combination of two or more SHP2 mutations selected from E76K, P491S, and S502P.
- a “patient” or “subject” is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus.
- prevent refers to keeping a disease or disorder from afflicting the subject. Preventing includes prophylactic treatment. For instance, preventing can include administering to the subject a compound disclosed herein before a subject is afflicted with a disease and the administration will keep the subject from being afflicted with the disease.
- a therapeutic agent e.g., a SHP2 inhibitor
- administering includes administering such an agent.
- RAS pathway and “RAS/MAPK pathway” are used interchangeably herein to refer to a signal transduction cascade downstream of various cell surface growth factor receptors in which activation of RAS (and its various isoforms and alleotypes) is a central event that drives a variety of cellular effector events that determine the proliferation, activation, differentiation, mobilization, and other functional properties of the cell.
- SHP2 conveys positive signals from growth factor receptors to the RAS activation/deactivation cycle, which is modulated by guanine nucleotide exchange factors (GEFs, such as SOS1) that load GTP onto RAS to produce functionally active GTP-bound RAS as well as GTP-accelerating proteins (GAPs, such as NF1) that facilitate termination of the signals by conversion of GTP to GDP.
- GTP-bound RAS produced by this cycle conveys essential positive signals to a series of serine/threonine kinases including RAF and MAP kinases, from which emanate additional signals to various cellular effector functions.
- RAS pathway mutation and “RAS/MAPK pathway activating mutation” are used interchangeably herein to refer to a mutation in a gene encoding a protein directly involved in the signaling processes of the RAS/MAPK signaling pathway and/or regulating (either positively or negatively) this signaling pathway that renders the pathway active, wherein such mutation may increase, change or decrease the activity level of said protein.
- proteins include but are not limited to Ras, Raf, NF1, SOS, and specific isoforms or alleotypes thereof.
- RTK-driven tumor refers to a tumor comprising a cell with one or more oncogenic mutation of an RTK, or a protein that is part of the RTK signaling complex, that causes high levels RTK signaling. Some such cells may be considered “addicted” to the RTK, and inhibition of RTK signaling leads to simultaneous suppression of downstream pathways, often resulting in cell growth, arrest, and death.
- RTK-driven tumors include, but are not limited to, non-small cell lung cancers (NSCLCs) with mutations in EGFR or ALK.
- NSCLCs non-small cell lung cancers
- SHP2 means “Src Homology 2 domain-containing protein tyrosine phosphatase 2” and is also known as SH-PTP2, SH-PTP3, Syp, PTP1D, PTP2C, SAP-2 or PTPN11. Numbering of SHP2 mutations in the present disclosure is according to Uniprot Isoform 2 (accession number Q06124-2) (SEQ ID NO: 1):
- AAwt ###AAmut is used to indicate a mutation that results in the wild-type amino acid AAwt at position ### in the polypeptide being replaced with mutant AAmut.
- a “therapeutic agent” is any substance, e.g., a compound or composition, capable of treating a disease or disorder.
- therapeutic agents that are useful in connection with the present disclosure include without limitation SHP2 inhibitors, ALK inhibitors, MEK inhibitors, RTK inhibitors (TKIs), and cancer chemotherapeutics. Many such inhibitors are known in the art and are disclosed herein.
- terapéuticaally effective amount is the amount of the drug, e.g., a SHP2 inhibitor, needed to elicit the desired biological response following administration.
- treatment refers to improving at least one symptom, pathology or marker of the subject's disease or disorder, either directly or by enhancing the effect of another treatment. Treating includes curing, improving, or at least partially ameliorating the disorder, and may include even minimal changes or improvements in one or more measurable markers of the disease or condition being treated. “Treatment” or “treating” does not necessarily indicate complete eradication or cure of the disease or condition, or associated symptoms thereof.
- the subject receiving this treatment is any subject in need thereof. Exemplary markers of clinical improvement will be apparent to persons skilled in the art.
- the present disclosure relates to, inter alia, compositions, methods, and kits for treating or preventing a disease or disorder (e.g., cancer) with a SHP2 inhibitor alone or in combination with another suitable therapeutic agent.
- a disease or disorder e.g., cancer
- a SHP2 inhibitor alone or in combination with another suitable therapeutic agent.
- SHP2 is an important signaling effector molecule for a variety of receptor tyrosine kinases (RTKs), including the receptors of platelet-derived growth factor (PDGFR), fibroblast growth factor (FGFR), and epidermal growth factor (EGFR).
- RTKs receptor tyrosine kinases
- PDGFR platelet-derived growth factor
- FGFR fibroblast growth factor
- EGFR epidermal growth factor
- SHP2 is also an important signaling molecule that regulates the activation of the mitogen activated protein (MAP) kinase pathway which can lead to cell transformation, a prerequisite for the development of cancer.
- MAP mitogen activated protein
- SHP2 is involved in signaling through the Ras-mitogen-activated protein kinase, the JAK-STAT and/or the phosphoinositol 3-kinase-AKT pathways.
- SHP2 mediates activation of Erk1 and Erk2 (Erk1/2, Erk) MAP
- SHP2 has two N-terminal Src homology 2 domains (N—SH2 and C—SH2), a catalytic domain (PTP), and a C-terminal tail.
- the two SH2 domains control the subcellular localization and functional regulation of SHP2.
- the molecule exists in an inactive conformation, inhibiting its own activity via a binding network involving residues from both the N—SH2 and PTP domains.
- SHP2 associates with the RTK signaling apparatus, and this induces a conformational change that results in SHP2 activation.
- Activating mutations of SHP2 have been associated with developmental pathologies such as Noonan syndrome and LEOPARD Syndrome and may also be found in multiple cancer types, including most RTK-driven tumors, leukemia, lung and breast cancer, gastric carcinoma, anaplastic large-cell lymphoma, glioblastoma and neuroblastoma.
- PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 109, 862-867 (2007). Matozaki, T., Murata, Y., Saito, Y., Okazawa, H. & Ohnishi, H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci. 100, 1786-1793 (2009). Mohi, M. G. & Neel, B. G. The role of Shp2 (PTPN11) in cancer. Curr. Opin. Genet. Dev. 17, 23-30 (2007).) ⁇ stman, A., Hellberg, C. & Böhmer, F. D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 6, 307-320 (2006).
- SHP2 plays a role in transducing signals originating from immune checkpoint molecules, including but not limited to programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
- PD-1 programmed cell death protein 1
- CTL-4 cytotoxic T-lymphocyte-associated protein 4
- inhibition of SHP2 function may promote activation of immune cells expressing checkpoint molecules, including anti-cancer immune responses.
- the present disclosure provides a method for patient stratification based upon the presence or absence of a SHP2 mutation or based upon the particular subtype of such a mutation.
- patient stratification means classifying one or more patient as having a disease or disorder (e.g., cancer) that is either likely or unlikely to be treatable with an allosteric SHP2 inhibitor.
- Patient stratification may comprise classifying a patient as having a tumor that is sensitive to treatment with an allosteric SHP2 inhibitor.
- the patient stratification may be based on the presence or absence of a tumor comprising one or more cell containing a SHP2 mutation that renders the mutated SHP2 protein sensitive or resistant to allosteric inhibitors of SHP2.
- any disease or condition associated with a SHP2 mutation may be identified, assessed, and/or treated according to the present disclosure.
- the SHP2 mutation leaves the mutated protein sensitive to allosteric inhibitors of SHP2.
- diseases or conditions comprising SHP2 mutations are known in the art.
- the present disclosure provides methods for treating a disease or condition selected from, but not limited to, Noonan Syndrome (e.g., Noonan syndrome caused by a mechanism other than a SHP2 mutation), LEOPARD Syndrome (e.g., LEOPARD Syndrome caused by a mechanism other than a SHP2 mutation); tumors of hemopoietic and lymphoid system including myeloproliferative syndromes, myelodysplastic syndromes, and leukemia, e.g., acute myeloid leukemia, and juvenile myelomonocytic leukemias; esophageal cancer; breast cancer; lung cancer; colon cancer; gastric cancer, neuroblastoma, bladder cancer, prostate cancer; glioblastoma; urothelial carcinoma, uterine carcinoma, adenoid and ovarian sereous cystadenocarcinoma, paraganglioma, phaeochromocytoma, pancreatic cancer, adrenocor
- Noonan Syndrome
- the methods for treating such diseases or disorders involve administering to a subject an effective amount of a SHP2 inhibitor or a composition (e.g., a pharmaceutical composition) comprising a SHP2 inhibitor.
- a SHP2 inhibitor or a composition comprising a SHP2 inhibitor.
- Any compound or substance capable of inhibiting SHP2 may be utilized in application with the present disclosure to inhibit SHP2.
- Non-limiting examples of such SHP2 inhibitors are known in the art and are disclosed herein.
- the compositions and methods described herein may utilize one or more SHP2 inhibitor selected from, but not limited to, any SHP2 inhibitor disclosed in Chen, Ying-Nan P et al., 148 Nature Vol 535 7 Jul. 2016, incorporated herein by reference in its entirety, including SHP099, disclosed therein.
- compositions and methods described herein may utilize one or more SHP2 inhibitor selected from, but not limited to any SHP2 inhibitor disclosed in PCT application PCT/US2017/041577 (WO2018013597), which is incorporated herein by reference in its entirety.
- the compositions and methods described herein may utilize one or more SHP2 inhibitor selected from, but not limited to any SHP2 inhibitor disclosed in PCT applications PCT/IB2015/050343 (WO2015107493); PCT/IB2015/050344 (WO2015107494); PCT/IB2015/050345 (WO201507495); PCT/IB2016/053548 (WO2016/203404); PCT/IB2016/053549 (WO2016203405); PCT/IB2016/053550 (WO2016203406); PCT/US2010/045817 (WO2011022440); PCT/US2017/021784 (WO2017156397); and PCT/US2016/060787 (WO2017079723); and PCT/CN2017/08
- compositions and methods described herein may utilize one or more SHP2 inhibitor selected from, but not limited to any SHP2 inhibitor disclosed in Chen L, et al., Mol Pharmacol. 2006 August; 70(2):562-70, incorporated herein by reference in its entirety, including NSC-87877 disclosed therein.
- SHP2 inhibitor selected from, but not limited to any SHP2 inhibitor disclosed in Chen L, et al., Mol Pharmacol. 2006 August; 70(2):562-70, incorporated herein by reference in its entirety, including NSC-87877 disclosed therein.
- the compositions and methods described herein may utilize TNO155, described under ClinicalTrials.gov Identifier: NCT03114319, available at world wide web address: clinicaltrials.gov/ct2/show/NCT03114319, incorporated herein by reference in its entirety.
- compositions and methods described herein may utilize one or more SHP2 inhibitor selected from, but not limited to RMC-3943, disclosed herein; RMC-4550, disclosed herein; a SHP2 inhibitor compound of Formula I, Formula II, Formula III, Formula I-VI, Formula I-V2, Formula I-W, Formula I-X, Formula I-Y, Formula I-Z, Formula IV, Formula V, Formula VI, Formula IV-X, Formula IV-Y, Formula IV-Z, Formula VII, Formula VIII, Formula IX, and Formula X, disclosed herein; a compound from Table A1, disclosed herein; and a compound from Table A2, disclosed herein.
- SHP2 inhibitor selected from, but not limited to RMC-3943, disclosed herein; RMC-4550, disclosed herein; a SHP2 inhibitor compound of Formula I, Formula II, Formula III, Formula I-VI, Formula I-V2, Formula I-W, Formula I-X, Formula I-Y, Formula I-Z, Formula IV, Formula V, Formula VI, Formula IV-X, Formula IV-Y, Formula
- A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- Y 1 is —S— or a direct bond
- Y 2 is —NR a —, —(CR a 2 ) m —, —C(O)—, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a ), —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —C(O)O—, —OC(O)—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)N(R a )O—,
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 , —C(O)R 5 , or —CO 2 R 5 ,
- R a is independently, at each occurrence, —H, -D, —OH, —C 3 -C 8 cycloalkyl, or —C 1 -C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 3 -C 8 cycloalkyl, —C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 R
- R 3 is independently —C 1 -C 6 alkyl or a 3- to 12-membered monocyclic or polycyclic heterocycle, wherein each alkyl or heterocycle is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, or —NH 2 ; or
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, or —NH 2 ;
- R 4 is independently —H, -D, or —C 1 -C 6 alkyl, wherein each alkyl is optionally substituted with one or more —OH, —NH 2 , halogen, or oxo; or
- R a and R 4 together with the atom or atoms to which they are attached, can combine to form a monocyclic or polycyclic C 3 -C 12 cycloalkyl or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein the cycloalkyl or heterocycle is optionally substituted with oxo;
- R 5 and R 6 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , or —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently, at each occurrence, 1, 2, 3, 4, 5 or 6;
- n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- Y 2 is —NR a —, —(CR a 2 ) m —, —C(O)—, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a ), —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —C(O)O—, —OC(O)—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)N(R a )O—,
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 , —C(O)R 5 , or —CO 2 R 5 ,
- R 2 is independently —OR b , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2
- R a is independently, at each occurrence, —H, -D, —OH, —C 3 -C 8 cycloalkyl, or —C 1 -C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 3 -C 8 cycloalkyl, —C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 R
- R 3 is independently —C 1 -C 6 alkyl or a 3- to 12-membered monocyclic or polycyclic heterocycle, wherein each alkyl or heterocycle is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, or —NH 2 ; or
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, or —NH 2 ;
- R 4 is independently —H, -D, or —C 1 -C 6 alkyl, wherein each alkyl is optionally substituted with one or more —OH, —NH 2 , halogen, or oxo; or
- R a and R 4 together with the atom or atoms to which they are attached, can combine to form a monocyclic or polycyclic C 3 -C 12 cycloalkyl or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein the cycloalkyl or heterocycle is optionally substituted with oxo;
- R 5 and R 6 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , or —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently, at each occurrence, 1, 2, 3, 4, 5 or 6;
- n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- Y 2 is —NR a —, —(CR a 2 ) m —, —C(O)—, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a )—, —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —C(O)O—, —OC(O)—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)N(R a )—
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 , —C(O)R 5 , or —CO 2 R 5 ,
- R 2 is independently —OR b , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2
- R a is independently, at each occurrence, —H, -D, —OH, —C 3 -C 8 cycloalkyl, or —C 1 -C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 3 -C 8 cycloalkyl, —C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 R
- R 3 is independently —C 1 -C 6 alkyl or a 3- to 12-membered monocyclic or polycyclic heterocycle, wherein each alkyl or heterocycle is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, or —NH 2 ; or
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, or —NH 2 ;
- R 4 is independently —H, -D, or —C 1 -C 6 alkyl, wherein each alkyl is optionally substituted with one or more —OH, —NH 2 , halogen, or oxo; or
- R a and R 4 together with the atom or atoms to which they are attached, can combine to form a monocyclic or polycyclic C 3 -C 12 cycloalkyl or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein the cycloalkyl or heterocycle is optionally substituted with oxo;
- R 5 and R 6 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , or —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently, at each occurrence, 1, 2, 3, 4, 5 or 6;
- n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are 5- to 12-membered monocyclic or 5- to 12-membered polycyclic;
- Y 1 is —S—, a direct bond, —NH—, —S(O) 2 —, —S(O) 2 —NH—, —C( ⁇ CH 2 )—, —CH—, or —S(O)—;
- Y 2 is —NR a —, wherein the bond on the left side of Y 2 , as drawn, is bound to the pyrazine ring and the bond on the right side of the Y 2 moiety, as drawn, is bound to R 3 ;
- R a and R 4 together with the atom or atoms to which they are attached, are combined to form a monocyclic or polycyclic C 3 -C 12 cycloalkyl or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein the cycloalkyl or heterocycle is optionally substituted with oxo; wherein the heterocycle optionally comprises —S(O) 2 — in the heterocycle;
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, —OR 6 , halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 ,
- R 2 is independently —NH 2 , —OR b , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, halogen, —C(O)OR b , —C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 ,
- R b is independently, at each occurrence, —H, -D, —OH, —C 1 -C 6 alkyl, —C 3 -C 8 cycloalkyl, —C 2 -C 6 alkenyl, —(CH 2 ) n -aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or —(CH 2 )n-aryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —
- R 3 is independently —H, —C 1 -C 6 alkyl, a 3- to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, —C 3 -C 8 cycloalkyl, or —(CH 2 ) n —R b , wherein each alkyl, spiroheterocycle, heterocycle, or cycloalkyl is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, —NH 2 , —OR b , —NHR b , —(CH 2 ) n OH, heterocyclyl, or spiroheterocyclyl;
- R 5 and R 6 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , —CF 3 , or —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OR, or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN; and
- n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are 5- to 12-membered monocyclic or 5- to 12-membered polycyclic;
- Y 1 is —S—, a direct bond, —NH—, —S(O) 2 —, —S(O) 2 —NH—, —C( ⁇ CH 2 )—, —CH—, or —S(O)—;
- Y 2 is —NR a —, wherein the bond on the left side of Y 2 , as drawn, is bound to the pyrazine ring and the bond on the right side of the Y 2 moiety, as drawn, is bound to R 3 ;
- R 3 is combined with R a to form a 3- to 12-membered polycyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more —C 1 -C 6 alkyl, halogen, —OH, —OR b , —NH 2 , —NHR b , heteroaryl, heterocyclyl, —(CH 2 ) n NH 2 , —(CH 2 ) n OH, —COOR b , —CONHR b , —CONH(CH 2 ) n COOR b , —NHCOOR b , —CF 3 , —CHF 2 , —CH 2 F, or ⁇ O;
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, —OR 6 , halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 ,
- R 2 is independently —NH 2 , —OR b , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, halogen, —C(O)OR b , —C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 ,
- R b is independently, at each occurrence, —H, -D, —OH, —C 1 -C 6 alkyl, —C 3 -C 8 cycloalkyl, —C 2 -C 6 alkenyl, —(CH 2 )n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or —(CH 2 )n-aryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5
- R 4 is independently —H, -D, —C 1 -C 6 alkyl, —C 1 -C 6 haloalkyl, —C 1 -C 6 hydroxyalkyl, —CF 2 OH, —CHFOH, —NH—NHR 5 , —NH—OR 5 , —O—NR 5 R 6 , —NHR 5 , —OR 5 , —NHC(O)R 5 , —NHC(O)NHR 5 , —NHS(O) 2 R 5 , —NHS(O) 2 NHR 5 , —S(O) 20 H, —C(O)OR 5 , —NH(CH 2 ) n OH, —C(O)NH(CH 2 ) n OH, —C(O)NH(CH 2 ) n R b , —C(O)R b , —NH 2 , —OH, —CN, —C(O)NR
- R 5 and R 6 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , —CF 3 , or —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OR, or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN; and
- n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are 5- to 12-membered monocyclic or 5- to 12-membered polycyclic;
- Y 1 is —S—, a direct bond, —NH—, —S(O) 2 —, —S(O) 2 —NH—, —C( ⁇ CH 2 )—, —CH—, or —S(O)—;
- Y 2 is —NR a —, —(CR a 2 ) m —, —C(O)—, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a ), —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —C(O)O—, —OC(O)—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)N(R a )O—,
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, —OR 6 , halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 ,
- R 2 is independently —OR b , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, halogen, —C(O)OR b , —C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6
- R a is independently, at each occurrence, —H, -D, —OH, —C 3 -C 8 cycloalkyl, —C 1 -C 6 alkyl, 3- to 12-membered heterocyclyl, or —(CH 2 ) n -aryl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , or wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently, at each occurrence, —H, -D, —OH, —C 1 -C 6 alkyl, —C 3 -C 8 cycloalkyl, —C 2 -C 6 alkenyl, —(CH 2 )n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or —(CH 2 )n-aryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5
- R 3 is independently —H, —C 1 -C 6 alkyl, a 3- to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C 3 -C 8 cycloalkyl, or —(CH 2 ) n —R b , wherein each alkyl, spiroheterocycle, heterocycle, or cycloalkyl is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, —NH 2 , —OR b , —NHR b , —(CH 2 ) n OH, heterocyclyl, or spiroheterocyclyl; or
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more —C 1 -C 6 alkyl, halogen, —OH, —OR b , —NH 2 , —NHR b , heteroaryl, heterocyclyl, —(CH 2 ) n NH 2 , —(CH 2 ) n OH, —COOR b , —CONHR b , —CONH(CH 2 ) n COOR b , —NHCOOR b , —CF 3 , —CHF 2 , —CH 2 F, or ⁇ O;
- R 4 is independently —H, -D, —C 1 -C 6 alkyl, —C 1 -C 6 haloalkyl, —C 1 -C 6 hydroxyalkyl —CF 2 OH, —CHFOH —NH—NHR 5 , —NH—OR 5 , —O—NR 5 R 6 , —NHR 5 , —OR 5 , —NHC(O)R 5 , —NHC(O)NHR 5 , —NHS(O) 2 R 5 , —NHS(O) 2 NHR 5 , —S(O) 20 H, —C(O)OR 5 , —NH(CH 2 ) n OH, —C(O)NH(CH 2 ) n OH, —C(O)NH(CH 2 ) n R b , —C(O)R b , —NH 2 , —OH, —CN, —C(O)NR 5 R
- R a and R 4 together with the atom or atoms to which they are attached, can combine to form a monocyclic or polycyclic C 3 -C 12 cycloalkyl or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein the cycloalkyl or heterocycle is optionally substituted with oxo; wherein the heterocycle optionally comprises —S(O) 2 — in the heterocycle;
- R 5 and R 6 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , —CF 3 , or —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OR, or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently, at each occurrence, 1, 2, 3, 4, 5 or 6;
- n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- Y 1 is —S— or a direct bond
- Y 2 is —NR a —, —(CR a 2 ) m —, —C(O)—, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a ), —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —C(O)O—, —OC(O)—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)N(R a )O—,
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 , —C(O)R 5 , or —CO 2 R 5 ,
- R 2 is independently —OR b , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2
- R a is independently, at each occurrence, —H, -D, —OH, —C 3 -C 8 cycloalkyl, or —C 1 -C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 3 -C 8 cycloalkyl, —C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 R
- R 3 is independently —H, —C 1 -C 6 alkyl, or a 3- to 12-membered monocyclic or polycyclic heterocycle, wherein each alkyl or heterocycle is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, or —NH 2 ; or
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, or —NH 2 ;
- R 4 is independently —H, -D, —C 1 -C 6 alkyl, —NH—NHR 5 , —NH—OR 5 , —O—NR 5 R 6 , —NHR 5 , —OR 5 , —NHC(O)R 5 , —NHC(O)NHR 5 , —NHS(O) 2 R 5 , —NHS(O) 2 NHR 5 , —S(O) 20 H, —C(O)OR 5 , —C(O)NR 5 R 6 , —S(O) 2 NR 5 R 6 , C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one
- R a and R 4 together with the atom or atoms to which they are attached, can combine to form a monocyclic or polycyclic C 3 -C 12 cycloalkyl or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein the cycloalkyl or heterocycle is optionally substituted with oxo; wherein the heterocycle optionally comprises —S(O) 2 — in the heterocycle;
- R 5 and R 6 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , or —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently, at each occurrence, 1, 2, 3, 4, 5 or 6;
- n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- Y 1 is —S— or a direct bond
- Y 2 is —NR a —, —(CR a 2 ) m —, —C(O)—, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a ), —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —C(O)O—, —OC(O)—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)N(R a )O—,
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 , —C(O)R 5 , or —CO 2 R 5 ,
- R 2 is independently —OR b , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2
- R a is independently, at each occurrence, —H, -D, —OH, —C 3 -C 8 cycloalkyl, or —C 1 -C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 3 -C 8 cycloalkyl, —C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 R
- R 3 is independently —H, —C 1 -C 6 alkyl, a 3- to 12-membered monocyclic or polycyclic heterocycle, C 3 -C 8 cycloalkyl, or —(CH 2 ) n —R, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, —NH 2 , —OR b , —NHR b , —(CH 2 ) n OH, heterocyclyl, or spiroheterocyclyl; or
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, —NH 2 , heteroaryl, heterocyclyl, —(CH 2 ) n NH 2 , —COOR b , —CONHR b , —CONH(CH 2 ) n COOR b , —NHCOOR b , —CF 3 , —CHF 2 , or —CH 2 F;
- R 4 is independently —H, -D, —C 1 -C 6 alkyl, —NH—NHR 5 , —NH—OR b , —O—NR 5 R 6 , —NHR 5 , —OR 5 , —NHC(O)R 5 , —NHC(O)NHR 5 , —NHS(O) 2 R 5 , —NHS(O) 2 NHR 5 , —S(O) 20 H, —C(O)OR 5 , —NH(CH 2 ) n OH, —C(O)NH(CH 2 ) n OH, —C(O)NH(CH 2 ) n R b , —C(O)R b , —NH 2 , —OH, —CN, —C(O)NR 5 R 6 , —S(O) 2 NR 5 R 6 , C 3 -C 8 cycloalkyl, aryl, heterocyclyl
- R a and R 4 together with the atom or atoms to which they are attached, can combine to form a monocyclic or polycyclic C 3 -C 12 cycloalkyl or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein the cycloalkyl or heterocycle is optionally substituted with oxo; wherein the heterocycle optionally comprises —S(O) 2 — in the heterocycle;
- R 5 and R 6 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , or —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently, at each occurrence, 1, 2, 3, 4, 5 or 6;
- n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- A is a 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- Y 1 is —S—, a direct bond, —NH—, —S(O) 2 —, —S(O) 2 —NH—, —C( ⁇ CH 2 )—, —CH—, or —S(O)—;
- Y 2 is —NR a —, —(CR a 2 ) m —, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a )—, —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)—, or —C(S)N(R a )—; wherein the bond on the left side of Y 2 , as
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 , —C(O)R 5 , or —CO 2 R 5 ,
- R 2 is independently —OR b , —NH 2 , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, halogen, —C(O)OR b , —C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 ,
- R a is independently, at each occurrence —OH, —C 3 -C 8 cycloalkyl, or —C 1 -C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 3 -C 8 cycloalkyl, —C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 R
- R 3 is independently —H, —C 1 -C 6 alkyl, a 3- to 12-membered monocyclic or polycyclic heterocycle, C 3 -C 8 cycloalkyl, or —(CH 2 ) n —R, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, —NH 2 , —OR b , —NHR b , —(CH 2 ) n OH, heterocyclyl, or spiroheterocyclyl; or
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, —NH 2 , heteroaryl, heterocyclyl, —(CH 2 ) n NH 2 , —COOR b , —CONHR b , —CONH(CH 2 ) n COOR b , —NHCOOR b , —CF 3 , —CHF 2 , or —CH 2 F;
- R 4 is independently —C 1 -C 6 alkyl, —NH—NHR 5 , —NH—OR 5 , —O—NR 5 R 6 , —NHR 5 , —OR 5 , —NHC(O)R 5 , —NHC(O)NHR 5 , —NHS(O) 2 R 5 , —NHS(O) 2 NHR 5 , —S(O) 20 H, —C(O)OR 5 , —NH(CH 2 ) n OH, —C(O)NH(CH 2 ) n OH, —C(O)NH(CH 2 ) n R b , —C(O)R b , —NH 2 , —OH, —C(O)NR 5 R 6 , —S(O) 2 NR 5 R 6 , C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of
- R a and R 4 together with the atom or atoms to which they are attached, are combined to form a monocyclic or polycyclic C 3 -C 12 cycloalkyl or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein the cycloalkyl or heterocycle is optionally substituted with oxo; wherein the heterocycle optionally comprises —S(O) 2 — in the heterocycle;
- R 5 and R 6 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , or —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently, at each occurrence, 1, 2, 3, 4, 5 or 6;
- n is independently, at each occurrence, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- One aspect of the invention relates to compounds of Formula IV:
- A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- Y 1 is —S— or a direct bond
- Y 2 is selected from the group consisting of: —NR a —, —(CR a 2 ) m —, —C(O)—, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a )—, —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —C(O)O—, —OC(O)—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 , —C(O)R 5 , or —CO 2 R 5 ,
- R 2 is independently —OR b , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —R 5 , —S(O) 2
- R a is independently, at each occurrence, selected from the group consisting of —H, -D, —OH, —C 3 -C 8 cycloalkyl, and —C 1 -C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently —H, -D, —C 1 -C 6 alkyl, —C 1 -C 6 cycloalkyl, —C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with —C 1 -C 6 alkyl, —OH, or —NH 2 ;
- R 4 is independently, at each occurrence, —H, -D, or —C 1 -C 6 alkyl, wherein each alkyl is optionally substituted with one or more —OH, —NH 2 , halogen, or oxo; or
- R a and R 4 together with the atom or atoms to which they are attached, can combine to form a monocyclic or polycyclic C 3 -C 12 cycloalkyl, or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein the cycloalkyl or heterocycle is optionally substituted with oxo;
- R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , and —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently 1, 2, 3, 4, 5 or 6;
- n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- Another aspect of the invention relates to compounds of Formula V:
- A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- Y 2 is selected from the group consisting of: —NR a —, —(CR a 2 ) m —, —C(O)—, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a )—, —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —C(O)O—, —OC(O)—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 , —C(O)R 5 , or —CO 2 R 5 ,
- R 2 is independently —OR b , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —R 5 , —S(O) 2
- R a is independently, at each occurrence, selected from the group consisting of —H, -D, —OH, —C 3 -C 8 cycloalkyl, and —C 1 -C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently —H, -D, —C 1 -C 6 alkyl, —C 1 -C 6 cycloalkyl, —C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S
- R 3 is independently, at each occurrence, selected from the group consisting of —C 1 -C 6 alkyl, or a 3- to 12-membered monocyclic or polycyclic heterocycle, wherein each alkyl or heterocycle is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, or —NH 2 ; or
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with —C 1 -C 6 alkyl, —OH, or —NH 2 ;
- R 4 is independently, at each occurrence, —H, -D, or —C 1 -C 6 alkyl, wherein each alkyl is optionally substituted with one or more —OH, —NH 2 , halogen, or oxo; or
- R a and R 4 together with the atom or atoms to which they are attached, can combine to form a monocyclic or polycyclic C 3 -C 12 cycloalkyl, or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein the cycloalkyl or heterocycle is optionally substituted with oxo;
- R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , and —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently 1, 2, 3, 4, 5 or 6;
- n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- Y 2 is selected from the group consisting of: —NR a —, —(CR a 2 ) m —, —C(O)—, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a )—, —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —C(O)O—, —OC(O)—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 , —C(O)R 5 , or —CO 2 R 5 ,
- R 2 is independently —OR b , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —R 5 , —S(O) 2
- R a is independently, at each occurrence, selected from the group consisting of —H, -D, —OH, —C 3 -C 8 cycloalkyl, and —C 1 -C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently —H, -D, —C 1 -C 6 alkyl, —C 1 -C 6 cycloalkyl, —C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S
- R 3 is independently, at each occurrence, selected from the group consisting of —C 1 -C 6 alkyl, or a 3- to 12-membered monocyclic or polycyclic heterocycle, wherein each alkyl or heterocycle is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, or —NH 2 ; or
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with —C 1 -C 6 alkyl, —OH, or —NH 2 ;
- R 4 is independently, at each occurrence, —H, -D, or —C 1 -C 6 alkyl, wherein each alkyl is optionally substituted with one or more —OH, —NH 2 , halogen, or oxo; or
- R a and R 4 together with the atom or atoms to which they are attached, can combine to form a monocyclic or polycyclic C 3 -C 12 cycloalkyl, or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein the cycloalkyl or heterocycle is optionally substituted with oxo;
- R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , and —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently 1, 2, 3, 4, 5 or 6;
- n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- One aspect of the invention relates to compounds of Formula IV-Y:
- A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- Y 1 is —S— or a direct bond
- Y 2 is selected from the group consisting of: —NR a —, —(CR a 2 ) m —, —C(O)—, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a )—, —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —C(O)O—, —OC(O)—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 , —C(O)R 5 , or —CO 2 R 5 ,
- R 2 is independently —OR b , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2
- R a is independently, at each occurrence, selected from the group consisting of —H, -D, —OH, —C 3 -C 8 cycloalkyl, and —C 1 -C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently —H, -D, —C 1 -C 6 alkyl, —C 1 -C 6 cycloalkyl, —C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —R 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —NR 5 S(O)NR 5 R 6 ,
- R 3 is independently, at each occurrence, selected from the group consisting of —H, —C 1 -C 6 alkyl, a 3- to 12-membered monocyclic or polycyclic heterocycle, C 3 -C 8 cycloalkyl, or —(CH 2 ) n —R, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, —NH 2 , —OR a , —NHR a , —(CH 2 ) n OH, heterocyclyl, or spiroheterocyclyl; or
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with —C 1 -C 6 alkyl, —OH, —NH 2 , heteroaryl, heterocyclyl, —(CH 2 ) n NH 2 , —COOR a , —CONHR b , —CONH(CH 2 ) n COOR a , —NHCOOR a , —CF 3 , CHF 2 , or CH 2 F;
- R 4 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —NH—NHR 5 , —NH—OR 5 , —O—NR 5 R 6 , —NHR 5 , —OR 5 , —NHC(O)R 5 , —NHC(O)NHR 5 , —NHS(O) 2 R 5 , —NHS(O) 2 NHR 5 , —S(O) 20 H, —C(O)OR 5 , —NH(CH 2 ) n OH, —C(O)NH(CH 2 ) n OH, —C(O)NH(CH 2 ) n R b , —C(O)R b , NH 2 , —OH, —CN, —C(O)NR 5 R 6 , —S(O) 2 NR 5 R 6 , C 3 -C 8 cycloalkyl, aryl, hetero
- R a and R 4 together with the atom or atoms to which they are attached, can combine to form a monocyclic or polycyclic C 3 -C 12 cycloalkyl, or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein the cycloalkyl or heterocycle is optionally substituted with oxo; wherein the heterocycle optionally comprises —S(O) 2 — in the heterocycle;
- R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , and —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently 1, 2, 3, 4, 5 or 6;
- n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- One aspect of the invention relates to compounds of Formula IV-Z:
- A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- Y 1 is —S—, a direct bond, —NH—, —S(O) 2 —, —S(O) 2 —NH—, —C( ⁇ CH 2 )—, —CH—, or —S(O)—;
- Y 2 is selected from the group consisting of: —NR a —, —(CR a 2 ) m —, —C(O)—, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a )—, —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —C(O)O—, —OC(O)—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 , —C(O)R 5 , or —CO 2 R 5 ,
- R 2 is independently —OR b , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —NH 2 , halogen, —C(O)OR a , —C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 ,
- R a is independently, at each occurrence, selected from the group consisting of —H, -D, —OH, —C 3 -C 8 cycloalkyl, and —C 1 -C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently —H, -D, —C 1 -C 6 alkyl, —C 1 -C 6 cycloalkyl, —C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —R 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —NR 5 S(O)NR 5 R 6 ,
- R 3 is independently, at each occurrence, selected from the group consisting of —H, —C 1 -C 6 alkyl, a 3- to 12-membered monocyclic or polycyclic heterocycle, C 3 -C 8 cycloalkyl, or —(CH 2 ) n —R, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, —NH 2 , —OR a , —NHR a , —(CH 2 ) n OH, heterocyclyl, or spiroheterocyclyl; or
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with —C 1 -C 6 alkyl, —OH, —NH 2 , heteroaryl, heterocyclyl, —(CH 2 ) n NH 2 , —COOR a , —CONHR b , —CONH(CH 2 ) n COOR a , —NHCOOR a , —CF 3 , CHF 2 , or CH 2 F;
- R 4 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —NH—NHR 5 , —NH—OR 5 , —O—NR 5 R 6 , —NHR 5 , —OR 5 , —NHC(O)R 5 , —NHC(O)NHR 5 , —NHS(O) 2 R 5 , —NHS(O) 2 NHR 5 , —S(O) 20 H, —C(O)OR 5 , —NH(CH 2 ) n OH, —C(O)NH(CH 2 ) n OH, —C(O)NH(CH 2 ) n R b , —C(O)R b , NH 2 , —OH, —CN, —C(O)NR 5 R 6 , —S(O) 2 NR 5 R 6 , C 3 -C 8 cycloalkyl, aryl, hetero
- R a and R 4 together with the atom or atoms to which they are attached, can combine to form a monocyclic or polycyclic C 3 -C 12 cycloalkyl, or a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein the cycloalkyl or heterocycle is optionally substituted with oxo; wherein the heterocycle optionally comprises —S(O) 2 — in the heterocycle;
- R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 ,
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently 1, 2, 3, 4, 5 or 6;
- n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- One aspect of the invention relates to compounds of Formula VII:
- A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 , —C(O)R 5 , or —CO 2 R 5 ,
- Y 1 is —S—, a direct bond, —NH—, —S(O) 2 —, —S(O) 2 —NH—, —C( ⁇ CH 2 )—, —CH—, or —S(O)—;
- X 1 is N or C
- X 2 is N or CH
- B including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl;
- R 2 is independently H, —OR b , —NR 5 R 6 , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —NH 2 , halogen, —C(O)OR a , —C 3 -C 8 cycloalkyl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5
- Y 2 is selected from the group consisting of: —NR a —, —(CR a 2 ) m —, —C(O)—, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a )—, —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —C(O)O—, —OC(O)—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)
- R a is independently, at each occurrence, selected from the group consisting of —H, -D, —OH, —C 3 -C 8 cycloalkyl, and —C 1 -C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently —H, -D, —C 1 -C 6 alkyl, —C 1 -C 6 cycloalkyl, —C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —R 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —NR 5 S(O)NR 5 R 6 ,
- R 3 is independently, at each occurrence, selected from the group consisting of —H, —C 1 -C 6 alkyl, a 3- to 12-membered monocyclic or polycyclic heterocycle, C 3 -C 8 cycloalkyl, or —(CH 2 ) n —R, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, —NH 2 , —OR a , —NHR a , —(CH 2 ) n OH, heterocyclyl, or spiroheterocyclyl; or
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with —C 1 -C 6 alkyl, —OH, —NH 2 , heteroaryl, heterocyclyl, —(CH 2 ) n NH 2 , —COOR a , —CONHR b , —CONH(CH 2 ) n COOR a , —NHCOOR a , —CF 3 , CHF 2 , or CH 2 F;
- R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , and —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently 1, 2, 3, 4, 5 or 6;
- n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 , —C(O)R 5 , or —CO 2 R 5 ,
- Y 1 is —S—, a direct bond, —NH—, —S(O) 2 —, —S(O) 2 —NH—, —C( ⁇ CH 2 )—, —CH—, or —S(O)—;
- X 1 is N or C
- X 2 is N or CH
- B including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl;
- R 2 is independently H, —OR b , —NR 5 R 6 , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —NH 2 , halogen, —C(O)OR a , —C 3 -C 8 cycloalkyl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5
- Y 2 is selected from the group consisting of: —NR a —, —(CR a 2 ) m —, —C(O)—, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a )—, —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —C(O)O—, —OC(O)—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)
- R a is independently, at each occurrence, selected from the group consisting of —H, -D, —OH, —C 3 -C 8 cycloalkyl, and —C 1 -C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently —H, -D, —C 1 -C 6 alkyl, —C 1 -C 6 cycloalkyl, —C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S
- R 3 is independently, at each occurrence, selected from the group consisting of —H, —C 1 -C 6 alkyl, a 3- to 12-membered monocyclic or polycyclic heterocycle, C 3 -C 8 cycloalkyl, or —(CH 2 ) n —R, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, —NH 2 , —OR a , —NHR a , —(CH 2 ) n OH, heterocyclyl, or spiroheterocyclyl; or
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with —C 1 -C 6 alkyl, —OH, —NH 2 , heteroaryl, heterocyclyl, —(CH 2 ) n NH 2 , —COOR a , —CONHR b , —CONH(CH 2 ) n COOR a , —NHCOOR a , —CF 3 , CHF 2 , or CH 2 F;
- R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , and —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently 1, 2, 3, 4, 5 or 6;
- n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 , —C(O)R 5 , or —CO 2 R 5 ,
- X 1 is N or C
- X 2 is N or CH
- B including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl;
- R 2 is independently H, —OR b , —NR 5 R 6 , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —NH 2 , halogen, —C(O)OR a , —C 3 -C 8 cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —
- Y 2 is selected from the group consisting of: —NR a —, —(CR a 2 ) m —, —C(O)—, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a )—, —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —C(O)O—, —OC(O)—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)
- R a is independently, at each occurrence, selected from the group consisting of —H, -D, —OH, —C 3 -C 8 cycloalkyl, and —C 1 -C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently —H, -D, —C 1 -C 6 alkyl, —C 1 -C 6 cycloalkyl, —C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —R 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —NR 5 S(O)NR 5 R 6 ,
- R 3 is independently, at each occurrence, selected from the group consisting of —H, —C 1 -C 6 alkyl, a 3- to 12-membered monocyclic or polycyclic heterocycle, C 3 -C 8 cycloalkyl, or —(CH 2 ) n —R, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, —NH 2 , —OR a , —NHR a , —(CH 2 ) n OH, heterocyclyl, or spiroheterocyclyl; or
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with —C 1 -C 6 alkyl, —OH, —NH 2 , heteroaryl, heterocyclyl, —(CH 2 ) n NH 2 , —COOR a , —CONHR b , —CONH(CH 2 ) n COOR a , —NHCOOR a , —CF 3 , CHF 2 , or CH 2 F;
- R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , and —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently 1, 2, 3, 4, 5 or 6;
- n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- Another aspect of the invention relates to compounds of Formula X:
- A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- R 1 is independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —OH, halogen, —NO 2 , —CN, —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S(O)NR 5 R 6 , —NR 5 S(O)R 6 , —C(O)R 5 , or —CO 2 R 5 ,
- X 1 is N or C
- X 2 is N or CH
- B including the atoms at the points of attachment, is a monocyclic or polycyclic 5- to 12-membered heterocycle or a monocyclic or polycyclic 5- to 12-membered heteroaryl;
- R 2 is independently H, —OR b , —NR 5 R 6 , —CN, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —NH 2 , halogen, —C(O)OR a , —C 3 -C 8 cycloalkyl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5
- Y 2 is selected from the group consisting of: —NR a —, —(CR a 2 ) m —, —C(O)—, —C(R a ) 2 NH—, —(CR a 2 ) m O—, —C(O)N(R a )—, —N(R a )C(O)—, —S(O) 2 N(R a )—, —N(R a )S(O) 2 —, —N(R a )C(O)N(R a )—, —N(R a )C(S)N(R a )—, —C(O)O—, —OC(O)—, —OC(O)N(R a )—, —N(R a )C(O)O—, —C(O)N(R a )O—, —N(R a )C(S)
- R a is independently, at each occurrence, selected from the group consisting of —H, -D, —OH, —C 3 -C 8 cycloalkyl, and —C 1 -C 6 alkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —NH 2 , wherein 2 R a , together with the carbon atom to which they are both attached, can combine to form a 3- to 8-membered cycloalkyl;
- R b is independently —H, -D, —C 1 -C 6 alkyl, —C 1 -C 6 cycloalkyl, —C 2 -C 6 alkenyl, or heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O; wherein each alkyl, cycloalkyl, alkenyl, or heterocycle is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 5 , —NR 5 R 6 , —SR 5 , —S(O) 2 NR 5 R 6 , —S(O) 2 R 5 , —NR 5 S(O) 2 NR 5 R 6 , —NR 5 S(O) 2 R 6 , —S(O)NR 5 R 6 , —S(O)NR 5 R 6 , —S(O)R 5 , —NR 5 S
- R 3 is independently, at each occurrence, selected from the group consisting of —H, —C 1 -C 6 alkyl, a 3- to 12-membered monocyclic or polycyclic heterocycle, C 3 -C 8 cycloalkyl, or —(CH 2 ) n —R b , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more —C 1 -C 6 alkyl, —OH, —NH 2 , —OR a , —NHR a , —(CH 2 ) n OH, heterocyclyl, or spiroheterocyclyl; or
- R 3 can combine with R a to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with —C 1 -C 6 alkyl, —OH, —NH 2 , heteroaryl, heterocyclyl, —(CH 2 ) n NH 2 , —COOR a , —CONHR b , —CONH(CH 2 ) n COOR a , —NHCOOR a , —CF 3 , CHF 2 , or CH 2 F;
- R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, —OR 7 , —SR 7 , halogen, —NR 7 R 8 , —NO 2 , and —CN;
- R 7 and R 8 are independently, at each occurrence, —H, -D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, a monocyclic or polycyclic 3- to 12-membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more —OH, —SH, —NH 2 , —NO 2 , or —CN;
- n is independently 1, 2, 3, 4, 5 or 6;
- n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- Another aspect of the present disclosure relates to compounds, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, in Table A1.
- Another aspect of the present disclosure relates to compounds, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof, in Table A2.
- aryl refers to cyclic, aromatic hydrocarbon groups that have 1 to 2 aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl or naphthyl. Where containing two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be joined at a single point (e.g., biphenyl), or fused (e.g., naphthyl).
- the aryl group may be optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment.
- substituents include, but are not limited to, —H, halogen, —O—C-C 6 alkyl, —C 1 -C 6 alkyl, —OC 2 -C 6 alkenyl, —OC 2 -C 6 alkynyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, —OH, —OP(O)(OH) 2 , —OC(O)C 1 -C 6 alkyl, —C(O)C 1 -C 6 alkyl, —OC(O)OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —S(O) 2 —C 1 -C 6 alkyl, —S(O)NHC 1 -C 6 alkyl, and —S(O)N(C 1 -C 6 alkyl)
- heteroaryl means a monovalent or multivalent monocyclic aromatic radical or a polycyclic aromatic radical of 5 to 24 ring atoms, containing one or more ring heteroatoms selected from N, S, P, and O, the remaining ring atoms being C.
- Heteroaryl as herein defined also means a bicyclic heteroaromatic group wherein the heteroatom is selected from N, S, P, and O.
- the aromatic radical is optionally substituted independently with one or more substituents described herein.
- Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazolyl, benzo[d]imidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazo[1,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[1,2-a]pyridinyl, indazolyl, 1-methyl-1H-indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazol
- Alkyl refers to a straight or branched chain saturated hydrocarbon.
- C 1 -C 6 alkyl groups contain 1 to 6 carbon atoms. Examples of a C 1 -C 6 alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, sec-butyl and tert-butyl, isopentyl and neopentyl.
- alkenyl means an aliphatic hydrocarbon group containing a carbon carbon double bond and which may be straight or branched having about 2 to about 6 carbon atoms in the chain. Certain alkenyl groups have 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl, or propyl are attached to a linear alkenyl chain. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, and i-butenyl.
- a C 2 -C 6 alkenyl group is an alkenyl group containing between 2 and 6 carbon atoms.
- alkynyl means an aliphatic hydrocarbon group containing a carbon carbon triple bond and which may be straight or branched having about 2 to about 6 carbon atoms in the chain. Certain alkynyl groups have 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl, or propyl are attached to a linear alkynyl chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, and n-pentynyl.
- a C 2 -C 6 alkynyl group is an alkynyl group containing between 2 and 6 carbon atoms.
- cycloalkyl means monocyclic or polycyclic saturated carbon rings containing 3-18 carbon atoms.
- cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl.
- a C 3 -C 8 cycloalkyl is a cycloalkyl group containing between 3 and 8 carbon atoms.
- a cycloalkyl group can be fused (e.g., decalin) or bridged (e.g., norbornane).
- cycloalkenyl means monocyclic, non-aromatic unsaturated carbon rings containing 4-18 carbon atoms.
- examples of cycloalkenyl groups include, without limitation, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and norborenyl.
- a C 4 -C 8 cycloalkenyl is a cycloalkenyl group containing between 4 and 8 carbon atoms.
- heterocyclyl or “heterocycloalkyl” or “heterocycle” refer to monocyclic or polycyclic 3 to 24-membered rings containing carbon and heteroatoms selected from oxygen, phosphorus, nitrogen, and sulfur and wherein there are no delocalized R electrons (aromaticity) shared among the ring carbon or heteroatoms.
- Heterocyclyl rings include, but are not limited to, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, and homotropanyl.
- a heteroycyclyl or heterocycloalkyl ring can also be fused or bridged, e.g., can be a bicyclic ring.
- heterocyclyl or “heterocycloalkyl” or “heterocycle” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 3-24 atoms of which at least one atom is chosen from nitrogen, sulfur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a —CH 2 — group can optionally be replaced by a —C(O)— or a ring sulfur atom may be optionally oxidised to form the S-oxides.
- Heterocyclyl can be a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulfur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a —CH 2 — group can optionally be replaced by a —C(O)— or a ring sulfur atom may be optionally oxidised to form S-oxide(s).
- heterocyclyl are thiazolidinyl, pyrrolidinyl, pyrrolinyl, 2-pyrrolidonyl, 2,5-dioxopyrrolidinyl, 2-benzoxazolinonyl, 1,1-dioxotetrahydro thienyl, 2,4-dioxoimidazolidinyl, 2-oxo-1,3,4-(4-triazolinyl), 2-oxazolidinonyl, 5,6-dihydro uracilyl, 1,3-benzodioxolyl, 1,2,4-oxadiazolyl, 2-azabicyclo[2.2.1]heptyl, 4-thiazolidonyl, morpholino, 2-oxotetrahydrofuranyl, tetrahydrofuranyl, 2,3-dihydrobenzofuranyl, benzothienyl, tetrahydropyrany
- halo or halogen means a fluoro, chloro, bromo, or iodo group.
- carbonyl refers to a functional group comprising a carbon atom double-bonded to an oxygen atom. It can be abbreviated herein as “oxo,” as C(O), or as C ⁇ O.
- “Spirocycle” or “spirocyclic” means carbogenic bicyclic ring systems with both rings connected through a single atom.
- the ring can be different in size and nature, or identical in size and nature. Examples include spiropentane, spirohexane, spiroheptane, spirooctane, spirononane, or spirodecane.
- One or both of the rings in a spirocycle can be fused to another carbocyclic, heterocyclic, aromatic, or heteroaromatic ring.
- One or more of the carbon atoms in the spirocycle can be substituted with a heteroatom (e.g., O, N, S, or P).
- a C 5 -C 12 spirocycle is a spirocycle containing between 5 and 12 carbon atoms.
- a C 5 -C 12 spirocycle is a spirocycle containing from 5 to 12 carbon atoms.
- One or more of the carbon atoms can be substituted with a heteroatom.
- spirocyclic heterocycle is understood to mean a spirocycle wherein at least one of the rings is a heterocycle (e.g., at least one of the rings is furanyl, morpholinyl, or piperadinyl).
- a spirocyclic heterocycle can contain between 5 and 12 atoms, at least one of which is a heteroatom selected from N, O, S and P.
- a spirocyclic heterocycle can contain from 5 to 12 atoms, at least one of which is a heteroatom selected from N, O, S and P.
- tautomers refers to a set of compounds that have the same number and type of atoms, but differ in bond connectivity and are in equilibrium with one another.
- a “tautomer” is a single member of this set of compounds. Typically a single tautomer is drawn but it is understood that this single structure is meant to represent all possible tautomers that might exist. Examples include enol-ketone tautomerism. When a ketone is drawn it is understood that both the enol and ketone forms are part of the disclosure.
- the SHP2 inhibitor may be administered alone as a monotherapy or in combination with one or more other therapeutic agent (e.g., an inhibitor of a MAP kinase pathway or an anti-cancer therapeutic agent) as a combination therapy.
- the SHP2 inhibitor may be administered as a pharmaceutical composition.
- the SHP2 inhibitor may be administered before, after, and/or concurrently with the one or more other therapeutic agent (e.g., an inhibitor of a MAP kinase pathway or an anti-cancer therapeutic agent).
- such administration may be simultaneous (e.g., in a single composition) or may be via two or more separate compositions, optionally via the same or different modes of administration (e.g., local, systemic, oral, intravenous, etc.).
- compositions and compounds can be accomplished via any mode of administration for therapeutic agents.
- modes include systemic or local administration such as oral, nasal, parenteral, transdermal, subcutaneous, vaginal, buccal, rectal or topical administration modes.
- the disclosed compounds or pharmaceutical compositions can be in solid, semi-solid or liquid dosage form, such as, for example, injectables, tablets, suppositories, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices.
- injectables tablets, suppositories, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices.
- they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, and all using forms well known to those skilled in the pharmaceutical arts.
- compositions suitable for the delivery of a SHP2 inhibitor (alone or, e.g., in combination with another therapeutic agent according to the present disclosure) and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, e.g., in Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995), incorporated herein in its entirety.
- Illustrative pharmaceutical compositions are tablets and gelatin capsules comprising a SHP2 inhibitor alone or in combination with another therapeutic agent according to the disclosure and a pharmaceutically acceptable carrier, such as a) a diluent, e.g., purified water, triglyceride oils, such as hydrogenated or partially hydrogenated vegetable oil, or mixtures thereof, corn oil, olive oil, sunflower oil, safflower oil, fish oils, such as EPA or DHA, or their esters or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and/or glycine; b) a lubricant, e.g., silica, talcum, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and/
- Liquid, particularly injectable, compositions can, for example, be prepared by dissolution, dispersion, etc.
- a SHP2 inhibitor (alone or in combination with another therapeutic agent according to the disclosure) is dissolved in or mixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form an injectable isotonic solution or suspension.
- a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like.
- Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the SHP2 inhibitor (alone or in combination with another therapeutic agent according to the disclosure).
- the SHP2 inhibitor can be also formulated as a suppository, alone or in combination with another therapeutic agent according to the disclosure, which can be prepared from fatty emulsions or suspensions; using polyalkylene glycols such as propylene glycol, as the carrier.
- the SHP2 inhibitor can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles, either alone or in combination with another therapeutic agent according to the disclosure.
- Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines.
- a film of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described for instance in U.S. Pat. No. 5,262,564, the contents of which are hereby incorporated by reference.
- SHP2 inhibitors can also be delivered by the use of monoclonal antibodies as individual carriers to which the disclosed compounds are coupled.
- SHP2 inhibitors can also be coupled with soluble polymers as targetable drug carriers.
- Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspanamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues.
- a SHP2 inhibitor can be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
- a polymer e.g., a polycarboxylic acid polymer, or a polyacrylate.
- Parental injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions.
- Injectables can be prepared in conventional forms, either as liquid solutions or suspensions or solid forms suitable for dissolving in liquid prior to injection.
- compositions comprising a SHP2 inhibitor (alone or in combination with another therapeutic agent according to the present disclosure) and a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier can further include an excipient, diluent, or surfactant.
- compositions comprising one or more SHP2 inhibitor for use in a method disclosed herein, e.g., a SHP2 monotherapy.
- Such compositions may comprise a SHP2 inhibitor and, e.g., one or more carrier, excipient, diluent, and/or surfactant.
- compositions comprising one or more SHP2 inhibitor and one or more additional therapeutic agent for use in a method disclosed herein, e.g., a SHP2 combination therapy.
- Such compositions may comprise a SHP2 inhibitor, an additional therapeutic agent (e.g., a TKI, a MAPK pathway inhibitor, an EGFR inhibitor, an ALK inhibitor, a MEK inhibitor) and, e.g., one or more carrier, excipient, diluent, and/or surfactant.
- compositions comprising one or more SHP2 inhibitor and one or more MK inhibitor for use in a method disclosed herein, e.g., a SHP2 combination therapy.
- Such compositions may comprise a SHP2 inhibitor, a MEK inhibitor and, e.g., one or more carrier, excipient, diluent, and/or surfactant.
- Such compositions may consist essentially of a SHP2 inhibitor, a MEK inhibitor and, e.g., one or more carrier, excipient, diluent, and/or surfactant.
- compositions may consist of a SHP2 inhibitor, a MEK inhibitor and, e.g., one or more carrier, excipient, diluent, and/or surfactant.
- a composition of the present disclosure may comprise, consist essentially of, or consist of (a) a SHP2 inhibitor; (b) a MEK inhibitor selected from one or more of Trametinib (GSK1120212); Selumetinib (AZD6244); Cobimetinib (GDC-0973/XL581), Binimetinib, Vemurafenib, Pimasertib, TAK733, RO4987655 (CH4987655); CI-1040; PD-0325901; Refametinib (RDEA 119/BAY 86-9766); RO5126766, AZD8330 (ARRY-424704/ARRY-704); and GSK1120212; and (c) one or more carrier, excipient
- compositions of the present disclosure may comprise, consist essentially of, or consist of (a) a MEK inhibitor; (b) a SHP2 inhibitor selected from (i) RMC-3943; (ii) RMC-4550; (iii) SHP099; (iv) a SHP2 inhibitor compound of any one of Formula I, of Formula II, of Formula III, of Formula I-V1, of Formula I-V2, of Formula I-W, of Formula I-X, of Formula I-Y, of Formula I-Z, of Formula IV, of Formula V, of Formula VI, of Formula IV-X, of Formula IV-Y, of Formula IV-Z, of Formula VII, of Formula VIII, of Formula IX, and of Formula X; (v) TNO155, (vi) a SHP2 inhibitor disclosed in international PCT application PCT/US2017/041577 (WO2018013597), incorporated herein by reference in its entirety; (vii) Compound C; (ix) a compound from Table A1, disclosed herein; (x)
- compositions can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present pharmaceutical compositions can contain from about 0.1% to about 99%, from about 5% to about 90%, or from about 1% to about 20% of the disclosed RMC-4550 by weight or volume.
- the dosage regimen utilizing the disclosed compound is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the patient; and the particular disclosed compound employed.
- a physician or veterinarian of ordinary skill in the art can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
- Effective dosage amounts of a SHP2 inhibitor when used for the indicated effects, range from about 0.5 mg to about 5000 mg as needed to treat the condition.
- Compositions for in vivo or in vitro use can contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed compound, or, in a range of from one amount to another amount in the list of doses.
- the compositions are in the form of a tablet that can be scored.
- the means for determine comprises a means for determining whether the sample comprises any of an allosteric inhibitor-resistant mutation to SHP2.
- the means for determine comprises a means for determining whether the sample comprises any of an allosteric inhibitor-sensitive mutation to SHP2.
- the means for determine comprises a means for determining whether the sample comprises any of the following mutations to SHP2: F285S, L262R, S189A, D61G, E69K, T73I, Q506P, E76K, P491S, or S502P.
- Such means include, but are not limited to direct sequencing, and utilization of a high-sensitivity diagnostic assay (with CE-IVD mark), e.g., as described in Domagala, et al., Pol J Pathol 3: 145-164 (2012), incorporated herein by reference in its entirety, including TheraScreen PCR; AmoyDx; PNAClamp; RealQuality; EntroGen; LightMix; StripAssay; Hybcell plexA; Devyser; Surveyor; Cobas; and TheraScreen Pyro.
- a high-sensitivity diagnostic assay with CE-IVD mark
- Example Embodiment I As follows:
- Example Embodiment I-1 A method of treating a subject having a disease or disorder associated with cells containing a mutant SHP2, comprising administering to the subject an allosteric SHP2 inhibitor, wherein the mutant SHP2 comprises an allosteric inhibitor-sensitive mutation.
- Example Embodiment I-1a An allosteric SHP2 inhibitor for use in a method of treating a subject having a disease or disorder associated with cells containing a mutant SHP2, wherein the mutant SHP2 comprises an allosteric inhibitor-sensitive mutation.
- Example Embodiment I-1b Use of an allosteric SHP2 inhibitor for the manufacture of a medicament for treating a subject having a disease or disorder associated with cells containing a mutant SHP2, wherein the mutant SHP2 comprises an allosteric inhibitor-sensitive mutation.
- Example Embodiment I-2a The method of Example Embodiment I-1, wherein the allosteric inhibitor-sensitive mutation is selected from the group consisting of F285S, L262R, S189A, D61G, E69K, T73I, Q506P, and a combination thereof.
- Example Embodiment I-2b The method of Example Embodiment I-1, wherein the allosteric inhibitor-sensitive mutation is selected from the group consisting of F285S, L262R, and S189A.
- Example Embodiment I-3 The method of Example Embodiment I-1, wherein the allosteric inhibitor-sensitive mutation is D61G.
- Example Embodiment I-4 The method of Example Embodiment I-1, wherein the allosteric inhibitor-sensitive mutation is selected from the group consisting of E69K, T73I, and Q506P.
- Example Embodiment I-5 The method of any one of the preceding Example Embodiments, wherein the cells are negative for an allosteric inhibitor-resistant mutation of SHP2.
- Example Embodiment I-6a The method of Example Embodiment I-5, wherein the allosteric inhibitor-resistant mutation is selected from the group consisting of E76K, P491S, S502P, and a combination thereof.
- Example Embodiment I-6b The method of Example Embodiment I-5, wherein the allosteric inhibitor-resistant mutation is selected from the group consisting of E76K and P491S
- Example Embodiment I-7 The method of Example Embodiment I-5, wherein the allosteric inhibitor-resistant mutation is S502P.
- Example Embodiment I-8 The method of any one of the preceding Example Embodiments, wherein the cells are determined to have the allosteric inhibitor-sensitive mutation prior to administering the SHP2 inhibitor.
- Example Embodiment I-9 The method of any one of the preceding Example Embodiments, wherein the cells are determined to not have the allosteric inhibitor-resistant mutation prior to administering the SHP2 inhibitor.
- Example Embodiment I-10 The method of any one of the preceding Example Embodiments, wherein the allosteric SHP2 inhibitor is selected from (i) Compound A; (ii) Compound B; (iii) Compound C; (iv) SHP099; (v) an allosteric SHP2 inhibitor compound of any one of Formula I, of Formula II, of Formula III, of Formula I-V1, of Formula I-V2, of Formula I-W, of Formula I-X, of Formula I-Y, of Formula I-Z, of Formula IV, of Formula V, of Formula VI, of Formula IV-X, of Formula IV-Y, of Formula IV-Z, of Formula VII, of Formula VIII, of Formula IX, and of Formula X; (vi) TNO155; (vii) a SHP2 inhibitor disclosed in international PCT application PCT/US2017/041577 (W2018013597), incorporated herein by reference in its entirety; (viii) a compound from Table A1, disclosed herein; (ix) a compound from Table A2,
- Example Embodiment I-11 The method of any one of the preceding Example Embodiments, wherein the disease or disorder is selected from tumors of hemopoietic and lymphoid system; a myeloproliferative syndrome; a myelodysplastic syndromes; leukemia; acute myeloid leukemia; juvenile myelomonocytic leukemia; esophageal cancer; breast cancer; lung cancer; colon cancer; gastric cancer; neuroblastoma; bladder cancer; prostate cancer; glioblastoma; urothelial carcinoma; uterine carcinoma; adenoid and ovarian sereous cystadenocarcinoma; paraganglioma; phaeochromocytoma; pancreatic cancer; adrenocortical carcinoma; stomach adenocarcinoma; sarcoma; rhabdomyosarcoma; lymphoma; head and neck cancer; skin cancer; peritoneum cancer; intestinal cancer (e.g.,
- Example Embodiment I-12 The method of any one of the preceding Example Embodiments, wherein the disease or disorder is an inherited developmental disorder selected from the group consisting of Noonan Syndrome and LEOPARD Syndrome.
- Example Embodiment I-13 The method of any one of any one of the preceding Example Embodiments, wherein the allosteric SHP2 inhibitor is administered in an effective amount.
- Example Embodiment I-14 A method of identifying a subject with SHP2 mutations susceptible to a SHP2 inhibitor, comprising genotyping a biological sample from the subject for SHP2 mutations, wherein the subject is identified as susceptible to the SHP2 inhibitor if the SHP2 mutations comprise an allosteric inhibitor-sensitive mutation.
- Example Embodiment I-14a An in vitro method of identifying a subject with SHP2 mutations susceptible to a SHP2 inhibitor, comprising genotyping, via an in vitro assay, a biological sample from the subject for SHP2 mutations, wherein the subject is identified as susceptible to the SHP2 inhibitor if the SHP2 mutations comprise an allosteric inhibitor-sensitive mutation.
- Example Embodiment I-14b An allosteric SHP2 inhibitor for use in a method of treating a subject identified by genotyping as having a disease or disorder with a SHP2 mutation that is susceptible to a SHP2 inhibitor, wherein the subject is identified as susceptible to the SHP2 inhibitor if the SHP2 mutations comprise an allosteric inhibitor-sensitive mutation.
- Example Embodiment I-14c Use of an allosteric SHP2 inhibitor for the manufacture of a medicament for treating a subject identified by genotyping as having a disease or disorder with a SHP2 mutation that is susceptible to a SHP2 inhibitor, wherein the subject is identified as susceptible to the SHP2 inhibitor if the SHP2 mutations comprise an allosteric inhibitor-sensitive mutation.
- Example Embodiment I-15a The method of Example Embodiment I-14, wherein the allosteric inhibitor-sensitive mutation is selected from the group consisting of F285S, L262R, S189A, D61G, E69K, T73I, Q506P, and a combination thereof.
- Example Embodiment I-15b The method of Example Embodiment I-14, wherein the allosteric inhibitor-sensitive mutation is selected from the group consisting of F285S, L262R, and S189A.
- Example Embodiment I-16 The method of Example Embodiment I-14, wherein the allosteric inhibitor-sensitive mutation is D61G.
- Example Embodiment I-17 The method of Example Embodiment I-14, wherein the allosteric inhibitor-sensitive mutation is selected from the group consisting of E69K, T73I, and Q506P.
- Example Embodiment I-18 The method of any one of Example Embodiments I-14 to I-15, wherein the method further comprises identifying the subject as not expressing a SHP2 allosteric inhibitor-resistant mutation.
- Example Embodiment I-19 The method of Example Embodiment I-18, wherein the SHP2 allosteric inhibitor-resistant mutation is selected from the group consisting of E76K, P491S, S502P, and a combination thereof.
- Example Embodiment I-20 The method of Example Embodiment I-18, wherein the allosteric inhibitor-resistant mutation is selected from the group consisting of E76K and P491S
- Example Embodiment I-21 The method of Example Embodiment I-18, wherein the allosteric inhibitor-resistant mutation is S502P.
- Example Embodiment I-22 The method of any one of Example Embodiments I-14 to I-21, wherein the allosteric SHP2 inhibitor is selected from (i) Compound A; (ii) Compound B; (iii) Compound C; (iv) SHP099; (v) an allosteric SHP2 inhibitor compound of any one of Formula I, of Formula II, of Formula III, of Formula I-V1, of Formula I-V2, of Formula I-W, of Formula I-X, of Formula I-Y, of Formula I-Z, of Formula IV, of Formula V, of Formula VI, of Formula IV-X, of Formula IV-Y, of Formula IV-Z, of Formula VII, of Formula VIII, of Formula IX, and of Formula X; (vi) TNO155, and (vii) a combination thereof.
- the allosteric SHP2 inhibitor is selected from (i) Compound A; (ii) Compound B; (iii) Compound C; (iv) SHP099; (v) an alloster
- Example Embodiment I-23 The method of any one of Example Embodiments I-14 through I-22, wherein the allosteric SHP2 inhibitor is in an effective amount.
- Example Embodiment I-24 A method of identifying a subject as resistant to an allosteric SHP2 inhibitor, comprising genotyping a biological sample from the subject for SHP2 mutations, wherein the subject is identified as resistant to the SHP2 inhibitor if the SHP2 mutations comprise an allosteric inhibitor-resistant mutation.
- Example Embodiment I-24a An in vitro method of identifying a subject as resistant to an allosteric SHP2 inhibitor, comprising genotyping, via an in vitro assay, a biological sample from the subject for SHP2 mutations, wherein the subject is identified as resistant to the SHP2 inhibitor if the SHP2 mutations comprise an allosteric inhibitor-resistant mutation.
- Example Embodiment I-25a The method of Example Embodiment I-24, wherein the allosteric inhibitor-resistant mutation is selected from the group consisting of E76K, P491S, S502P, and a combination thereof.
- Example Embodiment I-25b The method of Example Embodiment I-24, wherein the allosteric inhibitor-resistant mutation is selected from the group consisting of E76K and P491S
- Example Embodiment I-26 The method of Example Embodiment I-24, wherein the allosteric inhibitor-resistant mutation is S502P.
- Example Embodiment I-27 The method of any one of Example Embodiments I-24 to I-26, wherein the allosteric SHP2 inhibitor is selected from (i) Compound A; (ii) Compound B; (iii) Compound C; (iv) SHP099; (v) an allosteric SHP2 inhibitor compound of any one of Formula I, of Formula II, of Formula III, of Formula I-V1, of Formula I-V2, of Formula I-W, of Formula I-X, of Formula I-Y, of Formula I-Z, of Formula IV, of Formula V, of Formula VI, of Formula IV-X, of Formula IV-Y, of Formula IV-Z, of Formula VII, of Formula VIII, of Formula IX, and of Formula X; (vi) TNO155, and (vii) a combination thereof.
- the allosteric SHP2 inhibitor is selected from (i) Compound A; (ii) Compound B; (iii) Compound C; (iv) SHP099; (v) an all
- Example Embodiment I-28 The method of any one of Example Embodiments I-24 through I-27, wherein the allosteric SHP2 inhibitor is in an effective amount.
- Example Embodiment I-29 A diagnostic test for allosteric SHP2 inhibitor sensitivity, comprising a nucleic acid probe specific for an allosteric inhibitor-sensitive mutation of SHP2.
- Example Embodiment I-29a An in vitro diagnostic test for allosteric SHP2 inhibitor sensitivity, comprising a nucleic acid probe specific for an allosteric inhibitor-sensitive mutation of SHP2.
- Example Embodiment I-30 The diagnostic test of Example Embodiment I-29, wherein the allosteric inhibitor-sensitive mutation is selected from the group consisting of F285S, L262R, S189A, D61G, E69K, T73I, Q506P, and a combination thereof.
- Example Embodiment I-31 The diagnostic test of Example Embodiment I-29, wherein the allosteric inhibitor-sensitive mutation is selected from the group consisting of F285S, L262R, and S189A.
- Example Embodiment I-32 The diagnostic test of Example Embodiment I-29, wherein the allosteric inhibitor-sensitive mutation is D61G.
- Example Embodiment I-33 The diagnostic test of Example Embodiment I-29, wherein the allosteric inhibitor-sensitive mutation is selected from the group consisting of E69K, T73I, and Q506P.
- Example Embodiment I-34 A diagnostic test for allosteric SHP2 inhibitor insensitivity, comprising a nucleic acid probe specific for a SHP2 allosteric inhibitor-resistant mutation; wherein the allosteric inhibitor-resistant mutation is optionally selected from E76K, P491S, S502P.
- SHP2 (PTPN11) is a non-receptor protein tyrosine phosphatase and scaffold protein that functions downstream of multiple RTKs, integrating growth factor signals to promote RAS/MAPK activation.
- SHP2 is composed of three distinct structural domains: two SH2 domains at the N-terminus followed by a PTP catalytic domain. SHP2 adopts an autoinhibited conformation in the absence of RTK signaling. Mutations that destabilize the autoinhibited conformation are common in inherited RASopathies and certain cancers.
- Allosteric inhibitors that stabilize the autoinhibited conformation in wild-type SHP2 inhibit RAS/MAPK signaling, and tumor growth, in xenograft models driven by oncogenic mutations in the RAS/MAPK pathway. This study asked what is the effect of allosteric inhibitors on activated mutant SHP2.
- SHP2 can be activated in vitro by synthetic peptides containing diphosphotyrosine motifs. Mutations in the SH2-Catalytic domain interface can uncouple activation from phosphotyrosine peptide or protein binding. Molecules that bind specifically to the autoinhibited conformation function as allosteric inhibitors
- the present study examined the effect of allosteric inhibitors on mutant SHP2s.
- the following mutations associated with Noonan Syndrome, Juvenile Myelomonocytic Leukemia (JMML), and other human cancers were selected for further experimental study: D61G, E76K, S189A, L262R, F285S, P491S and S502P. Mutations refer to the SHP2 sequence numbered according to Uniprot Isoform 2 (accession number Q06124-2) (SEQ ID NO: 1).
- SHP2 Full-length SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains.
- SH2 Src Homology 2
- the latter activation step leads to the release of the auto-inhibitory interface of SHP2, which in turn renders the SHP2 protein tyrosine phosphatase (PTP) active and available for substrate recognition and reaction catalysis.
- PTP protein tyrosine phosphatase
- the catalytic activity of SHP2 was monitored using the surrogate substrate DiFMUP in a prompt fluorescence assay format. Mutant variants of SHP2 showed variable response to activating peptide, and the biochemical assay was repeated on all enzymes with and without activating peptide at a concentration of 500 nM.
- the phosphatase reactions were performed at room temperature in 384-well black polystyrene plates, flat bottom, non-binding surface (Corning, Cat #781077) using a final reaction volume of 50 ⁇ L and the following assay buffer conditions: 55 mM HEPES pH 7.2, 100 mM NaCl, 0.5 mM EDTA, 1 mM DTT, 0.001% Brij35, 0.002% BSA, 0.1% DMSO, 100 ⁇ M DiFMUP, 0.1, 0.3, or 2 nM enzyme, 0 or 500 nM activating peptide NsCs and 10 ⁇ M to 1.9 ⁇ M inhibitor.
- Diluted inhibitor (5 ⁇ L) was mixed with activated enzyme (25 ⁇ l) and incubated for 30 minutes at room temperature.
- 50 ⁇ l stop solution (0.1 mM sodium pervanadate) was added to each well, the plate was shaken briefly to mix, and read in endpoint mode on a SpectraMax M5 plate reader (Molecular Devices) using excitation and emission wavelengths of 340 nm and 450 nm. Data was imported into GraphPad Prism. Plots of fluorescence intensity vs. log Molar [compound] were created and modeled with a 3-parameter sigmoidal concentration response equation in order to estimate IC 50 .
- Compound C also known as Compound 33 on Tables 1-8) and 52 other allosteric inhibitors of SHP2 were tested for their potency in a biochemical assay of SHP2 activity.
- wildtype or mutant variants of SHP2 were incubated with each of compounds 1-53 for 30 minutes, prior to addition of the small molecule substrate DiFMUP (6,8-difluoro-4-methylumbelliferyl phosphate). Reactions were then allowed to proceed for 30 minutes and stopped by the addition of a phosphatase inhibitor, sodium pervanadate. De-phosphorylation of DiFMUP results in production of a fluorescent product. Product fluorescence was determined and plotted as a function of compound concentration in order to determine the IC 50 for each compound on each mutant using a four parameter sigmoidal dose response function in Prism (GraphPad).
- NsCs bis-phosphorylated activating peptide
- the experiments were repeated in the presence of a bis-phosphorylated activating peptide (termed “NsCs”) which comprises two tyrosine phosphorylated 9-mers (synthetic sequences designed to strongly bind both the N- and C-terminal SH2 domains) connected by a PEG8 linker.
- NsCs mimics the role of the cytosolic domain of a protein tyrosine kinase in this model system.
- the NsCs activating peptide has the following structure:
- the potencies of 52 compounds to inhibit the non-activated (apo) and activated forms of the various mutants, in comparison to the wild type SHP2, are summarized in Tables 1 to 8.
- the potency of each compound to inhibit non-activated mutant SHP2 is plotted versus the potency to inhibit wild-type SHP2 in FIG. 2 .
- the same plot for activated mutant and wild-type SHP2 is shown in FIG. 3 .
- mutations show a peptide-driven shift in inhibitor potency of varying magnitude.
- the peptide shifted IC 50 values 3-fold or less for S189A and F285S.
- S502P exhibited a peptide-driven potency shift of at least 100-fold, but the exact shift could not be determined because no inhibitory activity was detected for any compound (up to the highest test concentration of 10 ⁇ M) in the presence of activating peptide.
- the shift for S189A, F285S, D61G, and E76K are shown in FIG. 5 .
- the Flp-In T-REx-293 cell line was obtained from Gibco® and cultivated in high glucose DMEMTM containing 2 mM L-glutamine (Hyclone®), supplemented with 10% FBS (Hyclone®), 1% penicillin/streptomycin (Gibco®), 100 ⁇ g/mL ZeocinTM (Gibco®), and 15 ⁇ g/mL blasticidin (Gibco®) in a humidified cell culture incubator at 37° C., 5% CO2.
- Wild type or mutant SHP2 variants were synthesized and subcloned into the pcDNA5/FRT/TO vector (ThermoFisher). Plasmids were co-transfected with the pOG44 Flp recombinase expression plasmid (ThermoFisher®) into Flp-In T-REx-293 cells using X-tremegene 9 DNA transfection reagent (Sigma®), according to the manufacturer's instructions.
- Cells that underwent successful recombination were selected in high glucose DMEM containing 2 mM L-glutamine, supplemented with 10% FBS and, 1% penicillin/streptomycin, 200 ⁇ g/mL hygromycin B (Gibco®), and 15 ⁇ g/mL blasticidin (Gibco®) (recombinant selection media) in a humidified cell culture incubator at 37° C., 5% CO2, until colonies were visually discernible. Colonies were expanded in recombinant selection media in a humidified cell culture incubator at 37° C., 5% CO2 to establish isogenic SHP2 variant expression cell lines (T-REx-293-SHP2).
- T-REx-293-SHP2 cells for each tested variant were harvested and seeded in high glucose DMEM containing 2 mM L-glutamine, supplemented with 0.1% FBS and, 1% penicillin/streptomycin, 200 ⁇ g/mL hygromycin B, and 15 ⁇ g/mL blasticidin in 96-well assay plates at a density of 25,000 cells/well.
- ERK1/2 phosphorylation at Thr202/Tyr204 was assayed using the AlphaLISA SureFire Ultra HV pERK Assay Kit (Perkin Elmer®) following the manufacturer's instructions. Samples were read using an EnVision Multilabel Plate Reader (Perkin Elmer®) using standard AlphaLISA settings. Assay data was plotted and EC50 values were determined using four-parameter concentration-response model in GraphPad Prism 7. Data provided are mean+/ ⁇ standard deviation of duplicate values from representative experiments.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/064,317 US20210154190A1 (en) | 2018-04-10 | 2020-10-06 | Shp2 inhibitor compositions and methods for treating cancer |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862655648P | 2018-04-10 | 2018-04-10 | |
PCT/US2019/026543 WO2019199792A1 (en) | 2018-04-10 | 2019-04-09 | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
US17/064,317 US20210154190A1 (en) | 2018-04-10 | 2020-10-06 | Shp2 inhibitor compositions and methods for treating cancer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/026543 Continuation WO2019199792A1 (en) | 2018-04-10 | 2019-04-09 | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210154190A1 true US20210154190A1 (en) | 2021-05-27 |
Family
ID=66248820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/064,317 Pending US20210154190A1 (en) | 2018-04-10 | 2020-10-06 | Shp2 inhibitor compositions and methods for treating cancer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210154190A1 (zh) |
EP (1) | EP3773590A1 (zh) |
JP (1) | JP2021521155A (zh) |
KR (1) | KR20200143417A (zh) |
CN (1) | CN112203689A (zh) |
AU (1) | AU2019251207A1 (zh) |
BR (1) | BR112020020743A2 (zh) |
CA (1) | CA3096535A1 (zh) |
CO (1) | CO2020012588A2 (zh) |
IL (1) | IL277783B1 (zh) |
MX (1) | MX2020010719A (zh) |
SG (1) | SG11202009793TA (zh) |
TW (1) | TW201946627A (zh) |
WO (1) | WO2019199792A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11596633B2 (en) | 2017-09-07 | 2023-03-07 | Revolution Medicines, Inc. | SHP2 inhibitor compositions and methods for treating cancer |
US11661401B2 (en) | 2016-07-12 | 2023-05-30 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors |
US11673896B2 (en) | 2017-01-23 | 2023-06-13 | Revolution Medicines, Inc. | Pyridine compounds as allosteric SHP2 inhibitors |
US11673901B2 (en) | 2017-12-15 | 2023-06-13 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric SHP2 inhibitors |
US11702411B2 (en) | 2017-10-12 | 2023-07-18 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
US11739093B2 (en) | 2017-01-23 | 2023-08-29 | Revolution Medicines, Inc. | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
MX2018015625A (es) | 2016-06-14 | 2019-03-06 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de shp2. |
EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
EP3630770A1 (en) | 2017-05-26 | 2020-04-08 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
TW202003471A (zh) | 2018-03-21 | 2020-01-16 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
MX2020011528A (es) | 2018-05-02 | 2021-02-09 | Navire Pharma Inc | Inhibidores heterociclicos sustituidos de ptpn11. |
EP4356973A2 (en) | 2018-08-10 | 2024-04-24 | Navire Pharma, Inc. | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
CN111138412B (zh) | 2018-11-06 | 2023-09-15 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物及其应用 |
CN111647000B (zh) | 2019-03-04 | 2021-10-12 | 勤浩医药(苏州)有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
CN114190090A (zh) | 2019-06-07 | 2022-03-15 | 锐新医药公司 | Shp2抑制剂{6-[(2-氨基-3-氯吡啶-4-基)硫烷基]-3-[(3s,4s)-4-氨基-3-甲基-2-氧杂-8-氮杂螺[4.5]癸烷-8-基]-5-甲基吡嗪-2-基}甲醇的固体形式 |
EP4034539A1 (en) | 2019-09-24 | 2022-08-03 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of making and using the same |
CN112724145A (zh) * | 2019-10-14 | 2021-04-30 | 杭州雷索药业有限公司 | 用于抑制shp2活性的吡嗪衍生物 |
CN114901662A (zh) | 2019-11-08 | 2022-08-12 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
WO2021110796A1 (en) * | 2019-12-04 | 2021-06-10 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
CN111265529B (zh) * | 2020-02-22 | 2021-07-23 | 南京大学 | 蛋白酪氨酸磷酸酶shp2抑制剂在制备治疗银屑病药物中的应用 |
WO2021171261A1 (en) | 2020-02-28 | 2021-09-02 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
KR20240007279A (ko) * | 2021-05-13 | 2024-01-16 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | Shp2활성을 억제하는 헤테로고리 화합물, 이의 제조 방법 및 용도 |
WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
CN116063307A (zh) * | 2021-10-29 | 2023-05-05 | 中国药科大学 | Shp2与cdk4/6双靶点抑制化合物合成及其制备方法与应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
ATE441727T1 (de) * | 2001-10-01 | 2009-09-15 | Sinai School Medicine | Noonansyndromgen |
EP1948827B1 (en) * | 2005-10-21 | 2016-03-23 | The Regents of The University of California | C-kit oncogene mutations in melanoma |
AU2010284255B2 (en) | 2009-08-17 | 2016-11-17 | Memorial Sloan-Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
US8673913B2 (en) * | 2009-11-13 | 2014-03-18 | Case Western Reserve University | SHP-2 phosphatase inhibitor |
EP2826586A1 (en) | 2013-07-18 | 2015-01-21 | Siemens Aktiengesellschaft | A method and a system for machining an object |
ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
US9815813B2 (en) | 2014-01-17 | 2017-11-14 | Novartis Ag | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 |
JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
EP3310771B1 (en) | 2015-06-19 | 2020-07-22 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
CN112625028A (zh) | 2015-06-19 | 2021-04-09 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
ES2741746T3 (es) | 2015-06-19 | 2020-02-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
US11008372B2 (en) | 2015-11-07 | 2021-05-18 | Board Of Regents, The University Of Texas System | Targeting proteins for degradation |
WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
CA3026784A1 (en) | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic pyrazine derivatives useful as shp2 inhibitors |
SG11201900157RA (en) * | 2016-07-12 | 2019-02-27 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
-
2019
- 2019-04-09 CN CN201980037528.7A patent/CN112203689A/zh active Pending
- 2019-04-09 SG SG11202009793TA patent/SG11202009793TA/en unknown
- 2019-04-09 EP EP19719088.7A patent/EP3773590A1/en active Pending
- 2019-04-09 MX MX2020010719A patent/MX2020010719A/es unknown
- 2019-04-09 KR KR1020207032251A patent/KR20200143417A/ko active Search and Examination
- 2019-04-09 AU AU2019251207A patent/AU2019251207A1/en active Pending
- 2019-04-09 TW TW108112247A patent/TW201946627A/zh unknown
- 2019-04-09 IL IL277783A patent/IL277783B1/en unknown
- 2019-04-09 JP JP2020555352A patent/JP2021521155A/ja active Pending
- 2019-04-09 BR BR112020020743-8A patent/BR112020020743A2/pt unknown
- 2019-04-09 WO PCT/US2019/026543 patent/WO2019199792A1/en unknown
- 2019-04-09 CA CA3096535A patent/CA3096535A1/en active Pending
-
2020
- 2020-10-06 US US17/064,317 patent/US20210154190A1/en active Pending
- 2020-10-09 CO CONC2020/0012588A patent/CO2020012588A2/es unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11661401B2 (en) | 2016-07-12 | 2023-05-30 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors |
US11673896B2 (en) | 2017-01-23 | 2023-06-13 | Revolution Medicines, Inc. | Pyridine compounds as allosteric SHP2 inhibitors |
US11739093B2 (en) | 2017-01-23 | 2023-08-29 | Revolution Medicines, Inc. | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors |
US11596633B2 (en) | 2017-09-07 | 2023-03-07 | Revolution Medicines, Inc. | SHP2 inhibitor compositions and methods for treating cancer |
US11702411B2 (en) | 2017-10-12 | 2023-07-18 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
US11673901B2 (en) | 2017-12-15 | 2023-06-13 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric SHP2 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
TW201946627A (zh) | 2019-12-16 |
MX2020010719A (es) | 2020-11-06 |
CO2020012588A2 (es) | 2020-10-30 |
IL277783B1 (en) | 2024-03-01 |
WO2019199792A1 (en) | 2019-10-17 |
AU2019251207A1 (en) | 2020-11-19 |
KR20200143417A (ko) | 2020-12-23 |
BR112020020743A2 (pt) | 2021-02-02 |
CN112203689A (zh) | 2021-01-08 |
SG11202009793TA (en) | 2020-10-29 |
CA3096535A1 (en) | 2019-10-17 |
JP2021521155A (ja) | 2021-08-26 |
EP3773590A1 (en) | 2021-02-17 |
IL277783A (en) | 2020-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210154190A1 (en) | Shp2 inhibitor compositions and methods for treating cancer | |
US20240082243A1 (en) | Tubulin binding compounds and therapeutic use thereof | |
US11401280B2 (en) | Pyrimidinones as PI3K inhibitors | |
US20220031695A1 (en) | Shp2 inhibitor compositions for use in treating cancer | |
US8119637B2 (en) | Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor | |
AU2006334899B2 (en) | Triazole derivatives | |
CA2861609C (en) | Compounds for treating spinal muscular atrophy | |
US8912204B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
US20060089362A1 (en) | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | |
ES2927146T3 (es) | Ciertas triazolopirazinas, composiciones de estas y sus métodos de empleo | |
JP2019510006A (ja) | グリコシダーゼ阻害剤 | |
ES2470681T3 (es) | Derivados de Imidazotiadiazol | |
US20160222014A1 (en) | Compounds for regulating fak and/or src pathways | |
JP2019506430A (ja) | グリコシダーゼ阻害剤 | |
CN111349087B (zh) | 用于抑制肌成束蛋白的化合物和方法 | |
US20200039989A1 (en) | Small molecule inhibitors of dyrk/clk and uses thereof | |
US20220041590A1 (en) | Small molecule inhibitors of dyrk/clk and uses thereof | |
US20240059680A1 (en) | N-(2,3-dihydro-1,4-benzoxazin-4-yl)-3-isopropyl-7-(2,3,5-trifluorophenyl)benzo-thiophene-2-carboxamide derivatives and similar compounds for the treatment of heartworm infections | |
US20230002414A1 (en) | Azaheteroaryl compound and application thereof | |
TW202136253A (zh) | Trpml調節劑 | |
TW201441233A (zh) | 作爲β-分泌酶抑制劑之稠合多環的碸化合物及其使用方法 | |
US20200055847A1 (en) | Modulators of hedgehog (hh) signalling pathway | |
KR20230107419A (ko) | 암 치료 방법 | |
TW201103942A (en) | Thia-triaza-cyclopentazulenes | |
WO2024056077A1 (en) | Modified proteins and protein binders and degraders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
AS | Assignment |
Owner name: REVOLUTION MEDICINES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WILDES, DAVID E.;STAHLHUT-ESPINOSA, CARLOS;NICHOLS, ROBERT J.;SIGNING DATES FROM 20190313 TO 20190314;REEL/FRAME:065778/0258 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |